



(2018). Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: The IMPROVE RCT. *Health Technology Assessment*, 22(31), 1-122.  
<https://doi.org/10.3310/hta22310>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY-NC

Link to published version (if available):  
[10.3310/hta22310](https://doi.org/10.3310/hta22310)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the final published version of the article (version of record). It first appeared online via NIHR at <https://www.journalslibrary.nihr.ac.uk/hta/hta22310/#/n1>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

## Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: the IMPROVE RCT

*Pinar Ulug, Robert J Hinchliffe, Michael J Sweeting, Manuel Gomes, Matthew T Thompson, Simon G Thompson, Richard J Grieve, Raymond Ashleigh, Roger M Greenhalgh and Janet T Powell on behalf of the IMPROVE trial investigators*



# Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: the IMPROVE RCT

Pinar Ulug,<sup>1</sup> Robert J Hinchliffe,<sup>2</sup> Michael J Sweeting,<sup>3</sup> Manuel Gomes,<sup>4</sup> Matthew T Thompson,<sup>5</sup> Simon G Thompson,<sup>3</sup> Richard J Grieve,<sup>4</sup> Raymond Ashleigh,<sup>6</sup> Roger M Greenhalgh<sup>1</sup> and Janet T Powell<sup>1</sup>\* on behalf of the IMPROVE trial investigators

<sup>1</sup>Vascular Surgery Research Group, Imperial College London, London, UK

<sup>2</sup>Bristol Centre for Surgical Research, Department of Surgical Sciences, University of Bristol, Bristol, UK

<sup>3</sup>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

<sup>4</sup>Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK

<sup>5</sup>Vascular Surgery, St George's Hospital, London, UK

<sup>6</sup>Department of Radiology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK

\*Corresponding author

**Declared competing interests of authors:** Matthew T Thompson reports grants and personal fees from Endologix Inc. and Medtronic Ltd (Watford, UK) and personal fees from Gore Medical (Neward, DE, USA) outside the submitted work. Richard J Grieve is a member of the Health Technology Assessment Commissioning Board. Roger M Greenhalgh serves as a salaried director of Biba Medical Ltd (London, UK) and has an equity interest in the company and serves as an expert witness on behalf of patients with vascular disease.

Published May 2018

DOI: 10.3310/hta22310



This report should be referenced as follows:

Ulug P, Hinchliffe RJ, Sweeting MJ, Gomes M, Thompson MT, Thompson SG, *et al.* Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: the IMPROVE RCT. *Health Technol Assess* 2018;**22**(31).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.236

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/hta>

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 07/37/64. The contractual start date was in April 2009. The draft report began editorial review in April 2017 and was accepted for publication in November 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Ulug *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).



## NIHR Journals Library Editor-in-Chief

**Professor Tom Walley** Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

## NIHR Journals Library Editors

**Professor Ken Stein** Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key** Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Director of the NIHR Dissemination Centre, University of Southampton, UK

**Ms Tara Lamont** Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie** Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell** Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: the IMPROVE RCT

Pinar Ulug,<sup>1</sup> Robert J Hinchliffe,<sup>2</sup> Michael J Sweeting,<sup>3</sup> Manuel Gomes,<sup>4</sup> Matthew T Thompson,<sup>5</sup> Simon G Thompson,<sup>3</sup> Richard J Grieve,<sup>4</sup> Raymond Ashleigh,<sup>6</sup> Roger M Greenhalgh<sup>1</sup> and Janet T Powell<sup>1\*</sup> on behalf of the IMPROVE trial investigators

<sup>1</sup>Vascular Surgery Research Group, Imperial College London, London, UK

<sup>2</sup>Bristol Centre for Surgical Research, Department of Surgical Sciences, University of Bristol, Bristol, UK

<sup>3</sup>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

<sup>4</sup>Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK

<sup>5</sup>Vascular Surgery, St George's Hospital, London, UK

<sup>6</sup>Department of Radiology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK

\*Corresponding author [j.powell@imperial.ac.uk](mailto:j.powell@imperial.ac.uk)

**Background:** Ruptured abdominal aortic aneurysm (AAA) is a common vascular emergency. The mortality from emergency endovascular repair may be much lower than the 40–50% reported for open surgery.

**Objective:** To assess whether or not a strategy of endovascular repair compared with open repair reduces 30-day and mid-term mortality (including costs and cost-effectiveness) among patients with a suspected ruptured AAA.

**Design:** Randomised controlled trial, with computer-generated telephone randomisation of participants in a 1 : 1 ratio, using variable block size, stratified by centre and without blinding.

**Setting:** Vascular centres in the UK ( $n = 29$ ) and Canada ( $n = 1$ ) between 2009 and 2013.

**Participants:** A total of 613 eligible participants (480 men) with a ruptured aneurysm, clinically diagnosed at the trial centre.

**Interventions:** A total of 316 participants were randomised to the endovascular strategy group (immediate computerised tomography followed by endovascular repair if anatomically suitable or, if not suitable, open repair) and 297 were randomised to the open repair group (computerised tomography optional).

**Main outcome measures:** The primary outcome measure was 30-day mortality, with 30-day reinterventions, costs and disposal as early secondary outcome measures. Later outcome measures included 1- and 3-year mortality, reinterventions, quality of life (QoL) and cost-effectiveness.

**Results:** The 30-day mortality was 35.4% in the endovascular strategy group and 37.4% in the open repair group [odds ratio (OR) 0.92, 95% confidence interval (CI) 0.66 to 1.28;  $p = 0.62$ , and, after adjustment for age, sex and Hardman index, OR 0.94, 95% CI 0.67 to 1.33]. The endovascular strategy appeared to be more effective in women than in men (interaction test  $p = 0.02$ ). More discharges in the endovascular strategy group (94%) than in the open repair group (77%) were directly to home ( $p < 0.001$ ). Average 30-day costs were similar between groups, with the mean difference in costs being –£1186 (95% CI –£2997 to £625), favouring the endovascular strategy group. After 1 year, survival and reintervention rates were similar in the two groups, QoL (at both 3 and 12 months) was higher in the endovascular strategy group and the mean cost difference was –£2329 (95% CI –£5489 to £922). At 3 years, mortality was 48% and 56% in the endovascular strategy group and open repair group, respectively (OR 0.73, 95% CI 0.53 to 1.00;  $p = 0.053$ ), with a stronger benefit for the endovascular strategy in the subgroup of 502 participants in whom repair was started for a proven rupture (OR 0.62, 95% CI 0.43 to 0.89;  $p = 0.009$ ), whereas aneurysm-related reintervention rates were non-significantly higher in this group. At 3 years, considering all participants, there was a mean difference of 0.174 quality-adjusted life-years (QALYs) (95% CI 0.002 to 0.353 QALYs) and, among the endovascular strategy group, a cost difference of –£2605 (95% CI –£5966 to £702), leading to 88% of estimates in the cost-effectiveness plane being in the quadrant showing the endovascular strategy to be ‘dominant’.

**Limitations:** Because of the pragmatic design of this trial, 33 participants in the endovascular strategy group and 26 in the open repair group breached randomisation allocation.

**Conclusions:** The endovascular strategy was not associated with a significant reduction in either 30-day mortality or cost but was associated with faster participant recovery. By 3 years, the endovascular strategy showed a survival and QALY gain and was highly likely to be cost-effective. Future research could include improving resuscitation for older persons with circulatory collapse, the impact of local anaesthesia and emergency consent procedures.

**Trial registration:** Current Controlled Trials ISRCTN48334791 and NCT00746122.

**Funding:** This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 22, No. 31. See the NIHR Journals Library website for further project information.

# Contents

<b>List of tables</b>	<b>xiii</b>
<b>List of figures</b>	<b>xvii</b>
<b>List of abbreviations</b>	<b>xix</b>
<b>Plain English summary</b>	<b>xxi</b>
<b>Scientific summary</b>	<b>xxiii</b>
<b>Chapter 1 Introduction</b>	<b>1</b>
Objectives of the IMPROVE trial	3
<b>Chapter 2 Methods</b>	<b>5</b>
Trial design	5
Randomisation	5
Recruitment and progress	5
Data verification, role of the computerised tomography core laboratory in the diagnosis of aneurysm rupture, symptomatic unruptured aneurysm or other cause of admission	6
Participant follow-up	6
The IMPROVE trial approvals	6
Trial outcomes	7
Oversight of the trial	7
Patient and public involvement in the trial	8
Timelines for reporting of IMPROVE trial outcomes	8
Prespecified statistical analysis plans	8
<i>Individual patient data meta-analysis of three European ruptured aneurysm trials</i>	11
Statistical analysis	11
<i>Development of a new risk score</i>	12
<b>Chapter 3 Mortality and other 30-day outcomes in the IMPROVE trial and the other ruptured aneurysm trials</b>	<b>13</b>
Design of the recent randomised trials	13
The IMPROVE trial	14
Individual patient meta-analysis of the three recent European trials	17
Discussion	20
Summary	22
<b>Chapter 4 Factors other than the type of repair that influence 30-day survival of patients with a ruptured abdominal aortic aneurysm</b>	<b>23</b>
Transfer guidelines	23
Use of the IMPROVE trial as a large observational series of patients with abdominal aortic aneurysm rupture	24
<i>Time of presentation</i>	24
<i>Patient transfers: primary presentation compared with secondary presentation</i>	25
<i>Preoperative variables: fluid administration and blood pressure</i>	25
<i>General anaesthesia compared with local anaesthesia</i>	25
<i>Aortic morphology and the hostile aneurysm neck</i>	25
Summary	28

<b>Chapter 5 One-year outcomes, survival, reinterventions and health economics</b>	<b>29</b>
Overview	29
Additional methods for cost-effectiveness analyses: categories of resource use, handling of missing data and rationale for assumptions for the base-case and sensitivity analyses	29
Results	31
<i>Mortality</i>	31
<i>Reinterventions</i>	31
<i>Resource use</i>	31
<i>Health-related quality of life</i>	35
<i>Cost-effectiveness</i>	36
<i>Main findings of the IMPROVE trial at 12 months</i>	36
<i>Interpretation</i>	37
<i>Comparison with other studies</i>	37
<i>Limitations</i>	38
Summary	38
 <b>Chapter 6 Three-year outcomes, survival, reinterventions and health economics</b>	 <b>39</b>
Overview	39
Results	40
<i>Study population and treatments</i>	40
<i>Mortality in all 613 participants</i>	40
<i>Principal subgroup analysis: mortality in 502 participants with a confirmed rupture and repair started</i>	40
<i>Reinterventions in 502 participants with confirmed rupture and repair started</i>	41
<i>Narrative descriptions of some adverse outcomes requiring reintervention</i>	46
<i>Effect of baseline aortic morphology on reinterventions</i>	46
<i>Quality of life, resource use and cost-effectiveness for all 613 participants to 3 years</i>	46
Discussion	50
Summary	51
 <b>Chapter 7 Developing and validating a 48-hour mortality risk score following emergency admission for a ruptured abdominal aortic aneurysm</b>	 <b>53</b>
Overview	53
Modelling	53
<i>Participants for the development and validation of the risk score</i>	53
<i>Outcome measure</i>	54
<i>Candidate predictors</i>	54
<i>Missing data</i>	54
<i>Variable selection</i>	54
<i>Developing a bedside predictive model</i>	55
<i>Predictive performance</i>	55
<i>Comparison with other published ruptured-abdominal aortic aneurysm risk scores</i>	55
Results	55
<i>Participant characteristics</i>	55
<i>Risk score development</i>	56
<i>Calibration and discrimination</i>	56
<i>External validation</i>	57
<i>Comparison with other published risk scores</i>	58
<i>Performance of the risk scores in predicting 30-day mortality</i>	58
<i>Decision curve analysis</i>	58
Conclusions	60

<b>Chapter 8 Collaborative research projects emanating directly from the IMPROVE trial</b>	<b>63</b>
The development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes	63
The comparative aortic morphology of intact and ruptured abdominal aortic aneurysms	64
Computational fluid dynamics of ruptured abdominal aortic aneurysm	67
Morphological and computational flow dynamic characteristics of common iliac aneurysms	68
Added value from collaborations and future use of IMPROVE trial data	70
<b>Chapter 9 Concluding remarks and suggestions for further research</b>	<b>71</b>
Trial design	71
Implementation	71
Interpretation	72
<i>Contrasting results of the randomised trials in the elective setting and emergency setting</i>	73
<i>Metrics for reporting reinterventions after emergency aneurysm repair and patient perspectives</i>	74
Implications for future health care	74
Suggestions for further research	75
Final words	75
<b>Acknowledgements</b>	<b>77</b>
<b>References</b>	<b>81</b>
<b>Appendix 1 Trial progress and recruitment</b>	<b>91</b>
<b>Appendix 2 Additional tables and figures</b>	<b>101</b>



# List of tables

<b>TABLE 1</b> Baseline characteristics of IMPROVE trial participants, by randomised group	<b>16</b>
<b>TABLE 2</b> Place of discharge of IMPROVE trial participants, by randomised group and in-hospital mortality	<b>17</b>
<b>TABLE 3</b> Descriptive statistics for the three recent European ruptured AAA trials	<b>18</b>
<b>TABLE 4</b> Reported incidence of abdominal compartment syndrome and other mesenteric hypoperfusion syndromes, colonic ischaemia and mesenteric ischaemia, by randomised group across three randomised trials	<b>20</b>
<b>TABLE 5</b> Adjusted effect of main variables (age, sex, Hardman index and randomised group) on 30-day mortality in 558 participants (complete-case analysis)	<b>23</b>
<b>TABLE 6</b> Baseline morphological criteria according to treatment started for 458 participants with rupture and CT scans assessed in the core laboratory	<b>26</b>
<b>TABLE 7</b> The 30-day mortality by categories of neck length according to treatment started for rupture (complete case analysis with 409 participants)	<b>27</b>
<b>TABLE 8</b> Mortality for the 613 randomised participants and numbers of reinterventions in the 502 participants with ruptured AAA who had aneurysm repair started	<b>33</b>
<b>TABLE 9</b> Resource use and costs (GBP) up to 1 year, reported across all randomised participants	<b>34</b>
<b>TABLE 10</b> Quality of life, total costs (GBP) and cost-effectiveness outcomes up to 1 year	<b>35</b>
<b>TABLE 11</b> Incremental net monetary benefit (95% CI) (GBP) within the first year of randomisation, by subgroup, at the recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)	<b>36</b>
<b>TABLE 12</b> Causes of death, by randomised group and time period, in 613 participants	<b>41</b>
<b>TABLE 13</b> Baseline characteristics of the 502 participants in whom repair of a ruptured aneurysm had started, by randomised group	<b>43</b>
<b>TABLE 14</b> Reinterventions in the 502 participants in whom repair of a ruptured aneurysm had started	<b>44</b>
<b>TABLE 15</b> Quality-of-life (EQ-5D-3L) utility scores, life-years and QALYs up to 3 years. Results are reported after multiple imputation for the 613 participants who were randomised	<b>47</b>



<b>TABLE 16</b> Incremental net benefit (95% CI) (GBP) within 3 years of randomisation, by subgroup, at the recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)	47
<b>TABLE 17</b> Resource use and costs (GBP) up to 3 years, reported across all participants randomised. Results are reported after multiple imputation	48
<b>TABLE 18</b> Descriptive statistics of the candidate predictors for the three RCTs and two cohorts	56
<b>TABLE 19</b> Univariate analysis of candidate predictors using multiply imputed data	57
<b>TABLE 20</b> Discriminative performance of the developed IMPROVE risk score for predicting 48-hour mortality, validated both internally (using IMPROVE trial data) and externally (using data from the AJAX and ECAR RCTs and the Amsterdam and STAR cohorts). Comparisons with other published risk scores are also shown	57
<b>TABLE 21</b> Mean (SD) of key morphological variables (based on analysis sample)	65
<b>TABLE 22</b> Comparison of morphological parameters in intact and ruptured aneurysms, given separately for men and women	66
<b>TABLE 23</b> Categories of gross anatomy of common iliac aneurysms	70
<b>TABLE 24</b> The proportion of EVAR procedures compared with open repair procedures used for ruptured AAA repair in England, since the start of the IMPROVE trial	72
<b>TABLE 25</b> Comparison of mid-term health outcomes from randomised trials for endovascular vs. open repair for elective and ruptured AAA repair	73
<b>TABLE 26</b> Non-randomised patients, with reasons	96
<b>TABLE 27</b> Source of aneurysm-related reintervention data in 502 participants in whom repair of a rupture had started	98
<b>TABLE 28</b> Unit costs (GBP) for 1-year analyses	101
<b>TABLE 29</b> Survey of staff (who were present in the operating suite for endovascular repair and open repair); from 10 IMPROVE trial centres in November 2012	103
<b>TABLE 30</b> Resource use and costs (GBP) to 30 days, by randomised group	104
<b>TABLE 31</b> Variables considered for multiple imputations and imputation models considered	105
<b>TABLE 32</b> Quality-of-life (EQ-5D) health state profiles for participants with a proven rupture, who commenced an operation and who were alive and fully completed the questionnaire at 3 months and 12 months post randomisation	106

<b>TABLE 33a</b> Unadjusted and adjusted HRs for the endovascular strategy compared with open repair, for both all-cause mortality and aneurysm-related mortality for all available follow-up data: overall	107
<b>TABLE 33b</b> Unadjusted and adjusted HRs for the endovascular strategy compared with open repair, for both all-cause mortality and aneurysm-related mortality for all available follow-up data: by time period	107
<b>TABLE 34</b> Reinterventions in the first 3 years of follow-up, by operation commenced, for participants with a final diagnosis of ruptured AAA	107
<b>TABLE 35</b> Unadjusted and adjusted HRs for the endovascular strategy compared with open repair, for time to first AAA reintervention and time to any reintervention within the first 3 years of follow-up	109
<b>TABLE 36a</b> Indications for re-interventions within 90 days of randomisation	110
<b>TABLE 36b</b> Indications for re-interventions from 3 months to 3 years	111
<b>TABLE 37</b> The effect of aortic morphology on re-interventions in the first 3 years of follow up	112
<b>TABLE 38</b> Quality-of-life (EQ-5D-3L) utility scores, QALYs and life-years up to 3 years for participants with fully observed outcomes (complete cases)	113
<b>TABLE 39</b> Incremental net benefit (GBP) (95% CI) within 3 years of randomisation, by subgroup, at the recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)	113
<b>TABLE 40</b> Coefficients for the best-fitting model (backwards selection) and the clinically simplified (bedside) model	114
<b>TABLE 41</b> Derivation of previously published ruptured AAA risk scores	114
<b>TABLE 42</b> Discriminative performance of the developed IMPROVE risk score for predicting 30-day mortality, validated both internally (using IMPROVE trial data) and externally (using data from the AJAX and ECAR RCTs and the Amsterdam and STAR cohorts)	115



# List of figures

<b>FIGURE 1</b> Schematics of aneurysm repair, showing (left) open repair, (centre) endograft insertion for endovascular repair and (right) endovascular repair in progress	<b>1</b>
<b>FIGURE 2</b> Comparison of designs for three European trials comparing endovascular and open repair for a ruptured AAA	<b>13</b>
<b>FIGURE 3</b> A CONSORT diagram showing the flow of participants through the trial, with 30-day mortality for each group	<b>15</b>
<b>FIGURE 4</b> The 30-day mortality by randomised group across the three recent European ruptured aneurysm trials	<b>19</b>
<b>FIGURE 5</b> The 30-day mortality by randomised group	<b>19</b>
<b>FIGURE 6</b> Primary morphological variables for analysis	<b>26</b>
<b>FIGURE 7</b> Association between neck length and proximal aortic neck length	<b>27</b>
<b>FIGURE 8</b> A CONSORT diagram showing participant flow and follow-up to 3 years	<b>32</b>
<b>FIGURE 9</b> Kaplan–Meier estimates for overall survival, by randomised group	<b>42</b>
<b>FIGURE 10</b> Time to first reintervention for the 502 participants in whom repair of a ruptured aneurysm had started	<b>45</b>
<b>FIGURE 11</b> Quality of life (EQ-5D-3L) gained up to 3 years (shaded area) for 613 participants by randomised group	<b>46</b>
<b>FIGURE 12</b> (a) Uncertainty in the mean cost (GBP) and QALY differences and their joint distribution for the endovascular strategy compared with open repair for 613 participants; and (b) cost-effectiveness acceptability curve at 3 years, reporting the probability that the endovascular strategy is cost-effective at a range of alternative thresholds of willingness to pay for a QALY gain	<b>49</b>
<b>FIGURE 13</b> Change in C-index for five ruptured AAA risk scores compared with the reference score using age alone	<b>59</b>
<b>FIGURE 14</b> Decision curve showing the benefit of the IMPROVE ruptured AAA risk score in helping to make treatment decisions	<b>60</b>
<b>FIGURE 15</b> Rupture (marked by an x) usually occurs in regions of low TAWSS	<b>69</b>
<b>FIGURE 16</b> Time from NHS Site-Specific Information Form submission to NHS approval by December 2010	<b>93</b>
<b>FIGURE 17</b> Progress with centres that were able to recruit	<b>93</b>
<b>FIGURE 18</b> Recruitment to December 2011	<b>94</b>

<b>FIGURE 19</b> Progress of recruitment	<b>95</b>
<b>FIGURE 20</b> A CONSORT diagram for outcomes to 30 days	<b>97</b>
<b>FIGURE 21</b> Overview of the trial	<b>99</b>
<b>FIGURE 22</b> The HR of time to discharge from primary admission hospital (endovascular strategy/endovascular repair compared with open repair) by randomised group	<b>116</b>
<b>FIGURE 23</b> Effect of systolic blood pressure (lowest recorded) on probability of 30-day mortality (95% CIs are presented)	<b>116</b>
<b>FIGURE 24</b> Survival to 1 year in the AJAX, ECAR and IMPROVE trials	<b>117</b>
<b>FIGURE 25</b> Uncertainty in the mean cost (GBP) and QALY differences at 1 year after randomisation for 613 participants and their joint distribution for endovascular strategy compared with open repair	<b>119</b>
<b>FIGURE 26</b> Sensitivity analysis that considers the effect on the INMB at 1 year (at £30,000 per QALY) of alternative assumptions, compared with the base case for 613 participants	<b>119</b>
<b>FIGURE 27</b> Kaplan–Meier survival curves for overall aneurysm-related mortality for 613 participants, by randomised group	<b>120</b>
<b>FIGURE 28</b> Prespecified subgroup analyses showing HRs for the endovascular strategy group compared with the open repair group for overall mortality at 3 years in 613 participants	<b>120</b>
<b>FIGURE 29</b> Sensitivity analysis that considers the effect on the INMB at 3 years (at £30,000 per QALY) of alternative assumptions, compared with the base case for 613 participants	<b>121</b>
<b>FIGURE 30</b> Non-linear effects of (a) age, (b) admission systolic blood pressure and (c) neck length on the log-odds of mortality	<b>121</b>
<b>FIGURE 31</b> Calibration plots for the best-fitting model and the bedside model in the IMPROVE trial data set	<b>122</b>
<b>FIGURE 32</b> Variation of WSSs in the aorta with iliac bifurcation angle	<b>122</b>

# List of abbreviations

AAA	abdominal aortic aneurysm	HRQoL	health-related quality of life
AJAX	Amsterdam Acute Aneurysm trial	IFU	instructions for use
AUROC	area under receiver operating characteristic	IMPROVE	Immediate Management of the Patient with Rupture: Open Versus Endovascular repair
CI	confidence interval		
CIA	common iliac aneurysm	INB	incremental net benefit
CONSORT	Consolidated Standards of Reporting Trials	INMB	incremental net monetary benefit
CRF	case report form	NICE	National Institute for Health and Care Excellence
CT	computerised tomography	OR	odds ratio
ECAR	Endovasculaire versus Chirurgie dans les Anévrismes Rompus	QALY	quality-adjusted life-year
EQ-5D	EuroQol-5 Dimensions	QoL	quality of life
EQ-5D-3L	EuroQol-5 Dimensions, three-level version	RCT	randomised controlled trial
EVAR	endovascular aneurysm repair	SD	standard deviation
FP	fractional polynomial	SE	standard error
GBP	Great British pounds	STAR	STockholm Aneurysm Ruptures
HES	Hospital Episode Statistics	TAWSS	time-averaged wall shear stress
HR	hazard ratio	USD	US dollars
		WSS	wall shear stress



## Plain English summary

**R**upture of a swelling of the aorta (abdominal aortic aneurysm), the main blood vessel in the body, causes massive bleeding and leads to the death of about 6000 people annually in the UK. Many of these people do not reach hospital. The only hope is an emergency operation to repair the aorta and, even then, < 60% of people survive. The Immediate Management of the Patient with Rupture: Open Versus Endovascular repair (IMPROVE) trial compared two different methods for repairing the aorta, endovascular repair (the newer keyhole approach via a small cut in the groin, if the aorta is the right shape for this) and open repair (via a big cut in the belly).

A total of 613 participants (nearly one-quarter of them women) with a diagnosis of ruptured abdominal aortic aneurysm were randomised, half to an endovascular strategy and half to open repair, and followed for survival, further operations, recovery and quality of life, and treatment costs.

At 30 days after rupture (standard surgical reporting), almost two-thirds of each group were still alive, but those in the endovascular strategy group recovered quicker and went home sooner. The endovascular strategy appeared to be slightly more effective in saving lives in women than in men.

By 1 year after rupture, just over half of both the endovascular strategy group and the open repair group were alive, with no difference between the groups in the number of further operations needed. However, quality of life was better in the endovascular strategy group at both 3 and 12 months.

By 3 years after rupture, slightly more participants in the endovascular strategy group (54%) were alive than in the open repair group (46%); quality of life was good for both groups and the number of further operations was small.

At all time points, the endovascular strategy had non-significantly lower health-care costs.

Overall, the endovascular strategy was likely to be more cost-effective than open repair, with benefits observed for participants and health-care providers.





# Scientific summary

## Background

Ruptured abdominal aortic aneurysm (AAA) remains a common vascular emergency in the older population, causing  $\approx 6000$  deaths each year in the UK. Without repair of the burst aorta, death is almost inevitable. More than half of people with ruptured aneurysms die before reaching hospital, and not all patients who reach hospital are offered a life-saving repair. Until the early part of this century, the only type of repair available was open surgical repair, which carried a very high mortality of  $\approx 50\%$ . The first published case showing the feasibility of using the less invasive endovascular repair was from Nottingham in 1994 (Yusuf SW, Whitaker SC, Chuter TA, Wenham PW, Hopkinson BR. Emergency endovascular repair of leaking aortic aneurysm. *Lancet* 1994;**344**:1645). By 2007, systematic reviews had been published to suggest that endovascular aneurysm repair (EVAR) could halve the operative mortality for ruptured aneurysms. By then, the number of centres in the UK that were experienced in using EVAR in the elective situation was sufficient to consider a randomised trial of emergency EVAR compared with open repair for ruptures.

## Design

Because the applicability of EVAR is restricted by the morphology of the aorta, a trial of an endovascular strategy (EVAR if morphologically feasible, default open repair) compared with open repair was designed. Therefore, randomisation was carried out at the point of in-trial hospital diagnosis by a senior clinician, before a computerised tomography, which might delay transfer to theatre for emergency repair. To be able to join the trial, a centre had to have carried out at least five emergency EVARs with acceptable results. The sample size calculations indicated that a total of 300 participants in each group would be needed to have 90% power to show a significant reduction in 30-day operative mortality (the primary outcome measure) from 44.7% for open repair to 30.4% for the endovascular strategy group. It was also planned to follow up the participants for 12 months to allow us to carry out a cost-effectiveness evaluation.

## Results

Between September 2009 and July 2013, 613 eligible participants with an in-hospital diagnosis of ruptured aneurysm were randomised: 316 to the endovascular strategy group and 297 to the open repair group. These 613 participants were derived from a total cohort of 1275 patients who were admitted with a clinical diagnosis of ruptured aneurysm at the 30 trial centres during the same period.

The 613 participants had a mean age of 77 years and a mean aortic diameter of 8.3 cm and included 133 women (22%). The diagnosis of rupture was later confirmed, using a core laboratory, in 536 out of 613 participants (87%; of these, 60% were morphologically suitable for EVAR); 22 participants had an acute symptomatic aneurysm, 46 participants had an asymptomatic aneurysm or other acute diagnosis, and only nine participants had no aortic aneurysm.

Overall 30-day mortality was 35.4% in the endovascular strategy group and 37.4% in the open repair group [unadjusted odds ratio (OR) 0.92, 95% confidence interval (CI) 0.66 to 1.28;  $p = 0.62$ ], with similar results after adjustment for age, sex and Hardman index (an established morbidity score for ruptured aneurysms). There was weak evidence that the endovascular strategy was more effective in women than in men (interaction  $p = 0.02$ ). Most participants (555/613; 91%) adhered to the trial protocol. Among the 502 participants with a proven rupture and for whom repair commenced, the 30-day mortality was 32% (84/259 participants) in the endovascular strategy group and 36% (87/243 participants) in the open repair

group (OR 0.86, 95% CI 0.59 to 1.24). The average hospital costs, including reinterventions, within the first 30 days of randomisation were similar between the randomised groups: mean £13,433 [standard deviation (SD) £10,354] and mean £14,619 (SD £12,353) for the endovascular strategy group and open repair group, respectively. At 30 days, some participants remained in hospital (28 in the endovascular strategy group, compared with 47 in the open repair group), but 94% of discharges in the endovascular strategy group were directly to home compared with 77% in the open repair group.

The recruited participants were also used in a large cohort analysis to identify factors, other than type of repair, that might be associated with postoperative survival (30-day mortality). The cohort analyses showed that shorter aneurysm neck length, admission at weekends and out of hours, and very low admission systolic blood pressures were all associated with higher operative mortality. In contrast, the use of EVAR under local, rather than general, anaesthesia was associated with much lower operative mortality (adjusted OR 0.27, 95% CI 0.10 to 0.70). An additional important factor that influenced 30-day mortality was the morphological parameter of aneurysm neck length. Operative mortality was much lower in the group of participants with aneurysm neck lengths of > 15 mm than in the group of participants with aneurysm neck lengths of < 15 mm, irrespective of whether endovascular or open repair was used. This is likely to be an important finding, which partly explains why observation series report much lower operative mortality for EVAR than for open repair: participants with long aneurysm necks are the most morphologically suitable for, and most likely to receive, EVAR.

At 1 year after randomisation, two participants in the open repair group had emigrated and had been lost to follow-up for mortality. All-cause mortality was 41.1% for the endovascular strategy group and 45.1% for the open repair group (OR 0.85, 95% CI 0.62 to 1.17;  $p = 0.325$ ), with similar reintervention rates in each group (between 31 days and 1 year, there were 12 procedures involving 11 participants and 13 procedures involving nine participants in the endovascular and open repair groups, respectively). The average total hospital stay was 17 days in the endovascular strategy group and 26 days in the open repair group ( $p < 0.001$ ). Among participants surviving rupture, the average utility score on the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), was higher in the endovascular strategy group than in the open repair group [mean differences of 0.087 (95% CI 0.017 to 0.158) and 0.068 (95% CI -0.004 to 0.140) at 3 months and 12 months, respectively]. There were indications that quality-adjusted life-years (QALYs) were higher and costs were lower for the endovascular strategy, combining to give an incremental net monetary benefit of £3877 (95% CI £253 to £7408) or €4356 (95% CI €284 to €8323) at a willingness-to-pay threshold of £30,000 per QALY.

Soon after completion of randomisation, it was estimated that  $\approx 50\%$  of participants would remain alive at 3 years, and an application was made to extend participant follow-up for clinical effectiveness and cost-effectiveness evaluations to 3 years and to conduct individual patient data meta-analyses across the three recent European trials for the repair of ruptured aneurysm [Immediate Management of the Patient with Rupture: Open Versus Endovascular repair (IMPROVE), Amsterdam Acute Aneurysm trial (AJAX) (the Netherlands) and Endovasculaire versus Chirurgie dans les Anévrismes Rompus (ECAR) (France)] to 1 year. These meta-analyses all supported the main findings of the IMPROVE trial: no difference in mortality between the randomised groups at 1 year but more rapid participant recovery in the endovascular groups and the important effect of aneurysm neck length on 30-day mortality. IMPROVE was the only trial with full reporting to 3 years.

By 3 years after randomisation, a further two participants had emigrated and were lost to follow-up, this time in the endovascular strategy group. The mean participant follow-up was 4.9 years. Overall, there were 179 deaths (22.0 per 100 person-years) in the endovascular strategy group and 183 deaths (25.2 per 100 person-years) in the open repair group [hazard ratio (HR) 0.92, 95% CI 0.75 to 1.13;  $p = 0.41$ ]. However, at 3 years, the survival curves had their widest separation, before converging again by 6 years, and for the prespecified mid-term period (3 months to 3 years) results favoured the endovascular strategy group (HR 0.57, 95% CI 0.36 to 0.90). At 3 years, mortality was 48% and 56% in the endovascular strategy group and the open repair group, respectively (OR 0.73, 95% CI 0.53 to 1.00;  $p = 0.053$ ), with a more pronounced

effect for the endovascular strategy in the subgroup of 502 participants in whom repair was started for a proven rupture, in which the mortality rate was 42% and 54%, respectively (OR 0.62, 95% CI 0.43 to 0.89;  $p = 0.009$ ). There was also weak evidence that the endovascular strategy was more effective in women than in men, but no such finding was observed for any other subgroup. In both randomised groups, there were continuing aneurysm-related reinterventions, the rate being non-significantly higher in the endovascular strategy group but the reinterventions being more severe in the open repair group. At 3 and 12 months, quality of life (QoL) was better in the endovascular strategy group but, by 3 years, there was no difference; mean EQ-5D-3L scores were 0.74 and 0.73 in the endovascular strategy group and open repair group, respectively. This was similar to the age- and sex-matched population. At 3 years, the endovascular strategy group had gained a mean of 0.166 QALYs (95% CI 0.002 to 0.311 QALYs;  $p = 0.045$ ), the largest gains being for women and those with an admission Hardman index score of  $\geq 2$ . By 3 years, the average number of days in hospital for aneurysm-related care was 14.4 days and 20.5 days in the endovascular strategy group and open repair group, respectively, with a mean incremental cost of –£2607 (95% CI –£5949 to £735). The higher costs of open repair in primary admission had not been eroded by any excess of later aneurysm-related reinterventions in the endovascular strategy group. With survival, QoL and costs all favouring the endovascular strategy group at 3 years, there was an incremental net monetary benefit (INMB) of £7833 (95% CI £1655 to £14,011) for the endovascular strategy group, for a QALY valued at £30,000. The probability that the endovascular strategy is more cost-effective was  $> 90\%$  at all realistic thresholds of willingness to pay for a QALY gain. Therefore, at 3 years, the endovascular strategy appeared to be both clinically effective and cost-effective.

The overall survival curves for patients admitted to hospitals with a diagnosis of ruptured aneurysm show a very steep attrition rate during the first 48 hours. However, all current risk scores, which may be used to select patients for surgery, are based on 30-day survival, a time period during which intensive care and several specialties other than vascular surgery contribute to patient care. Additionally, none of the available risk scores uses morphological data such as neck length. Additional funding was awarded to develop a risk score for 48-hour mortality in patients presenting with a ruptured aneurysm and to validate the score using external trials and observational cohorts. The developed model included the predictors of age, sex, haemoglobin, creatinine, systolic blood pressure, aneurysm neck length, neck angle and acute cardiac ischaemia. A simplified model that could be used at the bedside was also developed. The calibration slope was estimated as 1.08 (95% CI 0.81 to 1.35;  $p = 0.54$ ) for the bedside score derived in the IMPROVE trial, indicating that both low and high predictions are well calibrated. The ability of the IMPROVE trial score to discriminate between patients who would and would not survive for 48 hours was reasonable, but not exceptional, with an area under receiver operating characteristic curve of 0.720 [standard error 0.025]. An external validation revealed that the score performed adequately in the ECAR trial and the Amsterdam cohort and did not perform well in AJAX or the Stockholm area cohort. Similarly, none of the previously published risk scores performed well in all of the different cohorts. The inability of risk scores to predict outcomes following emergency surgical repair with sufficient accuracy indicates that any risk score should be used only for either comparing different populations or adjusting population data, as the Hardman index was used in the IMPROVE trial. If the mortality risk of ruptured AAA repair cannot be predicted with sufficient accuracy, we suggest that the focus should shift to offering emergency repair to more patients and reducing the non-intervention rate.

## Collaborative projects

The trial has also formed the basis for several collaborative projects. First was a Delphi consensus approach (vascular surgeons and emergency medicine physicians) to develop guidelines for the equitable and rapid transfer of patients with a clinical diagnosis of a ruptured AAA from district general hospitals to vascular centres, which resulted in the Royal College of Emergency Medicine Best Practice Guidelines. Second was a project to investigate whether or not missing QoL data were really missing at random. A third study compares the morphology of intact and ruptured AAAs to try and identify morphological features, other than maximum aortic diameter, which may be helpful in predicting aneurysms at the highest risk of rupture.

Fourth is a study of common iliac aneurysms, which may have an undilated contralateral iliac artery, to assess computational flow dynamic characteristics associated with the natural history of these little-studied aneurysms. The last two of these collaborative projects are still in progress and the transfer guidelines will be updated as part of the ongoing National Institute for Health and Care Excellence AAA review.

## Conclusions

The primary outcome measure of the IMPROVE trial was mortality. Despite the lack of any significant difference in mortality (the primary outcome measure) between the randomised groups at 30 days and 1 year, by 3 years the story had changed. At 3 years, there was an interim mid-term survival benefit for the endovascular strategy, without an excess of aneurysm-related reinterventions. The more rapid recovery of the participants in the endovascular strategy group led to early gains in QoL. Together, these have led to an increase in QALYs for the endovascular strategy group, without additional costs compared with the open repair group. All of the outcomes favour the endovascular strategy, leading to it being highly likely that the endovascular strategy was cost-effective after 3 years.

The trial has also been the springboard for other important scientific projects including best practice guidelines for the transfer of patients with a suspected ruptured aneurysm into a vascular centre. Therefore, the results of this project should continue to influence the improvement of care for patients with a ruptured AAA.

## Trial registration

This trial is registered as ISRCTN48334791 and NCT00746122.

## Funding


Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

# Chapter 1 Introduction

**A** bdominal aortic aneurysm (AAA) is a common degenerative disease, with a current prevalence of  $\approx 2\%$  in men aged 65 years; the prevalence increases with age. AAA is about fourfold less common in women. Small AAAs are rarely associated with symptoms but their natural history is progressive enlargement until rupture occurs. Following several randomised trials, a screening programme for 65-year-old men was rolled out, between 2009 and 2013, to cover the UK. Elective aneurysm repair is recommended when the diameter is  $> 5.5$  cm (about three times the normal aortic diameter); the operative mortality for elective procedures for screen-detected aneurysms is low.<sup>1–3</sup> Without intervention, a ruptured AAA is fatal and the overall mortality is  $> 80\%$ . About half of patients with ruptured aneurysms die in the community. More than one-third of patients who arrive in accident and emergency departments do not reach the operating theatre alive. Among the patients who reach the operating theatre (for open surgical repair under general anaesthesia), only half will leave hospital alive. These stark figures changed little over the 50 years between 1960 and 2010.<sup>4</sup> Ruptured aneurysm is a common vascular emergency, involving various symptoms that are not specific to AAA rupture, usually back or abdominal pain and collapse. It tends to occur in elderly patients who often have comorbidities that may preclude a successful repair, especially if the diagnosis is not made promptly.

Ruptured aortic aneurysms are a common cause of death in the UK and, in the last century, infrarenal AAAs caused  $\approx 8000$  deaths per annum in England and Wales. The incidence of both AAAs and ruptured AAAs continued to increase year on year until about 2000 in both men and women.<sup>5,6</sup> More recently, the number of deaths from ruptured AAAs has declined rapidly because of the reducing prevalence of smoking in the population and the increasing number of elective aneurysm repairs in the population aged  $> 75$  years, using the minimally invasive endovascular repair.<sup>7</sup> Nevertheless, when this trial started in 2009, there were still 2581 deaths from AAA ruptures (285 of these in women) in England and Wales. Until about 2004, routine practice was to direct patients with a suspected ruptured AAA directly to the operating theatre for open repair, without preoperative computerised tomography (CT). In England, there were about 1300 open surgical repairs for ruptured aneurysms each year, with 30-day and in-hospital mortality being similar at 47–48%.<sup>4,8,9</sup>

For open AAA repair, the aneurysm is usually approached by a midline laparotomy, carefully moving aside the colonic viscera and cross-clamping the aorta, below the renal arteries wherever possible, and inserting a prosthetic inlay graft, using a tube configuration with sutured anastomoses to the aorta both proximally and distally to exclude the aneurysm wherever possible (*Figure 1*). When the aneurysm extends beyond the aorta into the common iliac arteries, the use of a bifurcated graft becomes necessary. These procedures



**FIGURE 1** Schematics of aneurysm repair, showing (left) open repair, (centre) endograft insertion for endovascular repair and (right) endovascular repair in progress.



are conducted under general anaesthesia and the patients require a critical care bed postoperatively. The in-hospital care of those patients undergoing open surgical repair of a ruptured aneurysm is costly, as many days are spent in the intensive care unit (a mean of 3.5 days for uncomplicated cases and 9.5 days for complicated cases) and the average hospital stay is long. Recuperation after discharge following open surgery for a ruptured aneurysm can take up to 6 months, having a further impact on the resources of the family, social care and general practice. Although the recovery may be slow, the evidence shows that the results of elective open repair are durable and there is no need for longer-term follow-up. Interestingly, the operative mortality of open surgery appears to be independent of hospital volume, although this may be influenced by case selection.<sup>10</sup>

Urgent CT angiography is necessary to confirm the diagnosis of ruptured aneurysm and plan the feasibility of endovascular repair. In general, aneurysm neck diameter, length and angulation should be  $\leq 3.4$  cm,  $\geq 10$  mm and  $< 60^\circ$ , respectively. Catheters are used to deliver the endograft through the femoral arteries, so that tortuous, very narrow or calcified femoral arteries are additional contraindications to endovascular repair. The femoral arteries are accessed via small incisions in the groin and, under imaging control, the endograft is delivered, positioned and secured in place (see *Figure 1*). This procedure requires specialist imaging equipment and the presence of a CT radiographer as part of the endovascular team. The configuration of the endograft is either bifurcated or aorto-uni-iliac. When the latter endografts are used, the contralateral iliac artery is occluded and a femoro-femoral crossover graft is used to supply blood to the contralateral limb. Endovascular repair can be conducted under local or regional anaesthesia, although general anaesthesia often is used and becomes necessary for most femoro-femoral crossover grafts. Some patients may not need to be transferred to a critical care bed and, in general, recovery is faster after endovascular repair than after open surgical repair. However, in contrast with open repair, continued surveillance of the endograft is necessary and reinterventions for endoleaks and other problems are not uncommon. This is likely to require at least two additional CT scans in the year following endovascular repair.

When this trial was first discussed, observational studies (synthesised in systematic reviews<sup>11–14</sup>) were reporting much lower 30-day mortality for endovascular repair of ruptured AAAs and some such studies<sup>11</sup> have suggested that this should become the new gold standard treatment of ruptured aneurysms without the need for a randomised trial. In addition, the in-hospital and 1-year costs of treating ruptured aneurysms by endovascular repair may be up to 40% lower than for treatment by open repair.<sup>15</sup> However, a single centre pilot randomised trial<sup>16</sup> with 32 participants, carried out in Nottingham, UK, showed a 30-day mortality of  $> 50\%$  for participants treated with either endovascular aneurysm repair (EVAR) or open repair.

By 2004, randomised trials had shown the advantage of EVAR for elective repairs through reducing 30-day operative mortality threefold compared with open repair,<sup>3,17</sup> and endovascular technology, no longer confined to academic centres, was widely available and preferred by patients. It remained an open question whether or not endovascular repair would have the same impact on reducing mortality from ruptured AAAs. Importantly, it was considered that only  $\approx 55\%$  of patients with a ruptured AAA would be anatomically suitable for endovascular repair, so that, for many patients, endovascular repair would not be an option.<sup>14</sup>

Therefore, the design of any randomised trials was a question of considerable debate. In the Netherlands, a small randomised trial<sup>18</sup> in the Amsterdam region started in 2007. This trial considered only patients with a ruptured AAA of relative haemodynamic stability after CT had demonstrated the anatomical feasibility of EVAR and then randomised these participants to either EVAR or open repair.<sup>18</sup> The primary outcome measure of this trial was combined mortality and morbidity at 30 days and, with optimistic power calculations, it was planned to randomise just 80 participants. Later, in 2010, the trial was extended to include 120 participants; the results were finally reported in late 2013.<sup>19</sup> A trial<sup>20</sup> with a similar design started in France in 2008, with the aim of recruiting 160 participants, but it used the rather weak methodology of randomising participants by week of the year. The French trial recruited 107 participants and reported the early outcomes in late 2014. Both the Dutch trial and the French trial had a selective recruitment policy. In contrast, the Immediate Management of the Patient with Rupture: Open Versus

Endovascular repair (IMPROVE) trial,<sup>21</sup> the last European trial to start, larger than all of the other trials combined, had a non-selective recruitment policy for participants with the clinical diagnosis of ruptured aneurysm, so that health policy implications could be addressed.

## Objectives of the IMPROVE trial

In participants with a clinical diagnosis of ruptured AAA who were randomised to either a strategy of endovascular repair (if feasible, with open repair when not feasible) or to a strategy of open repair:

1. Assess whether or not the endovascular strategy was associated with a lower 30-day and mid-term mortality (the primary outcome measure).
2. Determine the proportion of participants in each group who were discharged directly to home (disposal).
3. Assess whether or not the endovascular strategy was associated with lower 30-day costs.
4. Determine the proportion of participants who were suitable for endovascular repair and operational barriers to endovascular repair.
5. Assess whether or not an endovascular strategy was associated with improved 1-year survival and quality of life (QoL) and was cost-effective.
6. Identify subgroups of participants who derived greater benefit from endovascular repair.

The trial was initially funded by a Health Technology Assessment Emergency and Trauma Care initiative. As the trial progressed, it was extended to include three further objectives:

7. Assess whether or not an endovascular strategy was associated with improved 3-year survival and QoL and was cost-effective.
8. Conduct an individual patient meta-analysis of participants randomised in all of the European randomised trials [Amsterdam Acute Aneurysm trial (AJAX),<sup>19</sup> Endovasculaire versus Chirurgie dans les Anévrismes Rompus (ECAR)<sup>22</sup> and IMPROVE<sup>23</sup>], with respect to common 30-day and 1-year outcomes.
9. Develop a risk score for 48-hour mortality for patients with a ruptured AAA.

In addition, the resources and information gathered during the trial have stimulated associated projects including the development of best practice guidelines<sup>24</sup> for the transfer of patients and the influence of aortic morphology on mortality and reinterventions, as well as several collaborative projects.





## Chapter 2 Methods

The methods for the IMPROVE trial, given in this chapter, are reproduced, in part, from published work.<sup>23</sup> © The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

### Trial design

The IMPROVE trial was a multicentre randomised trial that randomised patients with a clinical diagnosis of ruptured AAA to either an endovascular strategy of immediate CT and emergency EVAR, with open repair for those who were anatomically unsuitable for EVAR (endovascular strategy group), or to the standard treatment of emergency open repair (open repair group). This trial was conducted in 30 eligible centres (29 in the UK and one in Canada). The eligibility of each centre to participate in the trial was determined by its clinical credentials, including audited volumes of elective EVAR of > 20 cases per year out of ≥ 50 cases of aortic surgery, evidence of good interdisciplinary teamworking, team availability for ≥ 66% of the week, rapid access to emergency CT (target of 20 minutes) and audited experience of emergency EVAR (five or more cases). The trial protocol and the guidelines for fluid management, anaesthesia and management of abdominal compartment syndrome as well as statistical analysis plans are available at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/) (accessed 16 November 2017).

All patients aged > 50 years with a clinical diagnosis of ruptured AAA or ruptured aortoiliac aneurysm, diagnosed by a senior trial hospital clinician (either in emergency medicine or vascular surgery), were recorded and were eligible for inclusion. The first brief consent process could be written, verbal or from a relative and, if necessary, in England only, from a non-treating physician, using the Mental Capacity Act 2005.<sup>25</sup> Participants were re-consented for continued participation in the trial during the recovery period.

Patients were excluded if they had had a previous aneurysm repair or a current rupture of an isolated internal iliac aneurysm, aorto-caval or aorto-enteric fistulae, a recent anatomical assessment of the aorta (e.g. awaiting elective EVAR), a connective tissue disorder or if intervention was considered futile (patient moribund).

### Randomisation

An independent contractor (Sealed Envelope Ltd, London, UK) provided telephone randomisation, with computer-generated assignation of participants in a 1 : 1 ratio, using variable block size and stratified by centre. The date and time of randomisation, together with type of initial consent (written/verbal/other), were recorded automatically. The randomisation was communicated by e-mail to the trial manager, site principal investigator and trial co-ordinator. Participants were randomised either to an endovascular strategy (immediate CT followed by EVAR if locally determined as anatomically suitable and open repair when not suitable) or to immediate open repair, with CT being optional. Because this was a surgical trial, neither investigators nor participants could be masked to the treatment allocation. Adherence to the allocated treatment group, wherever possible, was reinforced by on-site training and newsletters.

### Recruitment and progress

The first participant was randomised into the trial in September 2009; recruitment was initially slow because of the regulatory difficulties in opening centres. By the end of the recruitment phase, 29 centres had been opened in the UK and one had been opened in Canada, but some of the UK sites were

subsequently closed by mergers and the creation of larger vascular centres. Recruitment closed in July 2013 after 613 eligible participants had been randomised, 316 to the endovascular strategy and 297 to open repair. Full details of the progress of the trial are given in *Appendix 1*.

### **Data verification, role of the computerised tomography core laboratory in the diagnosis of aneurysm rupture, symptomatic unruptured aneurysm or other cause of admission**

All consent forms were audited, and source data for a minimum of 15% of participants at each centre were verified. Admission CT scans were sent for analysis in the trial core laboratory (St George's Hospital, London) and were subject to expert review for the presence of rupture. Aneurysm rupture was defined in accordance with the protocol. Briefly, evidence on CT scans of the presence of blood or haematoma outside the aneurysm wall (abdominal aorta and/or common iliac artery) constituted a diagnosis of aneurysm rupture. If no CT scan was available, the diagnosis of rupture was made intraoperatively. In those participants who had not undergone CT or laparotomy, diagnosis was deduced from the underlying cause of death. All participants who were randomised in the UK were registered to obtain automatic reporting of the date and cause of death from the Office for National Statistics (via NHS Digital).

Participants who were admitted with symptoms attributable to an AAA but in whom there was no robust evidence of aortoiliac rupture (core laboratory diagnosis or laparotomy findings), and who underwent repair semielectively during the same admission, were categorised as having 'symptomatic, non-ruptured aneurysm'. Other participants had primary hospital discharge diagnoses that were unrelated to AAAs.

The core laboratory also measured detailed aneurysm morphology in accordance with the method previously described.<sup>26</sup> The repeatability of the key variables of maximum aortic diameter, neck diameter, neck length, neck conicality, proximal and distal neck angles and maximum common iliac diameter was assessed using Bland–Altman methods.<sup>27</sup>

### **Participant follow-up**

Participants were followed up closely through their primary hospital admission, and the following were reported: stays in intensive therapy units and other high-dependency units and readmissions to theatre with types of complications and adverse events. Participants also were followed up at 3, 12 and 36 months with questionnaires for QoL [EuroQoL-5 Dimensions (EQ-5D)] and use of health resources, in addition to clinical follow-up for aneurysm-related complications and reinterventions. Between the primary hospital discharge and 3 years, participants were followed up for aneurysm-related reinterventions both prospectively and by annual audit of hospital notes, with a final QoL questionnaire on trial exit at 36 months. Mortality reporting, including the cause, for all UK participants was from the Office for National Statistics (via NHS Digital) and was from local state sources for Canadian participants. All of the case report forms (CRFs) are provided at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/), accessed 16 November 2017. In addition, because > 90% of participants were recruited from England, Hospital Episode Statistics (HES) data were used to cross-check reinterventions and identify those taking place at non-trial centres for the 12- and 36-month analyses.

### **The IMPROVE trial approvals**

Ethics approval for the participation of patients in England and Wales was from the South Central Berkshire Research Ethics Committee (08/H0505/173), in Scotland from the Scotland A Research Ethics Committee 08/MRE00/90 and in Canada from the University of Western Ontario Health Sciences Research Ethics Board (17698). Approval for the use of routine NHS data for participants lost to follow-up in England and Wales was obtained from the National Information Governance Board [Ethics and Confidentiality Committee (ECC) 4-03 (f) 2012].

## Trial outcomes

The primary outcome measure was survival at 30 days after randomisation. The trial, comparing the groups as randomised, had 94% power to detect (as significant at 5%) a difference in 30-day mortality of 14% with 600 participants enrolled. This was based on estimated 30-day mortalities of 47% and 21% for participants receiving open repair and EVAR, respectively,<sup>4,14</sup> an estimate of 55% of participants being anatomically suitable for EVAR after CT and an estimate that 5% of both randomised groups would not have a proven diagnosis of ruptured AAA and no 30-day mortality.<sup>16</sup> Hence, the estimated 30-day mortality was 44.7% in the open repair group  $[(0.95 \times 47) + (0.05 \times 0)]$  and 30.4% in the endovascular strategy group  $[(0.55 \times 21) + (0.4 \times 47) + (0.05 \times 0)]$ .

Early secondary outcome measures included 24-hour mortality, in-hospital mortality, costs of primary admission, number of reinterventions, time of discharge and the place to which the participant was discharged from the trial hospital after the primary admission. Details of specialist care bed-days, organ support and reinterventions were recorded primarily to inform costs. In the first 30 days, reinterventions were categorised as rebleeding, limb ischaemia, mesenteric ischaemia, abdominal compartment syndrome or other, with details of others being provided as free text. Complications such as strokes or myocardial infarction were not recorded separately from the need for specialist stroke or coronary care unit bed-days.

The unit costs of the stents and consumables used for rupture repair were taken from manufacturers' list prices and published sources (see *Appendix 2, Table 28*). Salary costs for rupture repair were calculated by combining staffing levels reported from a survey of 10 IMPROVE trial centres (see *Appendix 2, Table 29*) with published staffing costs. The costs per critical care bed-day by Healthcare Resource Group were taken from the Payment by Results database.<sup>28</sup> Unit costs for outpatient visits and community service use were obtained from a recommended source for health and social care costs.<sup>29</sup>

In addition, the impact of aortic morphology on reinterventions and mortality has been assessed. To optimise generalisability, most of these listed outcomes have also been assessed in an individual patient data meta-analysis that was conducted across all three recent European trials (see *Individual patient data meta-analysis of three European ruptured aneurysm trials*).

Longer-term outcomes measures (at 1 and 3 years) took a health economic perspective, in addition to measuring mortality and reinterventions. QoL, using the EQ-5D, was reported at 3, 12 and 36 months after randomisation, and the costs of aneurysm-related care were evaluated to 3 years. This enabled cost-effectiveness evaluations at 1 and 3 years. The detailed methods for the health economic and other analyses are encompassed within their statistical analysis plans ([www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017) and are detailed in *Chapter 5*.

## Oversight of the trial

The Trial Steering Committee, chaired by Professor Ian Roberts (members listed in *Appendix 1*), was responsible for ensuring that adequate recruitment strategies were in place and that the ethics framework for conducting this emergency surgery trial was adhered to.

An independent Data Monitoring Committee, chaired by Professor Charles Warlow (members listed in *Appendix 1*), reviewed the data, with interim analyses carried out after the enrolment of 50, 200 and 400 participants, and agreed that it was safe to continue the trial. The statistician on this committee was the responsible statistician for the Dutch ruptured aneurysm trial (AJAX).<sup>19</sup>

The Trial Management Committee, chaired by Professor Janet T Powell (members listed in *Appendix 1*), took responsibility for the day-to-day running and timely reporting of the trial. The progress of the trial and recruitment information are detailed in *Appendix 1*.

## Patient and public involvement in the trial

Before the trial was designed, a group of seven patients was consulted. Their viewpoints were incorporated into the trial design (e.g. place of discharge from primary admission) and can be found in the published supplement to the 1-year outcomes paper.<sup>23</sup>

The Trial Steering Committee included Anne Cheetham, the wife of a patient who survived an open repair of a ruptured AAA after a stormy course. She also is active in the Circulation Foundation (a peripheral arterial disease charity).

At the end of the trial, a small group of patients and members of the public (associated with the Circulation Foundation) were consulted about their views on the seriousness and fear of reinterventions that may become necessary after the original aneurysm repair. Their view of the severity of reinterventions (detailed at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017) was different from that of clinicians. These views of the patients and members of the public have been incorporated into the 3-year analysis results, in which reinterventions are also reported according to the views about the most severe reinterventions. Further research on the development and use of metrics that are important to patients is suggested in *Chapter 9*.

A patient focus group (run by Professor Matt Bown in Leicester) and Anne Cheetham provided input for the plain English summary of the trial.

## Timelines for reporting of IMPROVE trial outcomes

The reporting of IMPROVE trial outcomes took place in three phases: (1) 30-day outcomes, (2) 1-year outcomes and (3) 3-year outcomes. The 3-year outcomes analysis was delayed by 4/5 months because of changes in application procedures at NHS Digital (the provider of both mortality reporting and HES data).

## Prespecified statistical analysis plans

For each analysis conducted, a prespecified analysis plan was prepared and approved by the Trial Management Committee and by the Data Monitoring and Ethics Committee for the main 30-day, 1- and 3-year analyses. The analysis plans were then placed on the trial websites ([www.improvetrial.org](http://www.improvetrial.org) and [www.imperial.ac.uk/medicine/improvetrial](http://www.imperial.ac.uk/medicine/improvetrial)). These analysis plans, together with full details of the different analyses, are provided at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/) (accessed 16 November 2017).

All analyses, except the causal analyses, were intention-to-treat analyses. The primary outcome measures assessed the proportion of participants surviving for 30 days in each of the randomised groups, following an intention-to-treat policy using a Pearson's chi-squared test without continuity correction. The primary outcome measure was then adjusted for age, sex and Hardman index using logistic regression (with the age and Hardman index considered as continuous), providing an adjusted odds ratio (OR) (Hardman index is a validated risk scoring system for ruptured aneurysms).<sup>30,31</sup> Missing baseline data were multiply imputed using chained equations to increase the precision of the estimates;<sup>32</sup> the variables used for imputation are provided at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/) (accessed 16 November 2017). Sensitivity analyses were undertaken: (1) including centre as a random effect in a generalised linear mixed model and (2) restricting analysis to participants with a confirmed diagnosis of rupture only. A complier average causal effects model was also fitted to obtain an unbiased estimate of the potential policy effect if participants had adhered to trial allocation.<sup>33</sup> Specifically, participants who were randomised to the endovascular strategy but who were subsequently found to be not anatomically suitable and thus were treated by open repair were considered to have adhered to trial allocation. Otherwise, reasons for crossover were classified as non-adherence (see [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/), accessed 16 November 2017, for further details). Prespecified subgroup analyses were conducted for all outcomes (age, sex and Hardman index).

Secondary end-point analyses were undertaken to assess time to in-hospital mortality and time to discharge using competing risks methodology, with in-hospital mortality and discharge as the two competing risks. Gray's non-parametric test was used to compare cumulative incidence curves.<sup>34</sup> Hospital costs were also evaluated, with full details of the methods provided at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/) (accessed 16 November 2017).

A causal analysis in the ruptured AAA population only was conducted to determine the effect of an endovascular strategy compared with open repair in this population if all participants had adhered to the IMPROVE trial policy design (i.e. a CT scan plus EVAR if found anatomically suitable compared with open repair). The causal analysis estimates the effect of the interventions in participants, as randomised, on the primary outcome (30-day mortality) in a complier population.<sup>33</sup> This provides an unbiased estimate of the true treatment effect, subject to certain modelling assumptions,<sup>35</sup> which would not be possible with a per-protocol analysis.

For the causal analyses, participants who were randomised to the endovascular strategy who were found to be not anatomically suitable and underwent open repair were classified as having adhered to randomisation. Failure to receive the allocated treatment for any other reason was classified as non-adherence. Participants who had no operation (died before repair) were excluded from the analysis under the assumption that their outcome would be the same no matter what group they were randomised to. Participants who had a converted operation (EVAR converted to open repair) in the group randomised to the endovascular strategy, and who were anatomically suitable, were considered to have adhered to randomisation. Participants who had a converted operation after randomisation to open repair were classified as non-adherent.

Subsequent analyses of mortality and reinterventions at 1 and 3 years followed a similar pattern but included analysis of AAA-related mortality, reporting of other causes of death and full health economic evaluations. The reinterventions at these later time points were categorised as arterial, laparotomy related or other and according to their severity as perceived by (1) clinicians and (2) patients and members of the public (details of the coding of 30-day reinterventions and later reinterventions are provided at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017).

The cost analysis took a UK NHS and Personal Social Services perspective<sup>36</sup> and included costs up to 1 or 3 years after randomisation, for all randomised participants. Resource use measures were taken from the IMPROVE trial CRFs for the initial hospital admission, readmissions and outpatient visits to the study hospitals that were related to ruptured AAAs. Other outpatient visits and community service use (visits to the family doctor and home nursing) were taken from responses to a health services questionnaire administered to surviving ruptured AAA participants at 3 and 12 months after randomisation. The specific resource use categories included were (1) medical devices and consumables for each intervention (see *Appendix 2, Table 28*), (2) length of hospital stay during the primary admission, including critical and specialist unit bed-days and extent of organ support, (3) all reinterventions during the primary admission, whether or not directly associated with the ruptured aneurysm (including time in the operating theatre or endovascular suite), and use of devices and consumables, (4) readmissions related to the ruptured aneurysm (a sensitivity analysis was undertaken including all readmissions) and (5) outpatient and community services whether their use was related to the ruptured aneurysm or other conditions. The unit costs of the stents and consumables used for rupture repair were taken from manufacturers' list prices and published sources (see *Appendix 2, Table 28*). Salary costs for rupture repair were calculated by combining staffing levels reported from a survey of 10 IMPROVE trial centres (see *Appendix 2, Table 29*) with published staffing costs.

Health-related QoL (HRQoL) was measured using a generic measure, the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), which requires patients to describe their health on five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension requires patients to state whether they have 'no problems' 'some problems' or 'severe problems'. A participant's described health at each time point was valued in accordance with health state preferences from the general population to calculate EQ-5D-3L utility scores, which are anchored on a scale from 0 (death) to 1 (perfect health).<sup>37</sup>



Quality-adjusted life-years (QALYs) were assessed at 3 months, 1 year and 3 years. For survivors at 3 months, QALYs were calculated using the EQ-5D-3L scores at 3 months, assuming a EQ-5D score of 0 at randomisation and a linear interpolation between randomisation and 3 months. This implies that, at day 30, the EQ-5D utility score is approximately one-third of that at 3 months. For decedents between randomisation and 3 months, we assumed zero QALYs. For those surviving up to 12 months, we assumed a linear interpolation, using the EQ-5D-3L scores at 3 months and 12 months. For decedents between 3 months and 12 months for which a EQ-5D-3L score at 3 months was available, a linear interpolation was applied between EQ-5D-3L at 3 months and the date of death, at which point a EQ-5D-3L score of 0 was applied. A similar approach was used for decedents between 1 and 3 years.

The mean differences in 1- or 3-year QALYs and costs [measured in Great British pounds (GBP) and converted into US dollars (USD)]<sup>38</sup> between the endovascular strategy and the open repair strategy were reported. The differences in mean costs and QALYs were plotted on the cost-effectiveness plane and were used to calculate incremental net benefits (INBs) by valuing the incremental (difference in mean) QALYs at recommended thresholds of willingness to pay for a QALY gain<sup>36</sup> and subtracting from this the incremental costs.

Cost-effectiveness results were also reported for the prespecified subgroups (according to age, sex and Hardman index). Missing data on baseline covariates (Hardman index), QoL and costs were addressed with multiple imputation, using the same variables as the clinical analyses<sup>32</sup> (full details at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017). Sensitivity analyses were undertaken to assess whether or not the cost-effectiveness results were robust to alternative assumptions (rationale and details in *Chapter 5*). Additional work concerning methods and assumptions for missing QoL data is discussed in *Chapter 8*.

Total costs at 1 year and 3 years were calculated by combining the resource use with unit costs at 2012 and 2016 prices, respectively (in GBP), and then converting them to USD.<sup>38</sup> This conversion rate was based on purchasing power parities, which avoided the impact of short-term currency fluctuations, and recognised the relative purchasing power of the USA compared with the UK in 2012 and 2016. In the base case, incremental costs were reported as unadjusted mean differences between randomised groups, together with 95% confidence intervals (CIs).

The differences in average costs and QALYs between the randomised groups were used to calculate the incremental net monetary benefits (INMBs). We valued the incremental QALYs according to threshold of willingness to pay for a QALY gain recommended by the National Institute for Health and Care Excellence (NICE) (between £20,000 and £30,000 per QALY),<sup>36</sup> and subtracted from this the incremental cost. INBs were reported overall, and for the same prespecified subgroups as for the clinical end points.

The uncertainty around the differences in average costs and QALYs between the randomised groups is illustrated in the cost-effectiveness plane. We estimated the incremental costs and QALYs with a seemingly unrelated regression model.<sup>39</sup> To express the uncertainty in the estimation of the incremental costs and QALYs, we used the estimates of the means, variances and the covariance from the regression model to generate 500 estimates of incremental costs and QALYs from the joint distribution of these end points, assuming asymptotic normality. We then plotted these incremental costs and QALYs in the cost-effectiveness plane. We also reported cost-effectiveness acceptability curves, by calculating the probability that, compared with open repair, the endovascular strategy is cost-effective at alternative levels of willingness to pay for a QALY gain. Sensitivity analyses were conducted, varying the base-case assumptions, including costs of the devices, use of additional theatre staff, for participants with a proven ruptured AAA only and including hospital readmissions for all causes taken from the Health Resources Questionnaire (available at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017).

The rationale for the sensitivity analyses and details of resource use, multiple imputation and handling of missing data are described in *Chapter 5*.

### *Individual patient data meta-analysis of three European ruptured aneurysm trials*

The three recent European trials<sup>20,40,41</sup> for the management of ruptured AAAs have published their methods and results. AJAX<sup>19</sup> included only participants in whom CT revealed both probable rupture and aortic anatomy suitable for endovascular repair using aorto-uni-iliac stent grafts and all participants had to be eligible for both open and endovascular repair. AJAX randomised 116 participants in three centres between 2004 and 2011, using sealed envelopes for randomisation to either open or endovascular repair. The ECAR trial<sup>22</sup> had a similar selection methodology and design but used the additional criterion for haemodynamic stability of a systolic blood pressure of > 80 mmHg and used both aorto-uni-iliac and bifurcated stent grafts. The ECAR trial randomised 107 participants, with treatment allocation by weekly rotation to either open or endovascular repair, in 14 centres between 2008 and 2012. In contrast, the IMPROVE trial randomised participants with an in-hospital clinical diagnosis of ruptured aneurysm, before CT, either to an endovascular strategy (with open repair if endovascular repair was not anatomically feasible) or to open repair. The IMPROVE trial randomised 613 participants in 30 centres between 2009 and 2013.

The three data sets were merged, based on the largest trial (IMPROVE), enabling estimation of Hardman index scores for all participants.

## Statistical analysis

The primary analyses considered mortality according to the groups, as randomised, within each trial, irrespective of the different trial designs. The timing of death was assessed from randomisation (for the IMPROVE trial) and from hospital admission (for the AJAX<sup>19</sup> and ECAR<sup>22</sup> trials). Logistic regression analysis was used to estimate the OR of both 30- and 90-day mortality for endovascular repair (or endovascular strategy) compared with open repair, adjusting for trial to obtain a one-stage fixed-effect pooled estimate. Further analysis was conducted by estimating the OR separately for each trial and then pooling using random-effects meta-analysis, estimating between-study heterogeneity using a method of moments.<sup>42</sup> The proportion of between-trial variability beyond that expected by chance was quantified using the  $I^2$  statistic.<sup>43</sup> Analyses were then adjusted for age, sex and Hardman index score.<sup>30,31</sup> Multiple imputation using chained equations was used to account for missing baseline covariates in adjusted analyses.<sup>32</sup>

Secondary analyses were conducted on a restricted subgroup of more homogeneous participants from the three trials. The restrictions imposed were (1) a confirmed diagnosis of rupture and (2) anatomical suitability for EVAR. EVAR suitability was an entry criterion for inclusion in both the AJAX<sup>19</sup> and ECAR<sup>22</sup> trials. For the IMPROVE trial, suitability for EVAR was defined as local CT assessment of suitability; if not assessed locally, a 'within liberal instructions for use' definition from a core laboratory CT analysis was used.

Kaplan–Meier survival plots and cumulative incidence of time to primary hospital discharge, by randomised group, were produced within each trial separately and were accompanied by a log-rank test. A Cox proportional hazards model was used to assess whether or not the randomised groups differed in terms of the cause-specific hazard of primary hospital discharge (competing in-hospital mortality notwithstanding).

The age, sex and Hardman index scores of the subgroups were assessed for differences in the effect of the endovascular and open strategies by including an interaction term between the subgroup and randomised group in a logistic regression model.

The reporting of reinterventions was very different across the three trials; all trials reported on the use of occlusion balloons and the incidence of the abdominal hypoperfusion syndromes (abdominal compartment syndrome and mesenteric and colonic ischaemia),<sup>44</sup> although the abdominal compartment syndrome data for AJAX were collected retrospectively. The largest trial, IMPROVE, did not report complications such as myocardial infarction, whereas complications were reported for both the AJAX and ECAR trials.



In addition, AAA diameter, aortic neck diameter, aortic neck length and proximal neck  $\alpha$  angulation (aortic morphology) were assessed within each trial for their effect on 30-day mortality. These analyses are not a comparison between randomised groups and, therefore, were adjusted for the following potential confounding factors: age, sex (the AJAX and IMPROVE trials), Hardman index, admission systolic blood pressure, mean arterial pressure, treatment commenced and randomised group (the IMPROVE trial only). Each of the other four morphological variables was analysed, both adjusted and unadjusted for the other three variables.

### *Development of a new risk score*

The purpose of this work was to develop a novel, point-of-care, risk score based on both physiological and imaging data that are immediately available in the emergency department to identify patients with ruptured AAAs in whom aneurysm repair or transfer to a specialist centre for repair is futile. The definition of futile is death within 48 hours of presentation, either with or without aneurysm repair.

The principal outcome measure is mortality within 48 hours of randomisation. The secondary outcome measure is death within 30 days of randomisation.

Participants from the IMPROVE trial were used to develop the score, excluding participants with a final diagnosis other than ruptured AAA (incidental or symptomatic AAA) but including participants with aortoiliac ruptures. All participants with ruptured AAA or aortoiliac rupture were considered in the risk score regardless of whether or not an operation was carried out. These criteria resulted in 536 participants, before the exclusion of those with missing risk factor data (e.g. CT results were not available).

External validation of the risk score will be conducted in participants from the AJAX<sup>19</sup> and ECAR<sup>22</sup> randomised controlled trials (RCTs), the wider Amsterdam cohort for AJAX, which included those unsuitable for randomisation in AJAX, and data from Stockholm. There also will be internal validation of derived risk scores using 10-fold cross-validation.

Full details of the statistical analysis are provided at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/) (accessed 16 November 2017).


Other risk scores for ruptured AAAs have been proposed. From the available information in the IMPROVE, AJAX and ECAR trials, it may be possible to calculate these other risk scores. We will compare the discrimination (c-statistic) of the published risk scores, calculated in the IMPROVE, AJAX and ECAR trials, with the derived risk score. This will initially be done using 48-hour mortality as the outcome measure. However, as the published risk scores were derived from longer-term (in-hospital or 30-day) mortality, we will also compare the discrimination of these risk scores against our derived risk score using 30-day mortality as the outcome measure.

## Chapter 3 Mortality and other 30-day outcomes in the IMPROVE trial and the other ruptured aneurysm trials

The first pilot randomised trial of endovascular repair compared with open repair of ruptured AAAs was conducted in Nottingham and randomised 32 unselected patients between September 2002 and December 2004.<sup>45</sup> The 30-day mortality was 53% in each group. This contrasted with results from observational studies, which indicated that the 30-day mortality following emergency EVAR for ruptured AAAs was much lower, at about 25%.<sup>46,47</sup> Since the time of this initial trial, experience with EVAR, devices and imaging have all improved. Moreover, observational studies continued to report similarly low 30-day mortality for EVAR and reported a 30-day mortality of closer to 50% for open repair.<sup>14,48</sup> Therefore, there was a clear need for larger multicentre randomised trials.

### Design of the recent randomised trials

The first of the later randomised trials (AJAX)<sup>19</sup> started in the Netherlands in 2004 and had a selective recruitment design. Participants with a suspected rupture underwent CT. Next, if rupture was observed and the aortic morphology was suitable for EVAR, relatively haemodynamically stable patients were approached for consent for randomisation (using sealed envelopes) to either EVAR or open repair. Just 116 out of a target of 120 participants were randomised between 2004 and 2011 at three centres. A French trial (ECAR)<sup>22</sup> started in 2008, with even more selective patient recruitment: only haemodynamically stable patients (systolic blood pressure of > 80 mmHg) with aortic morphology suitable for EVAR were included and the randomisation was based on a weekly rotation of treatment (EVAR one week, open repair the next). This trial recruited 107 participants at 14 centres between 2008 and 2012. The IMPROVE trial was much larger, with a total target recruitment of 600 unselected patients (all-comers), randomised at the point of in-hospital clinical diagnosis, before CT, to confirm either the diagnosis or morphological suitability for EVAR. This trial randomised 613 participants between 2009 and 2013. The different trial designs are shown in Figure 2.



**FIGURE 2** Comparison of designs for three European trials comparing endovascular and open repair for a ruptured AAA.

The first results of 30-day mortality came from the Dutch trial (AJAX) in August 2013,<sup>14,19</sup> after recruitment to the IMPROVE trial had closed on 21 July 2013. AJAX reported a low 30-day mortality for both randomised groups (21% for the EVAR group and 25% for the open repair group;  $p = 0.66$ ); however, this was a secondary outcome measure. The primary outcome measure was 30-day mortality and major complications, which also did not differ significantly between the randomised groups.<sup>19</sup>


## The IMPROVE trial

The 30-day outcomes for the IMPROVE trial were first presented at the Annual Scientific Meeting of the Vascular Society of Great Britain and Ireland at the end of November 2013, followed by publication by the IMPROVE trial investigators.<sup>21</sup> in January 2014. Between September 2009 and July 2013, 613 participants with an in-hospital diagnosis of ruptured AAA, made by a senior hospital clinician, were randomised either to EVAR (with the default of open repair when EVAR was not anatomically feasible;  $n = 316$ ) or to open repair ( $n = 297$ ). Randomisation, which was computer based, was carried out by an independent contractor with the assignation of participants in a 1 : 1 ratio using variable block sizes. These 613 participants constitute 48% of 1275 patients admitted at the trial hospitals with a diagnosis of ruptured AAA during the trial recruitment period. The recruitment rate and list of participating centres are shown in *Appendix 1* and at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/), accessed 16 November 2017, respectively. A Consolidated Standards of Reporting Trials (CONSORT) diagram and the baseline characteristics of the randomised participants are given in *Figure 3* and *Table 1*, respectively.

The diagnosis of ruptured aneurysm was confirmed either by CT or in surgery in 275 out of 316 participants (87%) in the endovascular strategy group and in 261 out of 297 participants (88%) in the open repair group. In the endovascular strategy group, 64% of participants (174/272) were considered suitable for EVAR after CT. A further eight participants (3%) in the endovascular strategy group and 14 participants (5%) in the open repair group had a repair of a symptomatic intact aneurysm in the same admission. The 55 participants (33 in the endovascular strategy group and 22 in the open repair group) with a final diagnosis unrelated to an AAA had a wide range of other primary diagnoses, varying from ruptured thoracic aortic aneurysm to urinary tract infection, but 45 of these participants (82%) had an asymptomatic AAA. One further participant had a thoracoabdominal aneurysm, and only 9 out of 613 participants (1.5%) did not have an aortic aneurysm.

The primary outcome measure was 30-day mortality. The overall 30-day mortality was 35.4% (112/316 participants) in the endovascular strategy group and 37.4% (111/297 participants) in the open repair group (OR 0.92, 95% CI 0.66 to 1.28;  $p = 0.62$ ). However, in each group, some participants died before aneurysm repair or breached the randomisation allocation. In the endovascular repair group, 28 participants who were morphologically suitable for EVAR (26 with rupture and 2 without rupture) received emergency open repair for operational reasons (e.g. staff or endovascular suite not available or not yet available when the patient was deteriorating). In the open repair group, 33 participants with a rupture had emergency EVAR, mainly because the anaesthetist deemed them unsuitable for general anaesthesia, and a further three participants had delayed elective repair with EVAR. The detailed results are presented in *Figure 3*. Overall, 548 out of 613 participants (89%) adhered to the trial protocol. Among 502 participants with a ruptured aneurysm who received repair, the 30-day mortality was 32% (84/259 participants) in the endovascular strategy group and 36% (87/242 participants) in the open repair group (OR 0.86, 95% CI 0.59 to 1.24).

Limited subgroup analyses (age, sex and Hardman index) were also conducted for the primary outcome measure (30-day mortality by randomised group). There were no clear differences between the randomised groups according to age (above or below 77 years) or Hardman index (0, 1 or  $\geq 2$ ). However, there was weak evidence that the endovascular strategy was more effective in women than in men ( $p = 0.02$ ). Among women, 30-day mortality was 37% (26/70 participants) in the endovascular strategy group and 57% (36/63 participants) in the open repair group, compared with 35% (86/246 participants) and 32% (75/234 participants), respectively, among men.



**FIGURE 3** A CONSORT diagram showing the flow of participants through the trial, with 30-day mortality for each group. Details of the post-randomisation exclusions ( $n = 10$ ) are given in *Appendix 1*.

**TABLE 1** Baseline characteristics of IMPROVE trial participants, by randomised group

Variable	Missing data (n)	Trial group	
		Endovascular strategy (N = 316)	Open repair (N = 297)
Age (years), mean (SD)	0	76.7 (7.4)	76.7 (7.8)
Male sex, n/N (%)	0	246/316 (78)	234/297 (79)
Admission blood pressure (mmHg), mean (SD)	12	N = 306	N = 295
Systolic		110.3 (32.9)	110.4 (31.2)
Diastolic		65.3 (21.4)	66.8 (22.5)
Admission haemoglobin (g/dl), mean (SD)	6	11.2 (2.5); N = 312	11.1 (2.3); N = 295
Admission creatinine (µmol/l), median (IQR)	13	117 (94–152); N = 312	115 (93–151); N = 288
Acute myocardial ischaemia ECG, n/N (%)	52	22/291 (8)	23/270 (8)
Loss of consciousness, n/N (%)	27	29/305 (10)	21/281 (7)
Hardman index score, <sup>a</sup> n (%)	74	N = 282	N = 257
0		93 (33)	69 (27)
1		130 (46)	126 (49)
2		46 (16)	48 (19)
3		11 (4)	12 (5)
4		2 (1)	2 (1)
5		0 (0)	0 (0)
CT carried out, n/N (%)	0	305/316 (97)	266/297 (90)
Maximum aortic diameter (mm), mean (SD)	86	84 (19); N = 263	81 (18); N = 264
Time from randomisation to theatre admission			
Ruptures (minutes), median (IQR)	6	47 (28–73)	37 (22–62)
Symptomatic aneurysms (hours), median (IQR)	2	3.6 (3.1–15.6)	3.0 (1.5–17.6)

ECG, electrocardiogram; IQR, interquartile range; SD, standard deviation.

a Scores 1 point each for age > 76 years, acute myocardial ischaemia on ECG, haemoglobin < 9.0 g/dl, creatinine > 190 µmol/l and loss of consciousness after admission.

The secondary outcome measures at 30 days included 24-hour mortality, in-hospital mortality (*Table 2*), number of reinterventions, time and place of discharge, and costs. The first three of these outcomes were similar between the randomised groups and are reported in full by Powell *et al.*<sup>21</sup> In the endovascular strategy group, nearly all of the patients discharged (94%) within 30 days were discharged home, compared with only 77% in the open repair group ( $p < 0.001$ ) (see *Table 2*). The mean resource use costs to 30 days was £13,433 [standard deviation (SD) £10,354] in the endovascular strategy group and £14,619 (SD £12,353) in the open repair group (mean difference –£1186, 95% CI –£2997 to £625) (see *Appendix 2, Table 30*).

The mean use of critical care was 4.5 bed-days (SD 5.9 bed-days) in the endovascular strategy group, compared with 6.3 bed-days (SD 7.7 bed-days) in the open repair group. Postoperatively, renal replacement therapy was used in 78 participants: 32 in the endovascular strategy group and 46 in the open repair group, but only one participant, in the open repair group, was discharged on dialysis. Specialist coronary care was used in 11 participants (total of 38 bed-days), nine in the endovascular strategy group and two in the open repair group (total of 4 bed-days) within 30 days of randomisation; there was no additional coronary care

**TABLE 2** Place of discharge of IMPROVE trial participants, by randomised group and in-hospital mortality

Discharge status	Trial group, n (%)	
	Endovascular strategy (N = 316)	Open repair (N = 297)
Discharged alive from trial hospital		
Yes	201 (64)	183 (62)
No	115 (36)	114 (38)
Place of discharge		
Home	189 (94)	141 (77)
Another hospital: routine bed	7 (3)	28 (15)
Another hospital: intensive care	0 (0)	1 (1)
Nursing home	0 (0)	3 (2)
Residential home	1 (1)	3 (2)
Sheltered accommodation	1 (1)	0 (0)
Other	3 (1)	7 (4)

**Note**

Reprinted with permission from the *British Medical Journal* 2014;**348**:f7661.<sup>21</sup> Copyright © 2014, British Medical Journal Publishing Group. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>.

between 30 and 90 days. A total of 28 participants in the endovascular strategy group and 47 participants in the open repair group were still in hospital 30 days after randomisation.

## Individual patient meta-analysis of the three recent European trials

By 2015, four European trials had reported results, and searching the published literature and clinical trial databases did not reveal any further trials. The ECAR trial<sup>22</sup> was presented to the European Society for Vascular Surgery in September 2014 and published results in 2015, with 30-day mortality rates (the primary outcome measure) similar to those reported in AJAX:<sup>19</sup> 19% for the EVAR trial group and 24% for the open repair group. Unfortunately, half of the data for the Nottingham trial<sup>16</sup> had been lost, but the other three trials agreed to pool their data for an individual patient meta-analysis.

The baseline descriptions of the participants in the three trials are compared in *Table 3*. The IMPROVE trial had recruited older patients, less haemodynamically stable patients (lower admission blood pressure) and a higher proportion of women than the other two trials. There were other important differences too, with the AJAX and ECAR trials using predominantly aorto-uni-iliac configurations of endografts so that the procedure could not be completed under local anaesthesia, and the ECAR trial aggressively monitoring for abdominal hypoperfusion syndromes postoperatively (abdominal compartment syndrome and colonic and mesenteric ischaemia).

Survival to 30 days by trial and by randomised group is shown in *Figure 4*. Additionally, the Kaplan–Meier curves for restricted IMPROVE trial participants who were morphologically suitable for endovascular repair (and more similar to the participants in the AJAX and ECAR trials) are shown in *Appendix 2, Figure 24*. Mortality was higher for both randomised groups in the IMPROVE trial than in either the AJAX or ECAR trials. However, restricting the IMPROVE trial population to those patients who were morphologically suitable for EVAR reduced the mortality in both groups. When the results from the three trials were pooled in a

**TABLE 3** Descriptive statistics for the three recent European ruptured AAA trials

Numbers, clinical details and baseline variables	Trial		
	AJAX (N = 116)	ECAR (N = 107)	IMPROVE (N = 613)
Randomised group, n (%)			
EVAR/endovascular strategy	57 (49.1)	56 (52.3)	316 (51.5)
Open repair	59 (50.9)	51 (47.7)	297 (48.5)
Ruptured AAA suitable for EVAR, <sup>a</sup> n (%)	N = 113	N = 104	N = 310
EVAR/endovascular strategy	57 (50.4)	54 (51.9)	168 (54.2)
Open repair	56 (49.6)	50 (48.1)	142 (45.8)
Procedure started, n (%)			
EVAR	57 (49.1)	56 (52.3)	192 (31.3)
Aorto-uni-iliac	49 (86)	43 (77)	39 (20)
Open repair	59 (50.9)	50 (46.7)	331 (54.0)
Tube	50 (88)	26 (54)	268 (81)
No aneurysm repair	0 (0)	1 (0.9)	90 (14.7)
Age (years), mean (SD)	74.2 (9.4)	74.4 (10.6)	76.7 (7.6)
Male sex, n (%)	99 (85)	97 (91)	480 (78)
Maximum AAA diameter (cm), mean (SD)	7.6 (1.6)	7.7 (2.0)	8.4 (1.9)
Aneurysm neck length (mm), median (IQR)	25 (19–34)	22 (16–32)	22 (10–34)
Admission blood pressure (mmHg), <sup>b</sup> mean (SD)	87 (27); N = 113	108 (30); N = 104	81 (24); N = 601
Hardman index score, n (%)	N = 61	N = 105	N = 539
0	26 (43)	41 (39.0)	164 (30.4)
1	19 (31)	44 (41.9)	254 (47.1)
2	12 (20)	11 (10.5)	94 (17.4)
≥ 3	4 (7)	9 (8.6)	27 (5.0)

IQR, interquartile range.


a Suitability for EVAR in the IMPROVE trial was defined by a local assessment of suitability, if available; otherwise, a core laboratory assessment of 'within liberal instructions for use' was used to define suitability. Suitability was not assessed in 46 ruptured AAAs in the IMPROVE trial and one in the ECAR trial.

b Mean arterial blood pressure recorded only in the ECAR trial; for AJAX and IMPROVE, it was approximated by two-thirds diastolic + one-third systolic blood pressure.


meta-analysis, there was no evidence of heterogeneity (pooled OR 0.88, 95% CI 0.66 to 1.18) (*Figure 5*). When only patients with a ruptured aneurysm who were eligible for both EVAR and open repair were included (AJAX,  $n = 113$ ; ECAR,  $n = 104$ ; and IMPROVE,  $n = 310$ ), the pooled OR reduced slightly (OR 0.80) but the CI widened (95% CI 0.54 to 1.17) (see *Figure 5*).

There was little evidence of treatment effect changing according to age or Hardman index. There were no early deaths among women who had EVAR in the ECAR trial. However, in the pooled analyses, women benefited more than men from an endovascular strategy (OR 0.47, 95% CI 0.23 to 0.97). For abdominal compartment syndrome, the highest rate was reported from the ECAR trial. Over the three trials, there was no significant difference in the incidence of abdominal compartment syndrome between the randomised groups, although the AJAX team is currently conducting per-protocol analyses. However, there was an indication that the incidence of colonic and mesenteric ischaemia was lower after EVAR or an endovascular strategy than after open repair (pooled ORs 0.57, 95% CI 0.32 to 1.01) (*Table 4*). A higher rate of





**FIGURE 4** The 30-day mortality by randomised group across the three recent European ruptured aneurysm trials.



**FIGURE 5** The 30-day mortality by randomised group. (a) Restricted to 527 participants with a ruptured AAA who were eligible for both EVAR and open repair; and (b) 834 participants (two ECAR trial participants lost to follow-up before 30 days).



**TABLE 4** Reported incidence of abdominal compartment syndrome and other mesenteric hypoperfusion syndromes, colonic ischaemia and mesenteric ischaemia, by randomised group across three randomised trials

Trial	Trial group, n/N (%)	
	EVAR/endovascular strategy	Open repair
AJAX		
ACS	5/57 (9)	2/59 (3)
CMI	2/57 (4)	5/59 (8)
ECAR		
ACS	8/56 (14)	1/51 (2)
CMI	4/56 (7)	8/51 (16)
IMPROVE <sup>a</sup>		
ACS	14/259 (5.4)	13/243 (5.3)
CMI	14/259 (5.4)	19/243 (7.8)

ACS, abdominal compartment syndrome; CMI, chronic mesenteric ischaemia.

a The denominator is the number of ruptured aneurysms repaired.

ischaemic colitis after open repair than after endovascular repair has recently been reported in the analysis of a large US database.<sup>49</sup>

The three trials were set in different health-care systems, leading to differences in discharge policies, including the use of 'step-down' care. For instance, many of the French ECAR trial participants were discharged to other facilities for convalescent care, whereas more participants in the IMPROVE trial were discharged directly to home. Over the three trials, for those participants discharged alive from the main trial hospital, the primary hospital stay was shorter for participants in the EVAR or endovascular strategy groups [pooled hazard ratio (HR) for discharge 1.24, 95% CI 1.04 to 1.47] (see *Appendix 2, Figure 22*).

The individual patient data meta-analyses have been reported with 90-day mortality<sup>50</sup> as the primary outcome measure;<sup>51</sup> again, there was no difference in mortality between the randomised groups, but EVAR appeared to be more effective in women than in men.

## Discussion

The best evidence comes from the synthesis of evidence from randomised trials, and 30-day mortality is the standard surgical outcome measure. This best evidence, from the 836 participants from the three recent trials, shows that there is no significant difference in 30-day mortality between EVAR or an endovascular strategy and open repair (pooled OR 0.88, 95% CI 0.66 to 1.18), with no evidence of heterogeneity. The absolute differences between the trials, lowest mortality in the ECAR trial and highest mortality in the IMPROVE trial, probably relate to the selection criteria for participants in the three trials, AJAX and ECAR being highly selective and IMPROVE being unselective and 'real world'. The influence of some of these selection criteria on 30-day mortality is explored and discussed in *Chapter 4*. The flexibility of individual patient meta-analysis also allowed only specific participant subsets to be included in the analysis. All trials included some participants in whom rupture was not confirmed, at laparotomy in the AJAX and ECAR trial and either at CT scan or at laparotomy in the IMPROVE trials. At 30 days, there was no evidence that EVAR offered a survival advantage in participants with a confirmed rupture who were eligible for both endovascular and open repair, although the pooled OR had reduced to 0.80.

One of the surprising findings from the IMPROVE trial was that there was weak evidence that an endovascular strategy was more effective in women than in men, partly attributable to the very high mortality after open repair in women. Despite the scant number of women in the other two trials, this finding was maintained on meta-analysis. This could suggest that EVAR should be a more common treatment option for women, although further research is needed. There was no clear effect of age.

These main findings from the trials have not been universally welcomed. The AJAX and ECAR trials have been dismissed as being too small and criticised for their use of aorto-uni-iliac endografts; certainly both trials took a long time to recruit not very many patients. The IMPROVE trial was more 'real world' but has been criticised for including participants who did not have a ruptured aneurysm or who died before repair could be accomplished. This serves to highlight the difference in time taken to start definitive repair with either EVAR or open repair. In each trial, the time taken to bring a participant to endovascular repair was significantly longer than for a participant to have open repair started; this difference was 0.48 hours, 1.6 hours and 0.16 hours for the AJAX, ECAR and IMPROVE trials, respectively. There is weak evidence showing that time to treatment influences survival adversely.<sup>52,53</sup> This might have been a contributor to mortality in the EVAR groups of the AJAX and ECAR trials but, for the IMPROVE trial, the time difference was much shorter. Misdiagnosis might also contribute to the mortality rate in the EVAR group because diagnosis, even after CT, can be in doubt.<sup>27</sup> In both the AJAX and IMPROVE trials, other bleeding diagnoses were shown to be the cause of admission in a few participants at laparotomy, whereas, at endovascular repair, such diagnoses would have been missed. Since the inception of the trials and since publication of the trial results, there have been several observational studies to show how team training and protocols can enhance performance and reduce mortality.<sup>54,55</sup> This could include improved reading of CT scans and a reduction in the time to start EVAR. Team training could also limit misjudgement about attempting EVAR because, in the randomised trials, conversion to open repair was associated with 100% mortality. However, part of the reported reduction in mortality from team training might also have been achieved by different selection of patients for repair; few other studies report the number of untreated patients.

The appropriate time to subject new technologies to a randomised trial is controversial. The IDEAL (Idea, Development, Exploration, Assessment and Long-term follow-up) recommendations<sup>56</sup> suggest that a trial should be considered when an intervention is sufficiently well evolved to warrant evaluation, but without the expectation that the intervention will continue to develop. Before the start of the IMPROVE trial, the uptake of EVAR for ruptured aneurysms was low and patchy and NICE recommended emergency EVAR for evaluation purposes only.<sup>57</sup> Therefore, the IMPROVE trial might have started when experience and team training for emergency EVAR was rather limited in some centres. However, with its widespread coverage of experienced EVAR centres that participated across the UK, the trial has acted as stimulus to evaluate the new technology. Data taken from HES for 2014/15 show that, in England, 36.4% of emergency aneurysm repairs in men and 31.7% in women were conducted using EVAR (Professor Jonathon Michaels, University of Sheffield, 2016, personal communication).

Other criticisms of the IMPROVE trial include the fact that we did not highlight the relatively low mortality in the participants who actually received EVAR<sup>58</sup> and that, partly because of the improvements in intensive care medicine, there may be many 'long-stayers' and, therefore, 90-day outcome measures are more relevant than 30-day outcome measures.<sup>59</sup> Even after 90 days, there was no difference in mortality between the randomised groups in any of the three trials considered.<sup>51</sup> Surprisingly, few sources in the literature have highlighted another important outcome measure for patients: time to discharge and place of discharge. Regarding this outcome, there is a clear benefit from the EVAR/endovascular strategy, with times to discharge being much shorter than after open repair, which was observed in all three trials. These trials were set in different health-care systems and only the IMPROVE trial specifically reported discharge to home, which was much more common after the endovascular strategy (94%) than after open repair (77%).

## Summary

Neither IMPROVE, the largest of the three recent trials, nor pooled data from the three trials identified that an endovascular strategy or EVAR led to lower 30-day mortality. At the time of rupture, the main clinical concern is to stop the bleeding and it is recognised that the initial repair, either endovascular or open, may need to be supported by further reinterventions beyond 30 days. For these reasons, longer-term follow-up is needed for all principal outcome measures, as well as patient QoL and cost-effectiveness, which were not assessed at 30 days, and to advise whether or not the benefits of an endovascular strategy for subgroups or secondary outcomes, observed in IMPROVE and the other trials, are maintained in the longer term.

## Chapter 4 Factors other than the type of repair that influence 30-day survival of patients with a ruptured abdominal aortic aneurysm

The type of aneurysm repair, endovascular or open surgery, is not the only factor that influences the outcome for patients with a ruptured AAA. First, the patient may present at the emergency department of a hospital that does not offer emergency vascular surgery and a decision will be made as to whether or not the patient should be transferred to a specialist vascular centre. Then, the time taken for patients to be transferred to a vascular centre could be influential.<sup>53,60</sup> Next, there is evidence that operative mortality after rupture is lower in the larger-volume vascular centres<sup>10</sup> and that, at least in England, operative mortality for all types of emergency surgery is lower if patients present within working hours.<sup>61</sup> Even larger-volume centres cannot usually offer sufficiently sized prospective case series in which to investigate other hospital, patient and clinical factors that may be associated with better or worse patient outcomes. To date, the largest patient series focused on endovascular repair reported on 473 patients who were treated between 1998 and 2011 from centres in two countries.<sup>10</sup> The IMPROVE trial recruited 613 eligible patients with a clinical diagnosis of abdominal aortic rupture between late 2009 and the summer of 2013. Some 536 participants had a confirmed aneurysm rupture, together with 22 urgent symptomatic aneurysms, making this the largest contemporary prospective cohort in which to investigate both the factors used for primary adjustment of 30-day mortality results (age, sex, Hardman index) and the role of factors, such as hospital presentation, time to surgery, fluid replacement therapy, aortic morphology and type of anaesthesia, on the outcomes of emergency surgery. As expected, Hardman index score was highly predictive of 30-day mortality, but mortality also increased with age; for each 5-year increase in age, the OR was 1.37 (95% CI 1.21 to 1.56) (*Table 5*).

### Transfer guidelines

At the beginning of the IMPROVE trial, we conducted a survey of the participating centres about the type of patient with a ruptured AAA who would accept for transfer from another hospital that did not offer emergency vascular surgery. It was clear that there was a wide disparity of opinion about suitable patients for transfer. This stimulated a Delphi consensus approach, working with the vascular surgeons, emergency

**TABLE 5** Adjusted effect of main variables (age, sex, Hardman index and randomised group) on 30-day mortality in 558 participants (complete-case analysis)

Variable	OR	95% CI	p-value (z-test)
Age (per 5-year increase) <sup>a</sup>	1.20	1.04 to 1.38	0.015
Sex			
Female	1.00	0.45 to 1.14	0.162
Male	0.72		
Hardman index score (per 1-unit increase)	1.62	1.26 to 2.08	< 0.001
Randomised group			
Open repair	1.00	0.62 to 1.28	0.535
Endovascular strategy	0.89		

<sup>a</sup> Not full effect of age because of dichotomised age being included in Hardman index. OR of age (per 5-year increase) excluding Hardman index from adjustment list is 1.37 (95% CI 1.21 to 1.56;  $p < 0.001$ ).

medicine physicians and anaesthetists from the IMPROVE trial centres, as well as emergency medicine physicians and senior trainees across the NHS Wessex Clinical Strategic Network. Eventually, this generated best practice guidelines,<sup>24</sup> endorsed by the Royal College of Emergency Medicine, the Vascular Society of Great Britain and Ireland and the Royal College of Radiologists.<sup>62</sup> These guidelines emphasise that there is no upper age limit for transferring patients and that all patients aged < 85 years, alert or with fluctuating consciousness, with moderate or minimal systemic disease and who need no or some help with daily living should be transferred, whereas those with cardiac arrest in current episode should not. Speed is accepted as important, and specialty trainees should be allowed to arrange transfer (target of  $\leq 20$  minutes of clinical diagnosis) if consultants are not on-site. CT confirmation of diagnosis is not necessary before transfer (although ultrasound assessment is desirable) and transfers should not be delayed by waiting for specific tests. A systolic blood pressure of  $\geq 70$  mmHg is sufficient for transfer without the need for intravenous fluids, unless deterioration occurs, in which case any fluids should be administered in small boluses only.

### Use of the IMPROVE trial as a large observational series of patients with abdominal aortic aneurysm rupture

Before the IMPROVE trial had closed to randomisation, the possibility of using the patient series to investigate a number of hypotheses relating to other factors that might influence 30-day survival had been discussed and analysis plans had been formulated to address the following hypotheses:

1. Thirty-day mortality is lower in patients randomised during routine working hours than at other times.
2. Patients transferred from other hospitals to trial centres have lower Hardman index scores and better outcomes than those arriving primarily at the trial centre.
3. Lowest blood pressure is not associated with 30-day survival because overadministration of fluid and/or blood products is associated with higher mortality.
4. General anaesthesia for endovascular repair is associated with higher operative mortality than local anaesthesia.
5. Aortic morphology, particularly increasing aneurysm diameter and hostile aneurysm necks, is associated with high 30-day mortality.

All of these analyses focused on the 558 participants who had a confirmed diagnosis of either ruptured AAA or acute symptomatic AAA.

#### Time of presentation

Those participants who were randomised out of hours had higher 30-day mortality (144/362) than those randomised within routine working hours (65/196) (primary adjusted OR 1.47, 95% CI 1.00 to 2.17;  $p = 0.048$ ).<sup>63</sup> However, there was little evidence that the efficacy of the endovascular strategy compared with open repair in those participants who were randomised out of hours was different from that in those randomised during routine working hours (test of interaction  $p = 0.100$ ). This suggestion that mortality is higher among patients who are admitted out of hours is supported by data from the National Inpatient Sample in the USA. Among 5800 ruptured AAA participants, the in-hospital mortality was significantly higher among those participants admitted at weekends than among those admitted during the week (OR 1.32, 95% CI 1.13 to 1.55;  $p = 0.0004$ ), and only 77% of those admitted at weekends underwent same-day repair, compared with 80% admitted during the week ( $p = 0.004$ ).<sup>52</sup> Given the large sample size, Groves *et al.*<sup>52</sup> tried to identify factors contributing to the increased (32% higher) mortality at the weekend. It was not related to differential use of EVAR but, at weekends, participants received blood transfusion more often than during the week. Higher mortality among patients admitted at weekends may be a widespread phenomenon – it also has been reported in Italy<sup>64</sup> and in Canada,<sup>65</sup> where in-hospital mortality was 42% at weekends compared with 36% during the week – and might be attributable to the lower availability of specialised teams for treating patients or to staffing levels more generally.

### **Patient transfers: primary presentation compared with secondary presentation**

The characteristics of participants with direct and secondary presentation to trial centres, including Hardman index scores, were similar, although a higher proportion of secondary presentation patients (221/335, 70%) were randomised out of hours. After adjustment for this, there was no difference in the 30-day mortality of those participants who were admitted directly to the trial centre and those (233 out of 335) transferred from other hospitals (adjusted OR 0.76, 95% CI 0.52 to 1.12). There are several potential explanations for this result, including the possibility that only lower-risk patients were transferred or that the highest-risk patients died during transfer. One recent study from the USA has suggested that 17% of patients die during transfer.<sup>60</sup>

### **Preoperative variables: fluid administration and blood pressure**

There was no evidence from IMPROVE trial participants that the volume of fluids administered before arrival in the operating theatre had a significant effect on postoperative mortality in a multivariable model. However, the volume of fluids given was recorded in only 302 participants. In contrast, there was a strong inverse association between the lowest in-hospital preoperative measured systolic blood pressure and mortality, with no significant association between this blood pressure measurement and the fluid volume administered. The association between the lowest systolic blood pressure and 30-day mortality showed no evidence of non-linearity [adjusted OR per 10-mmHg increase in blood pressure of 0.88 (95% CI 0.82 to 0.94)] (see *Appendix 2, Figure 23*). The 30-day mortality among participants whose blood pressure was above and below the threshold value of 70 mmHg was 34% and 51%, respectively.


### **General anaesthesia compared with local anaesthesia**

Overall, among participants undergoing EVAR ( $n = 186$ ), the 30-day mortality associated with procedures conducted under local anaesthesia only appeared to be substantially lower. After adjustment for age, sex, Hardman index, lowest systolic blood pressure and randomised group, local anaesthesia was associated with a fourfold reduction in 30-day mortality (adjusted OR 0.27, 95% CI 0.10 to 0.70;  $p = 0.007$ ). Local anaesthesia was more commonly used with bifurcated graft configurations whereas general anaesthesia was more commonly used with aorto-uni-iliac configurations because of the requirement for a femoro-femoral crossover graft, which causes considerable ischaemic leg pain that cannot be tolerated under local anaesthesia. Even after adjustment for graft configuration, the benefits of local anaesthesia remained highly significant. By 2016, there was increasing recognition that endovascular repair of ruptured AAA should be conducted under local anaesthesia whenever possible.<sup>63,66,67</sup>

### **Aortic morphology and the hostile aneurysm neck**

Nearly all patients presenting with a clinical diagnosis of ruptured AAA undergo CT, so that rupture can be confirmed and aortic morphology can be assessed rapidly to determine whether or not the patient is a suitable candidate for EVAR. One liberal definition of suitability for endovascular repair that has been used by laboratories for centralised assessment of CT scans includes an aneurysm neck length of  $\geq 10$  mm, a neck diameter of  $< 32$  mm and a neck angle of  $< 60^\circ$ .<sup>68</sup> A retrospective Swiss study<sup>69</sup> found that the 30-day mortality for open repair among patients whose aneurysm falls outside this definition was eight to nine times higher than in those whose aneurysm complied with this definition, whereas a Dutch study<sup>70</sup> found no difference. Others have suggested that mortality following rupture in patients with very large aneurysms is worse than mortality in patients with smaller aneurysms,<sup>71</sup> but good-quality data to support such suggestions are scant.

The IMPROVE trial core laboratory held good-quality CT scans for 458 participants with confirmed AAA rupture. First, working to a predefined analysis plan, the main morphological features (*Figure 6*)<sup>72</sup> were compared in participants in whom treatment was initiated with either EVAR or open repair (*Table 6*). It is immediately evident that the main difference between the EVAR participants and the open repair participants is in the aneurysm neck length. Overall, if the aortic morphology was within the liberal instructions for use (IFU) defined in the previous paragraph, 30-day mortality was marginally lower than for participants with aortic morphology outside the liberal IFU (adjusted OR 0.64, 95% CI 0.41 to 1.01;  $p = 0.054$ ), with the association being stronger for those in whom open repair had started. There was a stronger and linear



**FIGURE 6** Primary morphological variables for analysis.

**TABLE 6** Baseline morphological criteria according to treatment started for 458 participants with rupture and CT scans assessed in the core laboratory

Morphological criteria	N	Trial commenced, mean (SD)		p-value <sup>a</sup>	Total, mean (SD) (N = 458)
		EVAR commenced (N = 177)	Open repair (N = 281)		
Within liberal IFU	389	108 (71.5)	119 (50.0)	< 0.001	227 (58.4)
Maximum aneurysm diameter (mm)	427	85.6 (18.2)	86.3 (17.0)	0.59	86.0 (17.4)
Aortic neck diameter at distal renal artery (mm)	374	25.1 (3.8)	25.9 (4.7)	0.21	25.6 (4.4)
Neck length (mm)	409	29.2 (14.8)	19.5 (15.8)	< 0.001	23.3 (16.1)
Conicality (% change per 1-mm length)	361	0.46 (0.89)	0.93 (1.99)	0.030	0.73 (1.63)
Proximal neck angle (degrees)	406	31.0 (19.0)	33.9 (20.9)	0.17	32.7 (20.2)
Maximum common iliac diameter (mm)	404	21.5 (8.1)	20.6 (9.3)	0.040	21.0 (8.8)


IFU, instructions for use.

<sup>a</sup> Wilcoxon rank-sum test for continuous variables and Pearson  $\chi^2$  test for binary variables.

inverse association of 30-day mortality with neck length (adjusted OR 0.72, 95% CI 0.57 to 0.92), again with the association being stronger for those in whom open repair had started; both ORs were adjusted for age, sex, Hardman index, lowest recorded systolic blood pressure and randomised group. The relationship between aneurysm neck length and mortality is shown in *Figure 7*, with data on neck length category and treatment started given in *Table 7*.

These results suggest that a single morphological parameter, aneurysm neck length, appears to have a significant influence on operative mortality following surgery for a ruptured AAA, independent of known confounders. As the aneurysm neck shortens, conventional EVAR either becomes impossible or, if attempted, carries a very high mortality rate. This relationship has also been suggested to hold for open repair.<sup>69</sup> We also observed a strong relationship between short aneurysm neck length and high mortality after open repair, which explains why mortality after open repair remains high; many of these patients have juxtarenal aneurysms. Open juxtarenal aneurysm repair requires cross-clamping of the aorta above





**FIGURE 7** Association between neck length and proximal aortic neck length. Univariate effect of quintiles of neck length on 30-day mortality (complete case analysis with 409 participants), after adjustment for age, sex, Hardman index, lowest recorded systolic blood pressure, randomised group and treatment commenced.

**TABLE 7** The 30-day mortality by categories of neck length according to treatment started for rupture (complete case analysis with 409 participants)

Treatment commenced	Neck length (mm), % (n/N)					Total, % (n/N)
	0-4	5-9	10-14	15-29	≥ 30	
Overall	50 (30/60)	49 (17/35)	43 (17/40)	29 (40/139)	24 (33/135)	34 (137/409)
EVAR	33 (2/6)	63 (5/8)	20 (2/10)	27 (18/66)	24 (17/71)	27 (44/161)
Open repair	52 (28/54)	44 (12/27)	50 (15/30)	30 (22/73)	25 (16/64)	38 (93/248)

the renal arteries, with inevitable compromise of the visceral circulation, especially in shocked patients. In contrast, for longer aneurysm necks ( $\geq 18$  mm when infrarenal aortic clamps for open repair can readily be deployed), the operative mortality rates for open repair and EVAR are closely similar ( $\approx 25\%$ ). Perhaps surprisingly, we did not identify any association between maximum aortic diameter (or any other morphological variable assessed) and mortality following repair of a ruptured AAA. Our findings may also help to explain why population-level observational studies and meta-analyses of observational studies report that, for ruptured aneurysms, operative mortality for EVAR is about half of that for open repair (the patients with long aneurysm necks have EVAR and those with short aneurysm necks have open repair), as well as why the mortality following the repair of a ruptured AAA is much higher in women than in men (in women, the AAA has a much shorter proximal neck).

These findings of the association between aneurysm neck length and mortality need to be verified in an independent cohort, but there are few large unselective cohorts available with detailed morphology of both endovascular and open repairs. However, we have shown, in an individual patient data meta-analysis, that the association for open repair was also observed for patients randomised in the AJAX<sup>19</sup> and ECAR<sup>22</sup> trials (in which all participants were morphologically eligible for EVAR).<sup>51</sup> There is support for such findings from Baderkhan *et al.*,<sup>73</sup> who reported, based on 112 participants undergoing EVAR, that both the number of reinterventions and 3-year mortality were significantly higher for those repaired within the IFU than for those repaired outside the IFU. However, others may hold different opinions: van Beek *et al.*<sup>70</sup> studied 279 consecutive participants undergoing open repair and concluded that participants with 'hostile' and 'friendly' aortic necks had similar 30-day mortality.<sup>70</sup>



For our work on risk scoring (see *Chapter 8*), we are using data from 192 unselected patients in the Stockholm area,<sup>74</sup> and the association will be tested in this cohort in the future. This future work will add depth to the current debate regarding whether or not aortic neck pathology influences survival following repair of ruptured aneurysms.

## Summary

To ensure that patients across the UK who present with a clinical diagnosis of ruptured AAA have similar access to transfer to specialist vascular centres, multidisciplinary best practice clinical guidelines for the transfer of patients with a clinical diagnosis of ruptured AAA have been developed. Using the participants from the IMPROVE trial as an observational cohort of participants with ruptured AAAs, we have been able to identify several important factors, other than the type of aneurysm repair (endovascular or open), that influence the outcome of this deadly disorder. Some of these findings suggest ways to improve the outcomes of patients with ruptured AAAs, particularly through the use of local anaesthesia for emergency EVAR. Other findings, such as the higher mortality for participants admitted out of hours or at weekends, are observed throughout surgery and have been noted in other large series. The guidelines for hypotensive haemostasis<sup>75–77</sup> have been developed in trauma patients aged < 55 years; in a much older population, we have shown the adverse effect of blood pressures of < 70 mmHg on mortality and this is just one piece of evidence that contributes to the debate about the definitions of hypotensive haemostasis in the elderly population.<sup>75–78</sup> The inverse association between proximal aneurysm neck length and 30-day mortality is probably crucial to understanding why observational series always report a much more favourable outcome for emergency EVAR than for emergency open repair; these observational series do not compare like with like, as patients with long aneurysm necks receive EVAR whereas those with short and challenging aortic necks receive open repair.

## Chapter 5 One-year outcomes, survival, reinterventions and health economics

Some of the material in this chapter has been reproduced in part from published work.<sup>23</sup> © The Authors 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

### Overview

A ruptured AAA is an acute event and the success of aneurysm repair is assessed predominantly by 30-day mortality. Although there are many reports of 30-day mortality (see *Chapter 3*), there are far fewer reports of outcomes at  $\geq 1$  year. The largest series reporting on the comparative effectiveness of endovascular repair and open repair in the longer term comes from the Medicare data set in the USA.<sup>47</sup> In propensity-matched cohorts, Edwards *et al.*<sup>47</sup> observed a relative survival advantage at 1 year for patients of all ages who had undergone EVAR rather than open repair, and this advantage persisted for 4 years, before being dissipated. Rather similar, more recent, results have come from the Vascular Study Group of New England.<sup>79</sup> Such studies, from large registries, focus on mortality and reinterventions only and provide no data concerning patient QoL, costs or cost-effectiveness. All previous studies of QoL come from the period when only open surgery was used for repair and use data from repairs that were conducted before 2000. There are a few reports of the relative cost-effectiveness of endovascular repair compared with open repair for ruptured aneurysms. One report comes from AJAX,<sup>80</sup> in which cost-effectiveness was reported as incremental cost-effectiveness per death prevented to 6 months. They found that, at 6 months, EVAR was not cost-effective. Another report, with the opposite conclusion, comes from a retrospective analysis of participants at a single UK centre but without QoL having been measured.<sup>81</sup> The French randomised trial, ECAR,<sup>22</sup> did not attempt to assess cost-effectiveness. Therefore, the IMPROVE trial<sup>23</sup> is the first study to assess the full cost-effectiveness of an endovascular strategy compared with open repair for ruptured aneurysms.

### Additional methods for cost-effectiveness analyses: categories of resource use, handling of missing data and rationale for assumptions for the base-case and sensitivity analyses

The specific resource use categories included in the cost-effectiveness analysis were (1) medical devices and consumables for each intervention (see *Appendix 2, Table 28*); (2) length of hospital stay during the primary admission, including critical and specialist unit bed-days and extent of organ support; (3) all reinterventions during the primary admission, whether or not directly associated with the ruptured aneurysm, including time in the operating theatre or endovascular suite, devices and consumables; (4) readmissions related to the ruptured aneurysm and a sensitivity analysis including all readmissions; and (5) outpatient and community service costs whether related to the ruptured aneurysm or other conditions.

Missing data on baseline covariates, resource use and QoL variables were handled with multiple imputation using chained equations. Under this approach, each variable was imputed, conditional on fully observed baseline variables, such as age and sex, and all other imputed variables, with the same variables being used for the clinical and health economic analyses. All the variables considered for multiple imputation and, for each variable, the number of missing values and the imputation model chosen are reported in *Appendix 2, Table 31*.

The major incomplete resource use components, such as time in the operating theatre, length of stay in critical care or on routine wards (within either primary admission or readmission) and the use of community care, were addressed with multiple imputation. For those participants with ruptured AAA for whom aneurysm repair was commenced, missing resource use components were imputed from those participants with ruptured AAA with observed resource use data. Participants who did not have a ruptured AAA, and had no information recorded on being in critical care, were assumed to stay on a routine ward for their entire hospital stay.

In the case of participants with a proven ruptured AAA who failed to return the QoL questionnaire that was administered at 3 or 12 months, their EQ-5D scores were imputed from those of other ruptured AAA survivors. For example, of the participants with ruptured AAA for whom repair had commenced and who were eligible for the 3-month follow-up, 66 did not complete the EQ-5D questionnaire. For these 66 participants with missing EQ-5D scores at 3 months, EQ-5D scores were imputed using EQ-5D data from those 252 participants with ruptured AAA who fully completed the EQ-5D questionnaire at 3 months (see *Appendix 2, Table 32*). Hence, these imputations did not use information from those participants who had died prior to either time point (who were assigned a EQ-5D score of 0), participants with a ruptured AAA in whom repair had not commenced or participants who had a symptomatic AAA. In the case of participants who were alive but otherwise ineligible for follow-up, we assumed that the EQ-5D score at either time point was the average of the EQ-5D scores at baseline for participants with ruptured AAA presenting for elective repair,<sup>41</sup> in that their EQ-5D scores were 0.75, 0.75 and 0.74 at baseline (preoperatively) and at 3 and 12 months postoperatively, respectively.

The main assumptions made in the base-case scenario, and how each was relaxed in sensitivity analyses, are shown in *Appendix 2, Figure 26*. The results of the sensitivity analysis were reported as the mean INB with corresponding 95% CIs. These assumptions, which were relaxed in the sensitivity analyses, included:

1. Covariate adjustment. The base case reported unadjusted mean differences of both incremental costs and QALYs, assuming randomisation had ensured that there were no imbalances in key prognostic factors such as age, sex and Hardman index. In the sensitivity analysis, we adjusted for any chance imbalances in age, sex and Hardman index using seemingly unrelated regression.
2. Distributional assumptions on costs and QALYs. The base case assumed that costs and QALYs were normally distributed when reporting the 95% CIs around incremental costs and QALYs. In sensitivity analyses, we assessed the robustness of the cost-effectiveness results to alternative distributional assumptions about both outcomes. The sensitivity analysis considered a gamma distribution for costs as they had a right-skewed distribution. For QALYs, the sensitivity analysis also considered a gamma distribution because a large proportion of decedents had 0 QALYs and the remainder of the distribution was, again, right-skewed.
3. Staffing levels in the operating theatre. In the base case, we assumed the minimum number of staff required in the operating theatre to undertake either type of repair. In sensitivity analyses, we allow for additional staff used in some IMPROVE trial centres according to the results of the staffing survey.
4. Prices of devices for the endovascular procedure (stent grafts). In the base case, unit costs for the devices and consumables of endovascular intervention were taken from manufacturing list prices, assuming all hospitals would pay the same for these items, irrespective of the number of cases. In sensitivity analysis, we considered a cost per case for the device of £4000–10,000, which may reflect, for example, differential prices according to the number of cases, because the pricing of endovascular stent grafts varied remarkably across different English hospitals because of different discounts.
5. Participants without proven rupture. For participants without a proven ruptured AAA, resource use beyond the primary admission and QoL data were not collected because postoperative participant consent was not required. In the base case, assumptions were made about EQ-5D-3L score based on participants from an elective surgery trial; participants who did not have an aneurysm repair were assumed to stay on a routine hospital ward for the primary admission and subsequently assumed to have no reinterventions or readmissions and one outpatient visit. To assess whether or not the overall cost-effectiveness results were sensitive to the inclusion of these participants and the requisite assumptions, we ran a sensitivity analysis in which we excluded them from the sample.

6. Readmissions. The base case only included costs from ruptured AAA-related readmissions to study centres that were recorded in the CRFs. Sensitivity analysis allowed for other readmissions, by using information collected in the health services questionnaire, although it was not always clear which of these admissions were aneurysm-related. For these readmissions, we assumed the average readmission cost from those readmissions recorded in the CRFs.

## Results

### Mortality

Between 3 months and 1 year after randomisation, two participants in the open repair group were lost to follow-up (leaving 295 participants in this group available for 1-year analysis). By 1 year, 98 participants in the endovascular strategy group and 103 participants in the open repair group had died (the flow of participants through the IMPROVE trial to 3 years is shown in *Figure 8*). At 1 year, mortality was 41.1% for the endovascular strategy group compared with 45.1% for the open repair group (OR 0.85, 95% CI 0.62 to 1.17). Details and causes of death are given in *Table 8*. As at 30 days, the endovascular strategy was more effective in women than men (interaction  $p = 0.034$ ). Again, we conducted an individual patient meta-analysis of mortality across the three recent European randomised trials, which included both participants as randomised and the 308 IMPROVE trial participants with a proven diagnosis of rupture only who were suitable for endovascular repair.<sup>82</sup> The survival curves to 1 year for each trial and for the restricted IMPROVE trial population are shown in *Appendix 2, Figure 24a*. By 1 year, the ECAR trial suffered from almost 20% of participants being lost to follow-up, so that the apparent separation of the survival curves was not significant. There was no significant difference in mortality between the randomised groups for any trial, with the pooled OR being 0.84 (95% CI 0.63 to 1.11), with no significant heterogeneity (see *Appendix 2, Figure 24b*). Even if only the restricted population from the IMPROVE trial was included in the meta-analysis, the pooled OR only reduced to 0.80 (95% CI 0.56 to 1.16); data are not shown. However, it is interesting to note the better survival of the participants from the IMPROVE trial who were anatomically suitable for endovascular repair (compare parts a and b in *Appendix 2, Figure 24a*), in keeping with our earlier findings that overall 30-day mortality was lower (irrespective of type of repair) in participants with long aneurysm necks.<sup>83</sup>


If the overall benefit of an endovascular strategy confers only a relative 15% lower mortality at 1 year, we would have needed to randomise almost 5000 participants to show a significant difference in 1-year mortality.

### Reinterventions

By 1 year, the number of reinterventions per person was very similar in the endovascular strategy group and the open repair group of the IMPROVE trial, with 78% of participants needing no reintervention in the endovascular strategy group compared with 77% in the open repair group and, overall, the reintervention rate of participants following hospital discharge was rather low. The very different reporting of complications and reinterventions across the IMPROVE,<sup>23</sup> AJAX<sup>80</sup> and ECAR<sup>22</sup> trials meant that a full meta-analysis was not feasible. In the IMPROVE trial, complications were not captured and reinterventions were reported mainly from a health economic perspective. However, a meta-analysis has been conducted for some of the rarer events, particularly amputation. In the IMPROVE trial, there were a total of nine amputations above the knee and more proximally, eight of which occurred within 1 year of randomisation. Within 1 year, five amputations were in the endovascular strategy group and three in the open repair group. However, seven out of eight of these amputations were in participants who received open repair. In a meta-analysis with AJAX (three amputations in the open repair group) and the ECAR trial (two amputations in the open repair group), the risk of amputation was much lower after EVAR (OR 0.20, 95% CI 0.05 to 0.88), with no evidence of heterogeneity.

### Resource use

The data came from CRFs and questionnaires from the 502 participants in whom repair of a rupture had started. Data completeness at 12 months in the endovascular strategy group was 89% for CRFs and 79% for questionnaires. Data completeness at 12 months in the open repair group was 91% for CRFs and 79% for questionnaires. The imputation of missing data, including for participants without a final diagnosis of ruptured



**FIGURE 8** A CONSORT diagram showing participant flow and follow-up to 3 years. a, Number of deaths/(alive + died); b, with 26 participants who had open repairs in breach of protocol; c, with 33 participants who had EVARs in breach of protocol; and d, participants withdrew consent to be contacted about completing EQ-5D questionnaires, but allowed their other data to be used (five participants per randomised group). Completion rates reported indicate fully completed questionnaires.

**TABLE 8** Mortality for the 613 randomised participants and numbers of reinterventions in the 502 participants with ruptured AAA who had aneurysm repair started

Variable	Missing data (n)	Trial group, n (%)	
		Endovascular strategy	Open repair
<b>Deaths</b>		<b>N = 316</b>	<b>N = 297</b>
Within 30 days	0	112 (35.4)	111 (37.4)
Before primary hospital discharge	0	115 (36.4)	114 (38.4)
Before overall hospital discharge	0	115 (36.4)	116 (39.1)
Within 1 year	2	130 (41.1)	133 (45.1)
Cause of death	2		
AAA		107 (33.9)	116 (39.3)
Myocardial disease		4 (1.3)	0 (0.0)
Pulmonary disease		6 (1.9)	4 (1.4)
Cancer		4 (1.3)	2 (0.7)
Stroke and other vascular		7 (2.2)	8 (2.7)
Other		2 (0.6)	3 (1.0)
<b>Participants with reinterventions<sup>a</sup></b>		<b>N = 259</b>	<b>N = 243</b>
AAA-related reintervention	0	55 (21.2)	49 (20.2)
Non-AAA-related reintervention	0	6 (2.3)	11 (4.5)
Number of reinterventions per person <sup>a</sup>			
0	0	201 (77.6)	187 (77.0)
1	0	42 (16.2)	38 (15.6)
2	0	11 (4.3)	13 (5.4)
≥ 3	0	5 (1.9)	5 (2.1)

<sup>a</sup> Among 502 participants with ruptured AAA who had aneurysm repair started.

AAA, has been discussed in *Additional methods for cost-effectiveness analyses: categories of resource use, handling of missing data and rationale for assumptions for the base-case and sensitivity analyses*.

Table 9 summarises the resource use up to 1 year after randomisation, related to primary admission, readmissions and community care. Operation time was lower for participants who were randomised to an endovascular strategy than for those randomised to the open repair procedure (see Table 9); mean time in theatre was 157 minutes (SD 100 minutes) and 180 minutes (SD 108 minutes) for endovascular strategy and open repair procedure, respectively. The endovascular strategy had, on average, a higher cost of medical devices (including the stent graft) and consumables compared with the open repair procedure (see Table 9). Participants in the endovascular group had a relatively lower mean cost in critical care compared with the open repair group (£6300 vs. £9280, respectively). Theatre and general medical costs were relatively similar between groups. Participants in the endovascular strategy stayed, on average, for fewer days in hospital compared with participants in the open repair group; mean time in hospital was 14 days (SD 21.6 days) compared with 20.1 days (SD 31.6 days), respectively. Participants in the endovascular strategy group were discharged earlier from critical care units (mean 5.1 days compared with 7.4 days in the open repair group) and fewer participants were transferred to other (secondary) hospitals than in the open repair group: 10 (3%) compared with 36 (12%), respectively. One participant in each randomised group was discharged on haemodialysis. The costs related to stay in secondary hospitals were lower for the endovascular strategy

**TABLE 9** Resource use and costs (GBP) up to 1 year, reported across all randomised participants

Component	Resource use		Cost (£)	
	Endovascular strategy (N = 316)	Open repair (N = 297)	Endovascular strategy (N = 316)	Open repair (N = 297)
Primary admission				
Time in emergency room (minutes), mean (SD) <sup>a</sup>	93 (370)	73 (157)	135 (138)	118 (50)
Devices and consumables, mean (SD)			4337 (2913)	2540 (2053)
Time in theatre (minutes), mean (SD) <sup>b</sup>	157 (100)	180 (108)	2057 (1299)	2110 (1276)
Days in critical care, mean (SD)	5.1 (10.6)	7.4 (11.1)	6300 (16,289)	9280 (15,003)
Days on routine ward, mean (SD) <sup>c</sup>	7.3 (12.2)	7.5 (12.5)	1973 (3213)	2044 (3406)
Participants with at least one reintervention, n (%) <sup>d</sup>	58 (18)	56 (19)		
Number of reinterventions, mean (SD)	0.26 (0.6)	0.32 (1.0)	545 (1388)	642 (1765)
Transfer to secondary hospital, n (%) <sup>e</sup>	10 (3)	36 (12)		
Number of days in secondary hospital, mean (SD)	0.7 (4.5)	4.7 (21.0)	174 (1158)	1208 (5452)
Readmissions				
Number of readmissions, n (%)	26 (8)	12 (4)		
Number of readmissions, mean (SD)	0.1 (0.5)	0.05 (0.2)	284 (1805)	119 (863)
Total days in hospital, mean (SD)	14.0 (21.6)	20.1 (31.6)		
Total hospital cost, mean (SD)			15,804 (19,318)	18,062 (20,296)
Outpatient and community care, mean (SD)				
Outpatient visits	3.2 (5.7)	2.9 (8.5)	397 (718)	292 (483)
Days in nursing home	0 (0)	1.8 (22.0)	0 (0)	192 (2309)
Family doctor visits	2.8 (3.9)	2.5 (3.8)	153 (216)	139 (209)
Community nurse visits	2.2 (6.7)	2.1 (7.4)	40 (120)	38 (134)
Outpatient and community care total costs			590 (902)	661 (1468)
Total cost, mean (SD)			16,394 (19,543)	18,723 (20,599)
Incremental cost (95% CI)			-2329 (-5489 to 922)	

a Includes costs of CT scan and contrast agent.

b The unit costs of the theatre time were £885 per hour for those who actually received an endovascular procedure and £675 per hour for those who actually received open repair (for further details, see [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017).

c Participants who did not undergo aneurysm repair (8.9%) were assumed to stay on a routine ward throughout the hospitalisation (details of sensitivity analyses are available in *Appendix 2, Figure 26*).

d Although the proportion of participants with reinterventions was not significantly different between groups, participants undergoing open repair had, on average, a higher number of reinterventions per participant.

e Includes those discharged to 'other' facilities, mainly rehabilitation facilities.

#### Notes

Results are reported after multiple imputation.

Unit costs are reported in *Appendix 2, Table 28*.



group than for the open repair group. The costs of outpatient visits and community care were comparable between randomised groups. The number of hospital readmissions up to 1 year after randomisation was higher for the endovascular group than for the open repair group: 26 readmissions (8%) and 12 readmissions (4%), respectively. Participants across the randomised groups had similar service use after hospital discharge, including outpatient, general practitioner and nurse visits (see *Table 9*).

The net effect of the higher intervention cost, but lower critical care and secondary hospital care costs, was that the mean total cost per participant was lower for the endovascular strategy group (£16,394) than that for the open repair group (£18,723); the mean cost difference at 1 year was –£2329 (95% CI –£5489 to £922).

### Health-related quality of life

At 3 months after randomisation, a higher proportion of participants in the endovascular strategy group than in the open repair group reported 'no problems' on the physical health dimensions (mobility, self-care and pain) of the EQ-5D-3L questionnaire (see *Appendix 2, Table 32*). For example, 74 participants (54%) in the endovascular group reported 'no problems' in mobility compared with 51 participants (45%) in the open repair group. At 12 months after randomisation, the distribution of the health status profiles was more similar between randomised groups, but a higher proportion of the open repair participants reported 'severe problems' with self-care, usual activities and pain. For example, seven participants (7%) randomised to the open repair group reported extreme pain at 12 months, compared with only one participant (1%) in the endovascular group (see *Appendix 2, Table 32*).

The mean EQ-5D-3L utility scores were higher in the endovascular strategy group compared with the open repair group (*Table 10*); the mean differences in the EQ-5D-3L score (among ruptured AAA survivors) were 0.087 (95% CI 0.017 to 0.158;  $p = 0.015$ ) and 0.068 (95% CI –0.004 to 0.140;  $p = 0.063$ ) at 3 and 12 months post randomisation, respectively. The QoL (using the EQ-5D-3L) reported at 1 year following emergency repair is very similar to that reported by participants undergoing elective repair.<sup>41</sup> This is an interesting finding given that participants enrolled in the randomised trial of elective EVAR compared with open repair were, on average, 3 years younger than those in the IMPROVE trial.

**TABLE 10** Quality of life, total costs (GBP) and cost-effectiveness outcomes up to 1 year

Outcome measure	Trial group, <i>n</i> (%)				
	Endovascular strategy		Open repair		Mean difference (95% CI)
	<i>n</i>	Mean (SD)	<i>n</i>	Mean (SD)	
EQ-5D-3L <sup>a,b</sup> at 3 months for ruptured AAA survivors	168	0.76 (0.24)	150	0.67 (0.32)	0.087 (0.017 to 0.158)
EQ-5D-3L <sup>a,b</sup> at 12 months for ruptured AAA survivors	161	0.77 (0.20)	140	0.71 (0.35)	0.068 (–0.004 to 0.140)
QALYs <sup>b,c</sup> for all randomised participants	316	0.40 (0.35)	297	0.35 (0.35)	0.052 (–0.005 to 0.108)
Total cost <sup>b</sup> (£)	316	16,394 (19,543)	297	18,723 (20,599)	–2329 (–5489 to 922)
INMB <sup>b,d</sup> (£) (95% CI)	3877 (253 to 7408)				

a The EQ-5D-3L is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).

b The EQ-5D-3L, QALY, cost and INB results are reported after multiple imputation to address missing values. The complete case results are shown in *Appendix 2, Table 32*.

c The QALY estimation for all randomised participants assumes that, for participants without a proven rupture, the QoL was the same as at baseline for participants included in the EVAR 1 trial<sup>41</sup> (see [www.journalslibrary.nihr.ac.uk/programmes/hta/073764#](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764#), accessed 16 November 2017, for further details).

d The INB for the endovascular strategy compared with open repair is calculated by multiplying the difference in mean QALYs by the NICE-recommended threshold of willingness to pay for the UK (£30,000 per QALY)<sup>36</sup> and subtracting from this the incremental cost.



The relative gains in both QoL and mortality led to a higher mean QALY value at 12 months for participants in the endovascular strategy (0.36 QALYs) compared with that in the open repair group (0.30 QALYs); incremental QALY gain was 0.052 (95% CI –0.005 to 0.108;  $p = 0.072$ ).

### Cost-effectiveness

At 12 months post randomisation, the QALY gain coupled with a lower mean total cost led to a positive INMB (assuming a threshold of £30,000 per QALY gain) for the endovascular strategy compared with the open repair randomised group: £3877 (95% CI £253 to £7408) (see *Table 10*). The uncertainty in the mean cost, mean QALYs and their joint (normal) distribution is represented on the cost-effectiveness plane (see *Appendix 2, Figure 25*). The majority of the points are in the quadrant that shows that the endovascular strategy has a lower mean cost and higher mean QALYs, suggesting that this intervention is likely to be cost-effective. The probability that the endovascular strategy compared with open repair is cost-effective is  $> 0.9$ , irrespective of how much the decision-maker or society is willing to pay for a QALY gain.

The cost-effectiveness of endovascular repair compared with open repair does not differ by participant subgroup (*Table 11*). Female participants appeared to benefit relatively more from the endovascular strategy – incremental QALY gain was 0.133 (95% CI 0.02 to 0.247) – but they also had higher costs, mostly associated with longer stays in critical care. The subgroup of participants with worse preoperative Hardman index scores (of  $\geq 2$ ) had similar results. The 95% CIs of the INB included zero for all subgroups, except for men (£37 to £8012). The results of the sensitivity analysis suggest that the relative cost-effectiveness of the endovascular strategy compared with open repair is robust to departures from the different base-case assumptions (see *Appendix 2, Figure 26*). For example, when we considered a higher cost (£10,000) for the endovascular stent, the INB remained positive, although the 95% CI included zero. Similarly, restricting the analysis to the participants with a proven ruptured aneurysm led to a similar 95% CI (£143 to £8467) of the INB compared with the base case.

### Main findings of the IMPROVE trial at 12 months

The IMPROVE trial showed no significant survival benefit at any time point for an endovascular strategy (using a standard endovascular device whenever anatomically and operationally possible, with open repair as a default option) compared with open repair during the first 12 months after randomisation, although, again, women benefited more than men from the endovascular strategy. There was no evidence of a

**TABLE 11** Incremental net monetary benefit (95% CI) (GBP) within the first year of randomisation, by subgroup, at the recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)<sup>36</sup>

	Incremental			
Subgroup	Cost (95% CI), £	QALYs (95% CI), £	INB (95% CI) <sup>a</sup> , £	p-value
Age (years)				
≤ 77	−2032 (−6579 to 2514)	0.025 (−0.050 to 0.101)	2797 (−2252 to 7846)	0.719
> 77	−2560 (−7005 to 1885)	0.064 (−0.012 to 0.140)	4483 (−501 to 9467)	
Sex				
Male	−3264 (−6831 to 302)	0.025 (−0.035 to 0.086)	4025 (37 to 8012)	0.661
Female	1882 (−4861 to 8626)	0.133 (0.020 to 0.247)	2112 (−5421 to 9646)	
Hardman index score				
0	−2513 (−8383 to 3357)	0.034 (−0.064 to 0.131)	3525 (−3064 to 10,114)	0.631
1	−2561 (−7277 to 2155)	0.020 (−0.061 to 0.101)	3161 (−2115 to 8437)	
≥ 2	−863 (−7350 to 5623)	0.114 (0.004 to 0.224)	4290 (−2898 to 11,478)	

<sup>a</sup> Results are following multiple imputation. Estimates were obtained from a regression model that included a randomised-group-by-subgroup interaction term. *p*-values were reported for this interaction coefficient.

difference in the number or rate of reinterventions (including those for endoleaks) at any time during the first year, with no significant interaction on the basis of age, sex or preoperative Hardman index. In contrast, there were gains for the endovascular strategy group compared with the open repair group with respect to patient-preferred outcomes of faster discharge, more home discharges and better HRQoL (using EQ-5D-3L) and, overall, the endovascular strategy was cost-effective. The cost-effectiveness results were robust to alternative departures from base-case assumptions, including prices for stent grafts, specification of the regression model and AAA type (ruptured, incidental or symptomatic).

### Interpretation

There are some potential reasons for why there was no difference in survival between the randomised groups. First, shock with systemic organ damage might lead to very high early mortality after ruptured AAA repair, irrespective of the type of repair. Second, the operative mortality from open repair was lower than was anticipated. Third, we now know that aortic anatomy, particularly aneurysm neck length, has an important influence on mortality. In particular, the group of patients who are not candidates for standard endovascular repair ( $\approx 40\%$ ) has the highest operative mortality, especially for open repair, and the group of patients who are anatomically suitable for the endovascular procedure has a much lower mortality after either EVAR or open repair.<sup>83</sup> Fourth, the trial was designed to be inclusive and consider whether or not the availability of an endovascular service would improve the outcome of all patients with a rupture, not just those anatomically suitable for EVAR. So, inevitably, the endovascular strategy group included a significant proportion of participants who had to be treated with open repair. Moreover, if the overall benefit of an endovascular strategy confers only a relative 15% lower mortality at 1 year, we would have needed to randomise almost 5000 participants to show a significant difference in 1-year mortality.

Among survivors, however, the findings suggesting faster recovery in the endovascular group are notable. These were (1) a shorter average hospital stay, (2) a greater probability of being discharged to home and (3) better HRQoL than the open repair group. The between-group mean differences in QoL, 0.087 (3 months) and 0.068 (1 year), exceed the minimum clinically important difference of 0.03,<sup>84</sup> although the mean difference was no longer statistically significant 1 year after randomisation. The average EQ-5D-3L utility scores of the endovascular strategy group at 3 and 12 months (0.76 and 0.78, respectively) were slightly higher than the scores for those undergoing elective EVAR in the EVAR 1 trial<sup>41</sup> (0.71 and 0.74, respectively), whereas the EQ-5D-3L scores of the open repair group at 3 and 12 months (0.69 and 0.74, respectively) were similar to the scores for those undergoing elective open repair (0.67 and 0.75, respectively). In addition, the risk of reintervention for endoleak up to 1 year post operation in the endovascular group (8%) was not significantly different to that in the open repair group, and seems generally lower than the 10–23% range suggested in previous reports.<sup>85,86</sup>

Participants were discharged home earlier and returned to 'normal' HRQoL quicker in the endovascular strategy group than in the open repair group, which translated into lower health-care costs. Together with the gains in survival and QoL, the endovascular strategy is likely to be good value for money in the UK NHS. Given the relative robustness of the results to the different analytical assumptions, this intervention is also likely to be cost-effective in other health-care settings.

### Comparison with other studies

At the time of writing, the Dutch AJAX<sup>80</sup> and French ECAR<sup>22</sup> trials have published outcomes at 6 months and 12 months, respectively. The individual participant data meta-analysis of these trials and the IMPROVE trial indicated that there was no significant survival benefit for the endovascular strategy compared with open repair, although there was some heterogeneity between studies/countries.<sup>82</sup> The ECAR trial did not report HRQoL or cost-effectiveness but AJAX found (1) no between-group differences in 6-month QoL and (2) that endovascular repair was not cost-effective.<sup>80</sup> These findings contrast with those from the IMPROVE trial, probably because the IMPROVE trial included a wider range of patients (more representative of total ruptured AAA caseload). In addition, AJAX used aorto-uni-iliac devices (with subsequent femoro-femoral crossover grafting) for endovascular repair (resulting in a more expensive procedure) and applied unit costs from a single centre.

### Limitations

First, this was a pragmatic trial and, among those participants with a ruptured AAA, the endovascular procedure was started in only 58% of those who were randomised to the endovascular strategy (with 26 endovascular-suitable participants receiving open repair for operational reasons) and 33 participants in the open repair group receiving endovascular repair (primarily because they were deemed unfit for general anaesthesia). Second, data completion was very good, including questionnaire responses, but  $\approx 40\%$  of randomised participants had missing QoL or resource use data (at either 3 or 12 months post randomisation). Missing data were addressed with multiple imputation, which assumes that any systematic differences in outcomes can be explained by the variables included in the imputation model. Third, there was no adjustment for testing of multiple hypotheses (except for subgroup analyses) but all reported outcomes were prespecified. Fourth, reinterventions and costs following EVAR for rupture may increase after 1 year and all participants were followed up for 3 years to address this (see *Chapter 6*).

### Summary

We have presented clinical effectiveness and cost-effectiveness evidence from a large randomised trial, conducted in the challenging setting of emergency patients requiring an immediate operation to avoid death. It was based on the randomisation of unselected patients, including appropriate representation of women, to optimise the generalisability of the findings, and all centres were accredited for providing EVAR in routine and emergency practice. In the IMPROVE trial, and in meta-analysis with the other two European trials, there is no evidence that an endovascular strategy or endovascular repair offers a survival benefit at 1 year. Although, in the IMPROVE trial, the endovascular strategy offers no overall survival benefit for participants with ruptured AAAs compared with open repair at 1 year after randomisation, this chapter outlines the evidence that suggests that a wider provision of emergency endovascular services is likely to be a cost-effective use of health-care resources.

## Chapter 6 Three-year outcomes, survival, reinterventions and health economics

### Overview

There are very few studies that have followed up patients with a ruptured AAA in the medium or longer term (> 12 months after rupture) and these, including one from the Vascular Study Group of New England<sup>79</sup> and one from the Amsterdam cohort with ruptured aneurysms,<sup>87</sup> are non-randomised and mainly retrospective. Such studies are subject to confounding by baseline aortic morphology<sup>83</sup> and other factors.

After full recruitment and analysis of 30-day results, longer-term projections of the mortality data from the IMPROVE trial suggested that  $\approx 50\%$  of the randomised participants remained alive at 3 years. Therefore, it was considered to be very important to incorporate accurate estimates of longer-term survival, QoL, reinterventions, cost and, hence, cost-effectiveness for future policy recommendations and, thus, the trial was extended to include 3 years of follow-up for all participants. Even at 1 year, the endovascular strategy was cost-effective, driven by better QoL scores than in the open repair group. Health-care costs were non-significantly lower in the endovascular strategy group than in the open repair group and there was no significant mortality difference between the groups.<sup>83</sup>

In randomised trials of the repair of intact aneurysms, the early survival benefit of endovascular repair compared with open repair is eroded within the first 2 or 3 years after aneurysm repair and, in the longer term, the rate of reinterventions after endovascular repair is double the rate after open repair.<sup>79,88,89</sup> Would similar trends following the repair of ruptured aneurysms erode the benefits of the more rapid recovery and early QoL gains after endovascular repair, and hence cost-effectiveness, in the medium or longer term? Data from the Vascular Study Group of New England suggested that, after 3–5 years, survival was similar for those participants who had endovascular repair and those who had open repair (although many participants had been lost to follow-up) and that patient comorbidities and shock on admission were the main determinants of longer-term survival.<sup>79</sup> The Amsterdam cohort study (the total population of ruptures admitted to Amsterdam hospitals from which AJAX participants were selected) was dominated by open repair participants but showed that any early survival benefit of endovascular repair had been eroded by 2 years; thereafter, survival was similar in participants treated by open repair or endovascular repair, with  $\approx 50\%$  of participants remaining alive at 3 years.<sup>90</sup> This Amsterdam cohort study also showed that, after 2 years, reinterventions were slightly, but not significantly, more common after endovascular repair than open repair but, for those discharged alive, reinterventions were twice as common after endovascular repair.

In this chapter, we report the follow-up of all participants from the IMPROVE trial for mortality for  $\geq 3$  years, to the end of July 2016, and the complete follow-up of the subgroup of greatest clinical interest, the 502 participants in whom repair of a ruptured aneurysm was commenced (for mortality, aneurysm-related reinterventions and QoL), to the 3-year time point, analysed by the group to which these participants were randomised. This, in turn, enables 3-year cost-effectiveness evaluations. The analysis plan prespecified the reporting for both the entire cohort of 613 participants and the principal sensitivity analysis for the 502 participants in whom repair of a ruptured aneurysm had started. The analysis plan paralleled that of the 1-year outcomes reported in *Chapter 5*, except for the classification of the severity of the reinterventions, an assessment of how baseline aortic morphology influenced reinterventions, the inclusion of two additional subgroups for analyses (by aneurysm neck length and lowest systolic blood pressure on admission) and the specification of mortality and reinterventions by time: acute (0–90 days), mid-term (3 months to 3 years) and beyond 3 years. To enable comprehensive reporting of all aneurysm-related reinterventions, including those at non-trial hospitals, the participants who were randomised in Scotland were audited carefully, including

the correspondence section of the notes and participant contact, as relevant. All reinterventions that took place in England were cross-validated by data from HES, which also provided details of aneurysm-related admissions and reinterventions at non-trial hospitals. However, because these data were available only for readmissions or reinterventions within 3 years of primary admission discharge, full reporting of aneurysm-related reinterventions beyond 3 years of follow-up was not possible. The cost-effectiveness analysis was therefore limited to the reporting of 3-year, rather than lifetime, outcomes, using the same methods as described in detail in *Chapters 2 and 5*.

## Results

### *Study population and treatments*

The CONSORT diagram (see *Figure 8*) shows the follow-up of participants to 3 years after randomisation. In the endovascular strategy group, 310 participants had an aortoiliac aneurysm, 27 had an asymptomatic AAA and another acute diagnosis, 14 had an acute symptomatic aneurysm, 275 had an AAA rupture and six did not have an aortic aneurysm. In the open repair group, 294 participants had an aortoiliac aneurysm, 19 had an asymptomatic AAA and another acute diagnosis, eight had an acute symptomatic aneurysm, 261 had an AAA rupture and three did not have an aortic aneurysm. In total, in 536 participants (259 in the endovascular strategy group and 243 in the open repair groups) blood was found to breach the aneurysm sac (rupture): 34 participants died before repair and repair was started in 502 participants (the critical subgroup for this analysis). In the endovascular strategy group, 300 out of 316 participants underwent CT, of whom 186 (62%) were considered anatomically suitable for EVAR; EVAR was commenced in 154 participants, and a further 26 participants underwent open repair against protocol (mainly because a staffed endovascular suite was not immediately available). In the open repair group, 33 participants underwent EVAR (mainly because they were poor candidates for general anaesthesia). Between 30 days and 3 years, two participants in each randomised group emigrated and were lost to follow-up. At randomisation, the mean age was 77 years, 22% of the participants were women and the mean AAA diameter was 8.3 cm (baseline characteristics by randomised group are given in *Table 1*).

### *Mortality in all 613 participants*

Overall follow-up for mortality was 4.9 years (median 4.7 years; range 0.1–7.1 years), with a mean of 2.5 person-years of observation (to death or censoring). There were 179 deaths (22.0 per 100 person-years) in the endovascular strategy group and 183 deaths (25.2 per 100 person-years) in the open repair group (*Table 12*) (HR 0.92, 95% CI 0.75 to 1.13;  $p = 0.41$ ), with similar findings for aneurysm-related mortality (HR 0.89, 95% CI 0.69 to 1.16;  $p = 0.41$ ) and after adjustment (see *Appendix 2, Figure 27 and Table 33a and b*). Kaplan–Meier survival curves (*Figure 9*) show a slight divergence after the acute phase (0–90 days), with lower mortality in the endovascular strategy group between 3 months and 3 years (HR 0.57, 95% CI 0.36 to 0.90), before the curves converge again by 6 years. At 3 years, mortality was 48% and 56% in the endovascular strategy group and open repair group, respectively (OR 0.73, 95% CI 0.53 to 1.00;  $p = 0.053$ ). The increased number of deaths in the open repair group between 3 months and 3 years was not aneurysm-related (see *Table 12*; this table also gives more detailed causes of death). Subgroup analysis suggested that the endovascular strategy might be more effective in reducing mortality in women than in men, but there were no differences associated with age or Hardman index (see *Appendix 2, Figure 28*). By 3 years, 48% and 56% of participants had died and the mean numbers of life-years were 1.72 and 1.61 in the endovascular strategy group and open repair group, respectively ( $p = 0.32$ ).

### *Principal subgroup analysis: mortality in 502 participants with a confirmed rupture and repair started*

The baseline characteristics of these participants are shown in *Table 13*. Kaplan–Meier curves for the 502 participants with a confirmed rupture and in whom repair had started follow a similar pattern to those for the full trial cohort (see *Figure 9b*) (overall HR 0.86, 95% CI 0.68 to 1.08;  $p = 0.19$ ). By 3 years, 109 out of 259 participants in the endovascular strategy group (42%) and 131 out of 243 participants in the open repair group (54%) had died. The OR for 3-year mortality was 0.62 (95% CI 0.43 to 0.89;  $p = 0.009$ ).

**TABLE 12** Causes of death, by randomised group and time period, in 613 participants

Time period	Cause of death	Trial group, <i>n</i> (%)		HR (95% CI)	<i>p</i> -value
		Endovascular strategy	Open repair		
All follow-up	AAA-related	112 (63)	120 (66)	0.92 (0.75 to 1.13)	0.41
	Cardiovascular	26 (14)	23 (13)		
	Pulmonary	13 (7)	15 (8)		
	Cancer	19 (11)	13 (7)		
	Other	9 (5)	12 (7)		
	Total	179	183		
Baseline to 3 months	AAA-related	104 (87)	112 (95)	0.98 (0.76 to 1.26)	0.88
	Cardiovascular	8 (7)	3 (3)		
	Pulmonary	5 (4)	0 (0)		
	Cancer	1 (1)	0 (0)		
	Other	2 (2)	3 (3)		
	Total	120	118		
3 months to 3 years	AAA-related <sup>a</sup>	5 (16)	5 (11)	0.57 (0.36 to 0.90)	0.015
	Cardiovascular	12 (38)	16 (34)		
	Pulmonary	5 (16)	10 (21)		
	Cancer	7 (23)	10 (21)		
	Other	2 (6)	6 (13)		
	Total	31	47		
> 3 years	AAA-related	3 (11)	3 (17)	1.44 (0.80 to 2.62)	0.23
	Cardiovascular	6 (21)	4 (23)		
	Pulmonary	3 (11)	5 (28)		
	Cancer	11 (39)	3 (17)		
	Other	5 (18)	3 (17)		
	Total	28	18		

<sup>a</sup> Including two deaths from later elective repair of the asymptomatic AAA identified at primary admission, one in each randomised group.


Because ≈12% of these 502 participants (26 in the endovascular strategy group and 33 in the open repair group) had not complied with their randomised treatment, a causal analysis was conducted for treatment compliers only; the OR for 3-year mortality was slightly lower (OR 0.54, 95% CI 0.34 to 0.85; *p* = 0.008).

Over the entire period of follow-up that compared the groups as randomised, the unadjusted HR for aneurysm-related mortality was 0.89 (95% CI 0.67 to 1.18; *p* = 0.41) and the adjusted HR was similar, at 0.92 (95% CI 0.69 to 1.23). A post hoc analysis showed that the effect of sex was stronger in this subgroup of 502 participants, particularly for aneurysm-related deaths (HR in women 0.44, 95% CI 0.24 to 0.81, and HR in men 1.09, 95% CI 0.79 to 1.52; interaction *p* = 0.010).


### Reinterventions in 502 participants with confirmed rupture and repair started

There were 230 aneurysm-related reinterventions recorded within 3 years of randomisation: 121 in the group assigned to an endovascular strategy and 109 in the group assigned to open repair (rate of

(a)



(b)



**FIGURE 9** Kaplan–Meier estimates for overall survival, by randomised group. For (a) all 613 participants who were randomised (log-rank test  $p = 0.40$ ); and (b) the 502 participants with a confirmed rupture for whom repair had started (log-rank test  $p = 0.186$ ).

reintervention HR 1.02, 95% CI 0.79 to 1.32;  $p = 0.88$ ). (In the entire cohort of 613 participants, there were two further aneurysm-related reinterventions, after repair of symptomatic, non-ruptured aneurysms, before 3 years.) The reinterventions, categorised by severity (details at [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017) and whether they were arterial, laparotomy related or other, are shown in *Table 14*. Overall, and by time period (acute 0–90 days or 3 months to 3 years), the reintervention rates in the 502 participants in whom repair of a ruptured aneurysm had started were not significantly different between the randomised groups, with  $\approx 28\%$  of each group needing at least one reintervention. The cumulative incidence of participants with at least one intervention to 3 years is shown in *Figure 10a* and the cumulative incidence of participants with at least one arterial or laparotomy-related reintervention (4\* and 5\*; see [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/), accessed 16 November 2017, for categorisation) for a life-threatening condition is shown in *Figure 10b*.



**TABLE 13** Baseline characteristics of the 502 participants in whom repair of a ruptured aneurysm had started, by randomised group

Variable	Missing data, (n)	Trial group, n (%)	
		Endovascular strategy (N = 316)	Open repair (N = 297)
Age (years), mean (SD)	0	76.0 (7.4)	76.2 (7.6)
Sex, n (%)	0		
Male		209 (81)	195 (80)
Female		50 (19)	48 (20)
Admission blood pressure (mmHg), n (%)	9		
Systolic		108.7 (33.1)	109.0 (31.1)
Diastolic		65.1 (22.0)	65.3 (22.7)
Admission haemoglobin (g/dl), mean (SD)	4	11.2 (2.5)	11.0 (2.3)
Admission creatinine (μmol/l), median (IQR)	11	122 (95–154)	116 (95–151)
Hardman index (0–5), n (%)	57		
0		83 (36)	60 (28)
1		103 (44)	97 (46)
2		36 (15)	43 (20)
3		9 (4)	10 (5)
4		2 (1)	2 (1)
5		0 (0)	0 (0)
CT carried out, n (%)	0		
Yes		251 (97)	216 (89)
No		8 (3)	27 (11)
Core-laboratory-measured maximum aortic diameter (cm), mean (SD)	68	8.7 (1.7)	8.4 (1.8)
Neck length (mm), mean (SD)	93	24 (17)	23 (16)
Time to AAA repair, randomisation to theatre admission (minutes), median (IQR)	5	47 (28–73)	37 (22–62)
IQR, interquartile range.			

New reinterventions for life-threatening conditions continued to occur at a much slower, but steady, rate between 3 months and 3 years in both of the randomised groups (see *Appendix 2, Table 34*). The HRs for risk of reintervention, both overall and by time, remained similar after adjustment (see *Appendix 2, Table 35*).

The aneurysm-related reinterventions were also assessed by indication for treatment received in the 502 ruptures in which repair was started (see *Appendix 2, Table 36*), both by intention to treat and by treatment received, although this latter comparison is subject to bias. It shows that the burden of reinterventions in the first 90 days is much higher after open repair (see *Appendix 2, Table 36a*). Nine of these reinterventions were carried out at readmission in the endovascular strategy group, compared with only one at a readmission in the open repair group. Between 3 months and 3 years, there were more reinterventions after EVAR (12.5 per 100 person-years and affecting 21% of participants) than after open repair (5.0 per 100 person-years affecting 9% of participants;  $p < 0.001$ ), but the majority of reinterventions after EVAR were minor arterial reinterventions (see *Appendix 2, Table 36b*).




**TABLE 14** Reinterventions in the 502 participants in whom repair of a ruptured aneurysm had started

AAA-related reintervention	Participants with ruptured AAA in whom repair started ( <i>N</i> = 502)	
	Endovascular strategy	Open repair
<b>Overall</b>		
Participants with at least one reintervention, <i>n/N</i> (%)	75/259 (29)	65/243 (27)
Reinterventions/person-years (rate per 100 person-years), (%)	121/463.8 (26.0)	109/387.3 (28.1)
Arterial, <i>n</i> (%)	93 (77)	62 (57)
Laparotomy, <i>n</i> (%)	16 (13)	34 (31)
Other, <i>n</i> (%)	12 (10)	13 (12)
Severity of arterial reintervention, <i>n</i> (%)		
1*	0 (0)	1 (2)
2**	24 (26)	10 (16)
3***	32 (34)	11 (17)
4****	9 (10)	5 (8)
5*****	28 (30)	35 (56)
Severity of laparotomy reintervention, <i>n</i> (%)		
Major	5 (31)	4 (12)
Minor	11 (69)	30 (88)
<b>0–90 days</b>		
Participants with at least one reintervention, <i>n/N</i> (%)	57/259 (22)	51/243 (21)
Reinterventions/person-years (rate per 100 person-years), (%)	81/43.6 (185.6)	88/38.9 (226.1)
Arterial, <i>n</i> (%)	60 (74)	49 (56)
Laparotomy, <i>n</i> (%)	11 (14)	27 (31)
Other, <i>n</i> (%)	10 (12)	12 (14)
Severity of arterial reintervention, <i>n</i> (%)		
1*	0 (0)	1 (2)
2**	13 (22)	6 (12)
3***	21 (35)	9 (18)
4****	5 (8)	3 (6)
5*****	21 (35)	30 (61)
Severity of laparotomy reintervention, <i>n</i> (%)		
Major	2 (18)	3 (11)
Minor	9 (82)	24 (89)
<b>3 months to 3 years</b>		
Participants with at least one reintervention, <i>n/N</i> (%)	27/167 (16)	15/146 (10)
Reinterventions/person-years (rate per 100 person-years), (%)	40/420.1 (9.5)	21/348.3 (6.0)
Arterial, <i>n</i> (%)	33 (83)	13 (62)
Laparotomy, <i>n</i> (%)	5 (13)	7 (33)
Other, <i>n</i> (%)	2 (5)	1 (5)


**TABLE 14** Reinterventions in the 502 participants in whom repair of a ruptured aneurysm had started (*continued*)

AAA-related reintervention	Participants with ruptured AAA in whom repair started ( <i>N</i> = 502)	
	Endovascular strategy	Open repair
Severity of arterial reintervention, <i>n</i> (%)		
1*	0 (0)	0 (0)
2**	11 (33)	4 (31)
3***	11 (33)	2 (15)
4****	4 (12)	2 (15)
5*****	7 (21)	5 (38)
Severity of laparotomy reintervention, <i>n</i> (%)		
Major	3 (60)	1 (14)
Minor	2 (40)	6 (86)

(a)



(b)

**FIGURE 10** Time to first reintervention for the 502 participants in whom repair of a ruptured aneurysm had started. (a) All reinterventions and (b) reinterventions for life-threatening conditions (arterial or laparotomy related).

### Narrative descriptions of some adverse outcomes requiring reintervention

A small group of patients and members of the public considered amputation to be the most adverse reintervention, whereas clinicians did not (see [www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/); accessed 16 November 2017). There were eight amputations within the first 3 years, five in the endovascular strategy group and three in the open repair group, but seven of these occurred following open repair. Other reinterventions that were considered to be very serious by the patients and members of the public included those for graft infection or secondary rupture, complete repetition of the primary operation and a permanent stoma. Such reinterventions ( $n = 19$ ) took place in eight participants in the endovascular strategy group and in 11 participants in the open repair group.


Overall, six cases of graft infection were reported. It is worth noting that, following EVAR, the only cases of graft infection were after implantation of aorto-uni-iliac endografts, with the infection being in the femoro-femoral crossover graft (two cases of graft infection in 36 aorto-uni-iliac grafts). It is also worth reporting that type I endoleak after EVAR was reported in 12 out of 186 participants (seven type Ia and five type Ib endoleaks), and 11 of these cases were detected > 6 months following repair. In due course, beyond 3 years, three cases of secondary rupture were reported; two cases following a type 1b endoleak and one case following a type 1a endoleak. Only one secondary rupture was reported after open repair.

### Effect of baseline aortic morphology on reinterventions

We also investigated whether or not baseline aortic morphology was associated with the rate of reinterventions (either arterial only or all aneurysm-related). These analyses included only participants with a CT scan measured in the core laboratory and excluded those with common iliac aneurysm (CIA) ruptures. The analyses were by treatment received and not by randomised group. The results (see *Appendix 2, Table 37*) show that both arterial aneurysm-related and all-aneurysm-related reinterventions tended to increase with an increasing CIA diameter, particularly following EVAR. Following EVAR, for all reinterventions the HR per 9-mm increase is 1.32 (95% CI 1.01 to 1.72) and for arterial reinterventions the HR is 1.48 (95% CI 1.13 to 1.93). For open repair, the strongest association was with increasing aneurysm neck diameter. However, given the multiple comparisons that were conducted, these results should be considered as hypothesis-generating only.

### Quality of life, resource use and cost-effectiveness for all 613 participants to 3 years

The response rate for the QoL questionnaires (EQ-5D-3L) at 3 years was very high (> 85%) (see *Figure 8*). Although the endovascular strategy group had better QoL in the first year after randomisation, by 3 years the QoL was similar between the randomised groups (*Figure 11*) and similar to that of an age- and sex-matched population. QoL, QALYs and resource use, all following multiple imputations, are shown in *Table 15*. Complete case analyses are given in *Appendix 2, Table 38*. The mean QALY gain at 3 years for the endovascular strategy group was 0.166 (95% CI 0.002 to 0.311 QALYs), appearing to be slightly higher for women and those with the highest baseline Hardman index scores but otherwise similar across subgroups (*Table 16*).



**FIGURE 11** Quality of life (EQ-5D-3L) gained up to 3 years (shaded area) for 613 participants by randomised group.

**TABLE 15** Quality-of-life (EQ-5D-3L) utility scores, life-years and QALYs up to 3 years. Results are reported after multiple imputation for the 613 participants who were randomised

EQ-5D-3L <sup>a</sup> for ruptured AAA survivors	Trial group, <i>n</i> (%)				Mean difference (95% CI)	<i>p</i> -value
	Endovascular strategy		Open repair			
	<i>n</i> <sup>b</sup>	Mean (SD)	<i>n</i> <sup>b</sup>	Mean (SD)		
3 months	168	0.76 (0.23)	150	0.66 (0.31)	0.097 (0.031 to 0.163)	0.004
12 months	161	0.78 (0.19)	140	0.71 (0.33)	0.068 (0.002 to 0.134)	0.045
36 months	150	0.74 (0.25)	112	0.73 (0.31)	0.013 (−0.069 to 0.096)	0.751
Life-years for all randomised participants	316	1.72 (1.43)	297	1.61 (1.41)	0.115 (−0.110 to 0.341)	0.315
QALYs (3-year) for all randomised participants <sup>c</sup>	316	1.22 (1.11)	297	1.05 (1.10)	0.174 (−0.005 to 0.353)	0.057

a The EQ-5D-3L is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).

b For EQ-5D-3L scores, *n* corresponds to the total number of participants eligible for follow-up. The 3-month EQ-5D-3L data are missing for 30 endovascular strategy participants (18%) and 38 open repair participants (27%); 36-month EQ-5D-3L data are missing for 33 endovascular strategy participants (22%) and 21 open repair participants (19%).

c This includes deceased participants and those without proven rupture, who were assumed to have, on average, the same QoL as elective participants.

**TABLE 16** Incremental net benefit (95% CI) (GBP) within 3 years of randomisation, by subgroup, at the recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)<sup>36</sup>

	Incremental		INB (95% CI) <sup>a</sup>	<i>p</i> -value
Subgroup	Cost (95% CI)	QALYs (95% CI)		
Sex				
Male ( <i>n</i> = 480)	−4066 (−7573 to −557)	0.092 (−0.099 to 0.283)	6824 (204 to 13,444)	0.440
Female ( <i>n</i> = 133)	2817 (−3806 to 9439)	0.358 (0.038 to 0.712)	7914 (−4401 to 20,229)	
Hardman index score				
0 ( <i>n</i> = 164)	−4017 (−9758 to 1725)	0.016 (−0.141 to 0.465)	8878 (−1686 to 19,442)	0.279
1 ( <i>n</i> = 254)	−2448 (−7022 to 2126)	0.005 (−0.244 to 0.254)	2594 (−5943 to 11,131)	
≥ 2 ( <i>n</i> = 121)	−923 (−7306 to 5461)	0.423 (0.092 to 0.755)	13,622 (2025 to 25,219)	
Neck length (mm)				
< 22 ( <i>n</i> = 234)	−769 (−5595 to 4057)	0.216 (−0.027 to 0.459)	7243 (−1216 to 15,702)	0.461
≥ 22 ( <i>n</i> = 247)	−4250 (−8859 to 358)	0.111 (−0.131 to 0.352)	7568 (−959 to 16,095)	
Lowest systolic blood pressure (mmHg)				
< 90 ( <i>n</i> = 263)	−3881 (−8604 to 842)	0.067 (−0.185 to 0.319)	5881 (−2949 to 14,711)	0.275
≥ 90 ( <i>n</i> = 305)	−1540 (−5879 to 2798)	0.213 (−0.013 to 0.439)	7932 (−14 to 15,878)	

a Results are following multiple imputation. Estimates were obtained from a regression model (adjusted for age, sex, Hardman index, neck length and lowest systolic blood pressure) that included a randomised-group-by-subgroup interaction term. *p*-values were reported for this interaction coefficient.


Table 17 summarises the resource use and costs up to 3 years after randomisation, related to primary admission and aneurysm-related readmissions, including those for reinterventions. This information is provided for the time periods of 0–1 years and 1–3 years. Between 1 and 3 years, participants were not asked to complete health resource usage questionnaires, in part because of problems with recall over this

**TABLE 17** Resource use and costs (GBP) up to 3 years, reported across all participants randomised. Results are reported after multiple imputation

Resource and time period	Resource use		Cost (£)	
	Endovascular strategy (N = 316)	Open repair (N = 297)	Endovascular strategy (N = 316)	Open repair (N = 297)
<b>Between randomisation and 1 year</b>				
Primary admission				
Days in critical care, mean (SD)	5.3 (12.0)	7.4 (11.9)	6672 (16,430)	9674 (16,446)
Days on routine ward, mean (SD)	7.0 (11.9)	7.8 (12.0)	1835 (3107)	2031 (3158)
Other resource use, <sup>a</sup> mean (SD)			6563 (3779)	4757 (2896)
Transfer to secondary hospital, n (%)	10 (3)	36 (12)		
Number of inpatient days, mean (SD)	0.7 (4.5)	4.8 (21.1)	175 (1159)	1245 (5479)
Total days in primary admission, mean (SD)	13.0 (20.5)	20.0 (31.9)	15,245 (18,356)	17,707 (20,842)
Readmissions				
One or more readmission, n (%)	27 (9)	11 (4)		
Number of inpatient days, mean (SD)	0.7 (4.6)	0.2 (1.5)	215 (1469)	57 (433)
Reinterventions				
One or more reintervention, n (%)	65 (23)	60 (22)	520 (1323)	655 (1711)
Outpatient and community care, <sup>b</sup> mean (SD)			525 (739)	829 (5772)
Total days in hospital up to 1 year, mean (SD)	13.7 (21.3)	20.2 (31.9)	16,505 (19,084)	19,248 (22,365)
<b>Between 1 and 3 years</b>				
Readmissions				
One or more readmission, n (%)	24 (8)	12 (4)		
Number of inpatient days, mean (SD)	0.7 (4.4)	0.3 (2.3)	270 (1667)	137 (981)
Reinterventions				
One or more reintervention, n (%)	20 (6)	11 (4)	107 (626)	98 (690)
Total days in hospital up to 3 years, mean (SD)	14.4 (23.4)	20.5 (32.1)	16,878 (19,624)	19,483 (22,412)
Incremental cost (95% CI)			–2605 (–5966 to 702)	
INMB <sup>c</sup> (95% CI)			7637 (1820 to 13,454)	
<sup>a</sup> Includes costs related to the emergency room, CT scan, devices, consumables and theatre.				
<sup>b</sup> Includes costs related to outpatient, general practitioner and district nurse visits.				
<sup>c</sup> The INB for endovascular repair compared with open repair is calculated by multiplying the mean difference in QALYs using the NICE-recommended willingness-to-pay threshold (£30,000 per QALY gain) <sup>36</sup> and subtracting from this the incremental cost.				

follow-up period. Therefore, the cost of any outpatient care and community care during this period is not included. Between 1 and 3 years, the proportion of participants being readmitted for aneurysm-related reasons was higher in the endovascular strategy group, but the proportion who received aneurysm-related reinterventions was similar in each group. Hospital stay was, on average, a few days shorter in the endovascular group than in the open repair group [mean total number of days in hospital 14.4 days (SD 23.4 days) compared with 20.5 days (SD 32.1 days), with a total incremental cost difference of –£2607 (95% CI –£5949 to £735)].

When the incremental costs and QALYs are represented on the cost-effectiveness plane, most of the estimates (88%) are in the quadrant that designates the endovascular strategy as 'dominant', with lower mean costs and higher mean QALYs (Figure 12a). The INMB of the endovascular strategy compared with open repair is positive, at £7367 (95% CI £1829 to £13,454), remains similar across subgroups (see Appendix 2, Table 39) and is robust to a range of assumptions (see Appendix 2, Figure 29). The probability that the endovascular strategy was more cost-effective was > 0.90 at all realistic thresholds of willingness to pay for a QALY gain (Figure 12b). Similarly, there was no significant evidence that the INMBs differed by participant subgroups.



**FIGURE 12** (a) Uncertainty in the mean cost (GBP) and QALY differences and their joint distribution for the endovascular strategy compared with open repair for 613 participants; and (b) cost-effectiveness acceptability curve at 3 years, reporting the probability that the endovascular strategy is cost-effective at a range of alternative thresholds of willingness to pay for a QALY gain.

## Discussion

This is the only randomised comparison of treatments for ruptured AAA with comprehensive mid-term (3-year) reporting. The IMPROVE trial was designed to test the hypothesis that an endovascular strategy (the availability of endovascular repair for those deemed morphologically suitable for EVAR) would offer a 30-day survival advantage compared with open repair for participants presenting with a clinical diagnosis of ruptured AAA. The early 30-day results did not support this hypothesis,<sup>21</sup> despite showing a more rapid patient recovery in the endovascular strategy group and later, at 1 year, evidence of better QoL and cost-effectiveness in this group.<sup>23</sup> However, at 3 years, the time point at which half of the participants remained alive, all of the evidence points in the same direction. There is far more convincing evidence for the benefits of being in the endovascular strategy group: interim survival is better and both QALYs gained and the INMB (cost-effectiveness) are much higher than the values at 12 months, without a significantly higher burden of aneurysm-related reinterventions, especially serious reinterventions.

Although all 613 randomised participants were followed up for mortality, more comprehensive follow-up (QoL, aneurysm-related hospital readmissions and aneurysm-related reinterventions) was limited to the subgroup of 502 participants in whom repair of a confirmed rupture was started and postoperative consent was obtained. The baseline characteristics of these 502 participants, including aortic morphology, were very similar between those assigned to the endovascular strategy group and those assigned to the open repair group. Although 34 out of 536 participants with a proven AAA rupture (blood outside the aneurysm sac) died before AAA repair was started, the number of participants who died was similar in each group (see the CONSORT diagram in *Figure 8*). Therefore, there should be little bias when comparing the outcomes between the groups as randomised for the principal sensitivity analysis with 502 participants. If anything, the longer time taken to start the repair in the endovascular strategy group would act as a bias against those assigned to an endovascular strategy (see *Tables 1 and 13*).

Over the entire period of follow-up to 7 years, there was no difference in survival between the two randomised groups, although the separation between the Kaplan–Meier curves was maximal at 3 years and of borderline significance in favour of the endovascular strategy group. At 3 years, the relative advantage of the endovascular strategy for women compared with men, first observed at 30 days (due mainly to the high perioperative mortality following open repair in women), had been attenuated, although the QALY gain at 3 years was higher in women than in men.

For the principal sensitivity analysis of 502 participants in whom repair of a confirmed rupture was started, the survival benefit of the endovascular strategy between 3 months and 3 years, and at 3 years, was more marked. This was supported by a causal analysis that suggested that mortality for treatment compliers randomised to an endovascular strategy was half of the mortality of treatment compliers in the open repair group. However, by 6 years of follow-up, the survival curves had, again, reconverged, although the number of data at this time point was limited.

In the 502 participants for whom repair of a ruptured AAA had started, overall aneurysm-related reinterventions were more severe and more often laparotomy related, rather than arterial, in the open repair group and hence were more likely to be conducted under general, rather than local, anaesthesia, and such factors might have contributed to the interim survival benefit for the endovascular strategy group at 3 years. The reconvergence of the survival curves beyond 3 years is also unexplained but, as in the situation of elective AAA repair, secondary ruptures and increased cancer deaths may have been contributory.<sup>89</sup> Observational series using administrative or registry data, which cannot fully account for selection bias, have also noted the reconvergence of survival curves at 4/5 years, following a strong survival benefit for EVAR during the acute period, but without discussion of underlying reasons for this.<sup>47,79</sup>

The burden of reinterventions reflects the number of reinterventions, their severity and the associated bed-days in hospital, and probably also the type of anaesthesia used (although type of anaesthesia was not recorded, local anaesthesia would probably be used more often than general anaesthesia for arterial

reinterventions, especially the less severe reinterventions). The recategorisation of reinterventions as arterial, laparotomy related or other, and by the severity of the procedure, has been useful. Particularly during the early part of follow-up, reinterventions were more severe in the open repair group (and more often laparotomy related rather than arterial). More surprisingly, new and serious reinterventions continued at a low but steady rate after the acute period (0–90 days) in both the open repair group and the endovascular group. Therefore, there was no significant excess of reinterventions in the endovascular strategy group in the later phase of follow-up, as has been indicated in other studies.<sup>47,87</sup>

The earlier advantage of better QoL in the endovascular strategy group was no longer evident at 3 years but, importantly, the mid-term survivors had a QoL similar to, or slightly better than, that of an age–sex matched population, supporting aneurysm repair in this older population (the mean age at rupture was 77 years). The earlier gains in QoL, coupled with the survival advantage between 3 months and 3 years of the endovascular strategy group, resulted in a significant, although modest, gain in QALYs at 3 years for this group. Apart from QoL, at 3 years all other health outcomes and costs indicated that the endovascular strategy was more favourable than open repair in this population. The cost differences observed at 30 days (non-significantly in favour of the endovascular strategy group) were not eroded by an increased burden of reinterventions in later follow-up. In contrast, elective endovascular repair has been associated with higher costs and is probably not cost-effective.<sup>91</sup> The longer-term follow-up strengthens the positive cost-effectiveness profile of the endovascular strategy group reported at 1 year and, by 3 years, the between-group differences in both QALYs and INMB were almost double those at 1 year. This cost-effectiveness of the endovascular strategy dominates open repair, irrespective of the decision-maker's willingness to pay for a QALY gain.

This study has several limitations. First and foremost, this was a pragmatic trial in a life-or-death emergency setting. This meant that not all randomised participants had a ruptured aneurysm, although 99% had an aortic aneurysm, and that there was significant non-compliance with allocated treatment in both randomised groups ( $\approx 10\%$  of each group). Second, some of the participants with a ruptured aneurysm died before their aneurysm could be repaired, but the number of participants in this category was similar in each randomised group. Third, after 30-days, follow-up was focused on the subgroup of 502 participants in whom repair of a ruptured aneurysm was started. However, this subgroup of 502 participants in whom repair of a ruptured AAA had started is the most clinically relevant group and was analysed by intention to treat; thus, there should be minimal bias. Fourth, after the acute period, only aneurysm-related reinterventions were reported, but these data were complete, including procedures at non-trial hospitals collected through data linkage with routine hospital statistics, and more than half of the reinterventions were audited. Fifth, although this is by far the largest randomised trial for the management of ruptured aneurysm, with hindsight, the sample size may have been insufficient, with the CIs for mortality often being relatively wide.

There are also several strengths to this study. First, recruitment was non-selective and over half of the potentially eligible patients at the trial centres were randomised, adding to the generalisability of the results. Second, it is the first randomised study with full prospective mid-term follow-up. Third, very few participants were lost to follow-up and the response rate to QoL questionnaires was excellent.

## Summary

The endovascular strategy (emergency EVAR if anatomically feasible) provides a better option for patients presenting with a ruptured AAA (especially women) with early gains in QoL, a QALY gain at 3 years and probably an interim survival advantage at 3 years without excessive aneurysm-related reinterventions, all of which combine to result in an endovascular strategy being highly likely to be cost-effective. Therefore, a strong case can be made for an endovascular strategy being more widely adopted within the NHS, and in our opinion all vascular centres should be able to offer emergency EVAR, as well as emergency open repair, at all times.





# Chapter 7 Developing and validating a 48-hour mortality risk score following emergency admission for a ruptured abdominal aortic aneurysm

## Overview

The purpose of this work was to develop a novel, point-of-care risk score to identify patients with a ruptured AAA in whom either immediate aneurysm repair or transfer to a specialist centre for repair would be potentially worthwhile and those in whom aneurysm repair may be futile. Important features of the risk score are that it is based on both physiological and imaging data that are immediately available in the emergency department and that it focuses on 48-hour mortality as the primary outcome measure, rather than in-hospital or 30-day mortality. The highest attrition rate following repair is in the first 48 hours (see *Figure 4*). The developed risk score would help to address the question of whether or not more patients in the UK should be offered the chance of aneurysm repair because there currently appears to be undertreatment in England compared with the USA.<sup>92</sup>

The outcome considered was death within 48 hours of presentation to the emergency department where an operation, if commenced, used either open repair or EVAR. Previous risk scores have been derived but are generally based on in-hospital mortality as an outcome and are therefore sensitive to changes and improvement in critical care.<sup>93</sup> Furthermore, few of these risk scores have been validated externally. We therefore used the opportunity presented by the collection of individual patient data from the three largest ruptured AAA trials undertaken worldwide and two observational cohorts [the wider Amsterdam cohort<sup>87</sup> and the STAR (STockholm Aneurysm Ruptures) cohort<sup>74</sup>] to (1) develop a 48-hour risk score in the IMPROVE trial, (2) externally validate the risk score in the AJAX, ECAR trials and the Amsterdam and STAR observational cohorts and (3) additionally assess the predictive capabilities of previously published risk scores, namely the Vascular Study Group of New England,<sup>93</sup> the Hardman index<sup>30</sup> and the Vancouver<sup>94</sup> ruptured AAA risk scores, within all RCTs and observational cohorts.

## Modelling

### *Participants for the development and validation of the risk score*

Participants from the IMPROVE RCT were used to develop the score; participants with a final diagnosis other than ruptured AAA (i.e. excluding incidental or symptomatic AAA) were excluded but those with aortoiliac ruptures were included. All participants with ruptured AAA or aortoiliac ruptures are considered in the risk score regardless of whether or not aneurysm repair was commenced.

External validation of the risk score was conducted in participants from the AJAX<sup>19</sup> and ECAR<sup>22</sup> RCTs. The inclusion criteria for randomisation in these two RCTs, and hence the participant population, were slightly different to those in the IMPROVE trial. The IMPROVE trial randomised patients with a clinical diagnosis of ruptured AAA, before confirmation of either rupture or suitability for EVAR, and participants did not have to be haemodynamically stable. The AJAX and ECAR trials required participants to undergo CT before randomisation to confirm the presence of an aneurysm with acute haemorrhage outside the aortic wall and that patients be suitable for both EVAR and open repair and be haemodynamically stable on arrival.<sup>19,22</sup> Therefore, we also undertook external validation using the wider Amsterdam cohort,<sup>87</sup> which included those participants who were unsuitable for randomisation in AJAX, as well as a large observational cohort of all patients presenting with ruptured AAAs in the Stockholm area (the STAR cohort<sup>74</sup>).

### Outcome measure

The principal outcome measure that is predicted is mortality within 48 hours of randomisation. The developed 48-hour risk score was also assessed to investigate whether or not it could reliably predict 30-day mortality.

### Candidate predictors

We predefined a set of variables for potential inclusion in the risk score based on the data available from the three trials of ruptured AAA (IMPROVE, AJAX and ECAR).

These variables included age, sex, admission systolic blood pressure, additional admission variables for the assessment of the Hardman index [haemoglobin, creatinine, acute myocardial ischaemia on electrocardiography and loss of consciousness] and four basic morphological features of the aneurysm that were measured using CT, which were chosen because they are required to assess the feasibility of EVAR and are relatively easy to measure in a time-critical situation (maximum aortic diameter, aortic neck diameter, aortic neck length and proximal neck angle). The AJAX and ECAR trials did not provide data regarding the volume of intravenous fluids administered or whether or not the participant suffered a preoperative cardiac arrest. Nevertheless, these variables were assessed for their predictive ability when developing the model in the IMPROVE trial data.

For the nine continuous candidate predictors (age, haemoglobin, creatinine, admission systolic blood pressure, volume of intravenous fluids administered, maximum aortic diameter, aortic neck diameter, aortic neck length and proximal aortic neck angle), non-linear relationships with the log-odds of mortality were investigated using fractional polynomials (FPs) based on complete data.<sup>95</sup> The powers of each predictor that were considered in the FP were  $-2$ ,  $-1$ ,  $-0.5$ ,  $0$ ,  $0.5$ ,  $1$ ,  $2$  and  $3$ , where, by convention in FP terminology,  $\chi^{(0)}$  was defined as  $\log(\chi)$ . A FP of degree  $-2$  was first considered with the best-fitting degree  $-2$  FP compared with the best-fitting degree  $-1$  FP using a chi-squared test of the difference in deviance (a  $p$ -value of  $> 0.1$  rejected the use of the more complex degree  $-2$  FP). Similarly, a degree  $-1$  FP was compared with just a linear relationship. Shapes of association were plotted for each final chosen FP for a predictor to assess biological plausibility.

### Missing data

To deal with missing data in the predictors, multiple imputation was carried out. The imputation model included all variables considered in the risk score plus the outcome measure (48-hour mortality), 30-day mortality, lowest systolic blood pressure, randomised group, preoperative cardiac arrest, operation received (EVAR, open repair or no operation) and hospital. Predictive mean matching was used for continuous variables and a chained equation strategy was used. Passive imputation was conducted for any non-linear relationships that were found in the prior FP exercise. Forty imputed data sets were generated. Systolic blood pressures, observed or imputed, that were  $< 33$  mmHg were set to the lowest presumed recordable value of 33 mmHg.

### Variable selection

A multivariable model was chosen using backwards selection, whereby all candidate predictors using their chosen FP transformation were initially included in the model. Estimates and standard errors (SEs) were obtained from pooling multiply imputed data sets using Rubin's rules to give (pooled) Wald  $p$ -values. The variable with the highest Wald  $p$ -value of  $\geq 0.157$  was then removed from the model (note that this  $p$ -value threshold approximately corresponds to a change in deviance of 2, and is akin to using the Akaike information criterion to carry out variable selection). This process was repeated until all remaining variables had a  $p$ -value of  $< 0.157$ .

The pooled coefficients of the selected variables across the multiply imputed data sets were used to define the risk score. The predicted probability (of mortality within 48 hours) for each person was obtained using the pooled coefficients applied to data from each imputed data set separately. The resulting  $M = 40$  linear predictors were then pooled using Rubin's rules before being transformed back to the probability scale to obtain a single risk prediction for each person.<sup>32</sup>

### **Developing a bedside predictive model**

For ease of use, it was also important to develop a simplified bedside prediction model, in which continuous covariates were dichotomised and coefficients from a fitted logistic model were converted to integers, to allow a simple summation of risks associated with an individual's risk factors. For each predictor, dichotomisation was implemented at a clinically relevant cut-off point or at a level close to the observed median.

### **Predictive performance**

The predicted probabilities of 48-hour mortality that were obtained from the continuous model and the bedside model were assessed in terms of calibration and discrimination. Calibration was assessed by plotting observed risks compared with predicted risks within deciles of predicted risk and reporting the estimated calibration slope from a Cox proportional hazards model with the risk score as the predictor.<sup>96</sup> Discrimination was assessed using the area under receiver operating characteristic (AUROC) curve, which assesses the ability of the prediction model to differentiate between those who do and do not experience the outcome. The AUROC gives an estimate of the probability of correctly identifying the case in a randomly chosen case-control pair of individuals, with a value of 1 indicating perfect discrimination and a value of 0.5 indicating that discrimination is no better than chance.

Internal validation (within the IMPROVE trial data set) was conducted using 10-fold cross-validation to avoid overoptimistic estimates of predictive performance caused by overfitting. Within each cross-validation, the FP and variable selection processes were re-derived using nine-tenths of the data to obtain a new prediction model, which was then validated on the remaining one-tenth of the data. This procedure was repeated 10 times for each nine-tenths split of the data and the average AUROC over these cross-validations was calculated to give an optimism-corrected estimate.

External validation was conducted using data from the AJAX and ECAR trials to give an assessment of how well the derived risk score applies in other populations. A further assessment of the model was carried out in the wider Amsterdam cohort<sup>87</sup> and the STAR cohort.<sup>74</sup>

### **Comparison with other published ruptured-abdominal aortic aneurysm risk scores**

For a comparison of the utility of the new ruptured AAA risk score for 48-hour mortality, we compared its predictive performance with the performance of other published risk scores using data from all three RCTs. Preoperative cardiac arrest was not comprehensively recorded in the three randomised trials and so was omitted from scores that used this variable. Furthermore, the use of a suprarenal clamp was not specifically recorded in these data sets and so a proxy (aortic neck length of < 10 mm) was used instead. This proxy was chosen based on a consensus arising from a questionnaire that asked 'What is the minimal length of aortic neck required to utilise an infrarenal clamp for AAA repair?', which was circulated at the June 2015 annual meeting of the British Society of Endovascular Therapy.

## **Results**

### **Participant characteristics**

A total of 536 IMPROVE trial participants with a final diagnosis of ruptured AAA met the inclusion criteria, of whom 135 (25%) died within 48 hours of randomisation. A total of 319 participants commenced open repair, 182 participants commenced EVAR and a further 35 participants did not receive an operation (were palliated or died before reaching theatre). There were 113 and 107 participants in the AJAX and ECAR trials, respectively, who met the inclusion criteria, of whom 17 (15%) and 15 (14%), respectively, died within 48 hours of randomisation. In the IMPROVE trial, participants were, on average, 2 years older and had larger aneurysms and a greater proportion of women were included (*Table 18*). In the Amsterdam cohort, 131 out of 514 patients (25%) died within 48 hours; the mortality rate was much higher in the STAR cohort, in which 107 out of 284 patients (38%) died, which was attributable, in part, to participants being an average of 4 years older. Patients in the STAR cohort also had, on average, lower admission systolic blood pressures and shorter aneurysm neck lengths, and a higher proportion had lost consciousness before arrival in the operating theatre.

**TABLE 18** Descriptive statistics of the candidate predictors for the three RCTs and two cohorts

Candidate predictor	Trial			Cohort	
	IMPROVE ( <i>N</i> = 536); 135 48-hour deaths (25%)	AJAX ( <i>N</i> = 113); 17 48-hour deaths (15%)	ECAR ( <i>N</i> = 107); 15 48-hour deaths (14%)	Amsterdam ( <i>N</i> = 525); 131 48-hour deaths (25%)	STAR ( <i>N</i> = 284); 107 48-hour deaths (38%)
Age (years), mean (SD) [ <i>N</i> ]	76 (8) [536]	74 (9) [113]	74 (11) [107]	75 (9) [515]	79 (9) [284]
Sex (male), <i>n</i> (%) [ <i>N</i> ]	424 (79) [536]	97 (86) [113]	97 (91) [107]	398 (77) [517]	215 (76) [284]
Admission haemoglobin (g/dl), mean (SD) [ <i>N</i> ]	11.1 (2.4) [530]	11.5 (2.3) [113]	10.6 (2.3) [107]	11.1 (2.5) [499]	11.1 (2.3) [273]
Admission creatinine (μmol/l), median (IQR) [ <i>N</i> ]	118 (95–153) [524]	106 (91–142) [107]	114 (91–136) [105]	110 (89–139) [478]	117 (90–140) [268]
Admission systolic blood pressure (mmHg), mean (SD) [ <i>N</i> ]	108 (32) [526]	120 (40) [110]	108 (30) [104]	113 (37) [440]	104 (39) [283]
Volume of i.v. fluids given before arrival in theatre (l), mean (SD) [ <i>N</i> ]	1.06 (1.13) [391]	–	–	–	–
Maximum aneurysm diameter (mm), mean (SD) [ <i>N</i> ]	86 (17) [460]	76 (16) [92]	77 (20) [106]	–	81 (19) [192]
Aneurysm neck diameter (mm), mean (SD) [ <i>N</i> ]	25 (4.3) [390]	26 (4.0) [92]	24 (4.5) [106]	–	29 (11) [192]
Neck length (mm), mean (SD) [ <i>N</i> ]	23 (17) [435]	27 (13) [92]	25 (14) [101]	21 (14) [271]	18 (18) [192]
Neck angle; proximal (degrees), mean (SD) [ <i>N</i> ]	33 (20) [432]	39 (21) [92]	34 (26) [96]	37 (22) [271]	23 (16) [192]
Acute ischaemia detected on ECG (yes), <i>n</i> (%) [ <i>N</i> ]	38 (7.7) [495]	12 (18.5) [65]	4 (3.7) [107]	42 (21.7) [194]	60 (43.2) [139]
Participant lost consciousness (yes), <i>n</i> (%) [ <i>N</i> ]	47 (9.2) [512]	13 (11.5) [113]	12 (11.2) [107]	–	68 (23.9) [284]
Cardiac arrest (yes), <i>n</i> (%) [ <i>N</i> ]	8 (1.5) [536]	–	–	–	–

–, not available; ECG, electrocardiogram; IQR, interquartile range; i.v., intravenous.

Reproduced from Sweeting et al.<sup>97</sup> © 2018 The Authors. BJS published by John Wiley & Sons, Inc., on behalf of BJS Society Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

### Risk score development

Unadjusted ORs for each candidate variable are given in *Table 19*, after multiple imputation. Most candidate predictors were correlated with the outcome. FP modelling indicated a cubic effect of age, an inverse squared effect of admission systolic blood pressure and a log-transformed effect of neck length on the log-odds of mortality (see *Appendix 2, Figure 30*). Following backwards variable selection, the final variables retained in the prediction model were (1) age, (2) sex, (3) admission haemoglobin, (4) admission creatinine, (5) admission systolic blood pressure, (6) aortic neck length, (7) aortic neck angle and (8) acute cardiac ischaemia. Coefficients based on transformations of these variables are shown in *Appendix 2, Table 40*. A simplified 'IMPROVE bedside score' also was derived using an integer points system (see *Appendix 2, Table 40*).

### Calibration and discrimination

Calibration plots are shown in *Appendix 2, Figure 31*, for both the IMPROVE score and the IMPROVE bedside score applied to the IMPROVE trial data. Both scores are generally well calibrated, particularly for individuals at a lower risk. The calibration slope was estimated as 1.07 (95% CI 0.83 to 1.32; *p* = 0.55) and 1.08 (95% CI 0.81 to 1.35; *p* = 0.54) for the IMPROVE score and IMPROVE bedside score, respectively, indicating that both low and high predictions are well calibrated.

**TABLE 19** Univariate analysis of candidate predictors using multiply imputed data

Variable	Univariate	
	OR <sup>a</sup> (95% CI)	p-value
Age (years) per 8-year increase	1.49 (1.18 to 1.80)	< 0.001
Admission haemoglobin (g/dl) per 2.4-g/dl increase	0.63 (0.50 to 0.76)	< 0.001
Admission creatinine (µmol/l) per 66-µmol/l increase	1.37 (1.11 to 1.62)	0.001
Admission systolic blood pressure (mmHg) per 32-mmHg increase	0.71 (0.56 to 0.86)	0.002
Volume of i.v. fluids given before arrival in theatre (l) per 1.13-l increase	1.28 (1.03 to 1.53)	0.014
Maximum aneurysm diameter (mm) per 17-mm increase	0.85 (0.67 to 1.03)	0.13
Aneurysm neck diameter (mm) per 4.3-mm increase	0.95 (0.74 to 1.16)	0.63
Neck length (mm) per 17-mm increase	0.64 (0.49 to 0.79)	< 0.001
Neck angle; proximal (degrees) per 20° increase	0.92 (0.72 to 1.12)	0.45
Sex (male)	0.44 (0.28 to 0.69)	< 0.001
Acute ischaemia detected on ECG (yes)	2.79 (1.46 to 5.34)	0.002
Participant lost consciousness (yes)	1.54 (0.80 to 2.94)	0.19

ECG, electrocardiogram; i.v., intravenous.  
 a Per SD increase for continuous variables and compared with the reference level for categorical variables.

The AUROCs of the model applied to the IMPROVE trial are provided in *Table 20*. The AUROC for this internal validation is derived using 10-fold cross-validation. The discriminative ability of the model is reasonable, but not exceptional, with an IMPROVE score AUROC of 0.720 (SE 0.025); this provides a slightly better predictive ability than the IMPROVE bedside score, which has an AUROC of 0.688 (SE 0.026).

### External validation

The IMPROVE score and IMPROVE bedside score were validated on the four external data sets (the AJAX and ECAR trials and the Amsterdam and Stockholm area cohorts).

**TABLE 20** Discriminative performance of the developed IMPROVE risk score for predicting 48-hour mortality, validated both internally (using IMPROVE trial data) and externally (using data from the AJAX and ECAR RCTs and the Amsterdam and STAR cohorts). Comparisons with other published risk scores are also shown

Model	Data set, AUROC (SE)				
	Development		Validation		
	IMPROVE (n = 536)	AJAX (n = 113)	ECAR (n = 107)	Amsterdam cohort (n = 514)	STAR cohort (n = 284)
IMPROVE score	0.720 (0.025) <sup>a</sup>	0.665 (0.062)	0.722 (0.073)	0.737 (0.024)	0.650 (0.034)
IMPROVE bedside score	0.688 (0.026) <sup>a</sup>	0.682 (0.055)	0.688 (0.079)	0.662 (0.025)	0.594 (0.035)
VSGNE <sup>93</sup>	0.638 (0.027)	0.628 (0.065) <sup>b</sup>	0.672 (0.068) <sup>b</sup>	0.655 (0.026) <sup>c</sup>	0.655 (0.033) <sup>b</sup>
Hardman index <sup>30</sup>	0.648 (0.026)	0.749 (0.050)	0.730 (0.068)	0.690 (0.026)	0.606 (0.035)
Vancouver <sup>94</sup>	0.635 (0.028)	0.609 (0.079) <sup>b</sup>	0.725 (0.069) <sup>b</sup>	0.642 (0.029) <sup>c</sup>	0.702 (0.033) <sup>b</sup>

VSGNE, Vascular Study Group of New England.  
 a Cross-validated AUROC (optimism corrected).  
 b Excluding cardiac arrest.  
 c Excluding preoperative cardiac arrest and loss of consciousness.

In AJAX, both AUROCs were < 0.70, whereas, in the ECAR trial, only the IMPROVE score gave an AUROC of > 0.70 (AUROC, 0.722; SE 0.073). In the two cohort studies, the Amsterdam cohort had a similar predictive performance to the ECAR trial, with a relatively high C-index for the IMPROVE score (0.737) but a low one for the IMPROVE bedside score (0.662), whereas the performance of both IMPROVE scores in the STAR cohort was relatively poor (AUROCs were < 0.650).

### Comparison with other published risk scores

We compared the developed IMPROVE risk scores with previously published risk scores, namely the Vascular Study Group of New England risk score,<sup>93</sup> the Hardman index<sup>30</sup> and the Vancouver risk score.<sup>94</sup> The derivation of each score is given in *Appendix 2, Table 41*.

In terms of discrimination, the developed IMPROVE risk score outperformed other published risk scores in the IMPROVE trial data, whereas the Hardman index score outperformed the new developed (IMPROVE) scores in the AJAX and ECAR trial data for 48-hour mortality (see *Table 20*). There is some heterogeneity in the performance of each risk score when applied to different populations. For example, the Hardman index score performed well in the AJAX and ECAR trials but less well in the Amsterdam and STAR cohorts, perhaps attributable to the fact that the randomised trials AJAX and ECAR recruited a selected population of participants with ruptured AAA (only patients with relative haemodynamic stability and morphologically suitable for EVAR). The overall performance of each risk score in comparison with the predictive ability (discrimination) using age alone is presented in *Figure 13*. The average C-index increase is pooled across cohorts, weighted by the study-specific number of events. The change in C-index is highest when using the IMPROVE score, although the increase is still rather modest:  $\Delta C = 0.08$  (95% CI 0.05 to 0.11).

### Performance of the risk scores in predicting 30-day mortality

The five different risk scores also were assessed for their ability to predict 30-day mortality, the results of which are given in *Appendix 2, Table 42*. The performance of two IMPROVE scores in the prediction of 48-hour mortality was similar; the difference in the C-index for 30-day mortality and for 48-hour mortality varied by study and risk score. For the three previously published risk scores (Vascular Study Group of New England, Hardman index and Vancouver) the 30-day C-indices were higher than the 48-hour C-indices in all studies except for the ECAR randomised trial, underlining the fact that these scores were developed using 30-day or in-hospital mortality as the outcome measure.


### Decision curve analysis

The clinical usefulness of any particular ruptured AAA risk score depends on the ability to make better decisions with a model than without it.<sup>98</sup> If the risk score was to be used to decide whom to operate on, or whom to transfer to a specialist centre, then a cut-off point is required to classify patients either as low risk (operate) or high risk (palliate).<sup>96</sup> The cut-off threshold should balance the benefit against the harms and, in an emergency setting, this threshold would naturally be very high because the harms of not treating ruptured AAA patients are dire. Nevertheless, there may be a range of very high-risk individuals in whom surgeons feel that it is futile to attempt an operation and that palliation is the best course of action. Following methodology developed by Vickers and Elkin,<sup>99</sup> the net benefit of treating patients at different risk cut-off points compared with treating none can be quantified and the value of a ruptured AAA risk score can be assessed. The cut-off value naturally defines the benefit-to-harm ratio that a surgeon is willing to accept. For example, supposing harms and benefits can be simply expressed in terms of quality-adjusted remaining life expectancy, a surgeon treating patients with a 48-hour mortality probability of  $\leq 98\%$  quantifies the consequence of not operating when it would have been of benefit to be 98 : 2 (49 times worse than the consequence of operating unnecessarily).<sup>96</sup>

*Figure 14* shows the net benefit decision curve for the full range of possible threshold probabilities.


The green horizontal line denotes the decision to treat no one (the net benefit being zero for all possible probability cut-off points). The blue line denotes the net benefit of treating everyone in relation to a chosen benefit-harm trade-off (the threshold probability) and the black line denotes the net benefit of treating only those with a mortality risk below the chosen threshold. The net benefit is higher than treating no one for





**FIGURE 13** Change in C-index for five ruptured AAA risk scores compared with the reference score using age alone. VSGNE, Vascular Study Group of New England. Reproduced from Sweeting *et al.*<sup>97</sup> © 2018 The Authors. BJS published by John Wiley & Sons, Inc., on behalf of BJS Society Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.





**FIGURE 14** Decision curve showing the benefit of the IMPROVE ruptured AAA risk score in helping to make treatment decisions. The graph shows the expected net benefit per patient relative to no treatment in any patient. Reproduced from Sweeting *et al.*<sup>97</sup> © 2018 The Authors. BJS published by John Wiley & Sons, Inc., on behalf of BJS Society Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

higher cut-off points in which the benefit-to-harm ratio is high. At a threshold probability of 1.0 (right hand side of the figure) surgeons would value an operation as infinitely better than no operation and hence the 'treat all' scenario gives the highest net benefit.

In *Figure 14*, the black line shows the net benefit if treatment decisions are based on the IMPROVE ruptured AAA risk score. The net benefit is almost identical to that of treating everyone for thresholds of > 50%. The benefit of a ruptured AAA risk score only becomes apparent for surgeons who would treat only low-risk individuals (i.e. with 48-hour mortality risk of  $\leq 40\%$ ). At a higher threshold of 90%, the ruptured AAA risk score would correctly identify all 401 survivors in the IMPROVE trial but it also correctly identifies only 2 out of 135 participants (1.5%) who died within 48 hours. This lack of sensitivity highlights why a ruptured AAA risk score is no better than a treat-all solution for most sensible thresholds.

## Conclusions

The developed ruptured AAA risk score has shown that there are some important predictors of survival to 48 hours after emergency admission, including two morphological variables (neck length and angle) that complicate emergency surgical repair by influencing the feasibility of endografting. Some of these predictors were found to have a non-linear relationship with the log-odds of mortality. The derived IMPROVE score performed adequately in the IMPROVE participants and outperformed other published risk scores in validation on some, but not all, external patient populations. In general, the published ruptured AAA risk scores to date do not have sufficient predictive accuracy to enable surgeons to make life or death decisions regarding providing an operation, as highlighted in the decision curve analyses. This conclusion is in agreement with the recent study<sup>100</sup> evaluating five different scoring systems for 30-day mortality in a cohort of Dutch patients (from outside the Amsterdam area) with a ruptured AAA. This study<sup>100</sup> evaluated the Vancouver score and Hardman index scores, together with the Glasgow<sup>101</sup> and Edinburgh<sup>102</sup> scores and the newly developed Dutch Aneurysm Score,<sup>103</sup> with areas under the curve ranging from 0.59 to 0.72. Vos *et al.*<sup>100</sup> also concluded that an almost perfect prediction is needed to withhold an intervention, and no current scoring system is capable of that.

The unconvincing performance of risk scores, when applied to data sets from which they were not derived, is disappointing. The IMPROVE risk score was novel in that it is the only risk score to focus on 48-hour mortality and to include morphological parameters. However, it does not really perform better than older

scores focusing on 30-day mortality when applied to other data sets, including population-based data sets such as those from the Stockholm area of Sweden and the Amsterdam area of the Netherlands. This would suggest that further research to assess the role of risk scores in the transfer of patients, from centres without emergency vascular cover to specialist vascular centres, would not be fruitful. The inability of risk scores to predict outcomes following emergency surgical repair with sufficient accuracy indicates that any risk score should be used only for comparing different populations or adjusting population data, as the Hardman index was used in the IMPROVE trial. If the mortality risk of ruptured AAA repair cannot be predicted with sufficient accuracy, we urge that the focus should shift to offering repair to more patients and to reducing non-intervention rates for emergency ruptured AAA repair, which are currently too high in England<sup>92</sup> and some other countries. In this context, it is of interest that, when we used a Delphi consensus approach to formulate guidelines for the transfer of patients to specialist vascular centres, cardiac arrest in the same admission was the only condition with complete agreement that the patients should not be transferred.<sup>62</sup> Nevertheless, there is some evidence that few patients (14%) may survive emergency repair of a ruptured AAA even after a preoperative cardiac arrest.<sup>104</sup> In such life or death situations, perhaps it is just not ethical to consider using risk scores to withhold treatment and we suggest that the focus should shift to ensuring that the wishes of the patient and their family are respected.



## Chapter 8 Collaborative research projects emanating directly from the IMPROVE trial

The collaborative individual patient data meta-analysis, which draws data from the three recent European randomised trials for the management of ruptured AAAs, has been discussed in the chapters focusing on the 30-day and 1-year outcomes of the IMPROVE trial (*Chapters 3 and 5*, respectively). The IMPROVE trial achieved its target recruitment because of the enthusiasm of the many local trial investigators and has provided detailed information about the morphology of ruptured AAAs from the core laboratory at St George's Hospital, London (under the supervision of grant applicants Matthew M Thompson and Robert J Hinchliffe). These factors have enabled the following four collaborative research projects, all of which had the approval of the IMPROVE Trial Management Committee and appropriate ethics approvals at collaborating centres as necessary:

1. The development of a practical approach to expert elicitation for RCTs with missing health outcomes, in collaboration with colleagues Alexina Mason, Manuel Gomes, Richard J Grieve and James Carpenter from the London School of Hygiene & Tropical Medicine.
2. The comparative morphology of intact and ruptured AAAs, in collaboration with colleagues at St George's Hospital CT core laboratory (including Alan Karthikesalingam, Matthew Grima and staff) and statisticians Mohammed Hudda and Michael J Sweeting.
3. Computational fluid dynamics of ruptured AAAs, in collaboration with Barry Doyle, Karol Miller and their students at the University of Western Australia.
4. Computational flow dynamics of CIAs, again in collaboration with Barry Doyle, Karol Miller and their students at the University of Western Australia as well as Maarit Venermo (University of Helsinki) and Igor Koncar (University of Belgrade).

### The development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes

The IMPROVE trial, like most RCTs, assessed participant HRQoL. In the IMPROVE trial, it was not possible to collect baseline data, but data were collected at three time points: 3 months, 12 months and 3 years after randomisation. Like most randomised trials with missing data, it was assumed that, after conditioning on the observed data, the probability of missing data does not depend on the participant's outcome and so the data are 'missing at random'.<sup>16,23</sup> This assumption is usually implausible, for example because participants in relatively poor health may be more likely to be non-responders to questionnaires or demit from routine clinical follow-up. Methodological guidelines recommend that trials undertake sensitivity analysis, which is best informed by elicited expert opinion, to assess whether or not conclusions are robust to alternative assumptions about the missing data. A major barrier to implementing these methods in practice is the lack of relevant practical tools for eliciting expert opinion.

We developed a new practical tool for eliciting expert opinion within the IMPROVE trial and demonstrate its use for the IMPROVE trial and its applicability to other randomised trials with missing QoL data. In the IMPROVE trial at 3 months post randomisation, 21% of participants did not complete HRQoL questionnaires (assessed using the EQ-5D-3L). We addressed this problem by developing a web-based tool that provides a practical approach to eliciting expert opinion about EQ-5D-3L differences between participants with missing data and those with complete data.

We developed an easy-to-use web-based elicitation tool using Shiny (RStudio Inc., Boston, MA, USA), a web application framework within the widely used statistical software, R (The R Foundation for Statistical Computing, Vienna, Austria),<sup>105</sup> which could be administered by e-mail or in conference breaks. We adopted a graphical approach, using three cartoon characters who had undergone either open repair or

endovascular repair of their ruptured AAA, minimised the administrative burden by collecting informed consent electronically and offered a £20 Amazon ([www.amazon.co.uk](http://www.amazon.co.uk); Amazon.com, Inc., Bellevue, WA, USA) gift card as a token of appreciation for completed surveys. 'Good practice' recommendations for eliciting expert opinion were followed, in particular by including a feedback question and allowing the experts to revise their answers.<sup>106</sup>

The scale of scores for the elicitation exercise is the same as the original scale for the EQ-5D-3L utility score, multiplied by 100 for ease of completion. The expert is provided with possible scores for typical patients, with six exemplar diagnoses on the scale between -20 and 100 (based on published literature), which were chosen as they were anticipated to be familiar to our experts and because they spanned the EQ-5D-3L scale.

A total of 26 experts participated in the elicitation exercise, the majority at the Annual Meeting of the Vascular Society of Great Britain and Ireland in Bournemouth in November 2015, because the Shiny tool was not compatible with all NHS interfaces. The elicited EQ-5D-3L scores were lower on average for the participants with missing data than for those with complete data, but there was considerable uncertainty in these elicited values.

We show how this expert opinion can define informative priors within a fully Bayesian framework to carry out sensitivity analyses that allow the missing data to depend on unobserved participant characteristics. The 'missing-at-random' analysis found that participants randomised to the endovascular strategy, compared with those randomised to open repair, had a higher average EQ-5D score, of 0.062 (95% CI -0.005 to 0.130). Our sensitivity analysis, which used the elicited expert information as pooled priors, found that the gain in average EQ-5D-3L score for the endovascular strategy, compared with open repair groups, was 0.076 (95% CI -0.054 to 0.198).

The estimated effect of randomised group on average EQ-5D-3L score was similar across the alternative approaches to the missing data, but the sensitivity analysis resulted in greater uncertainty about this mean difference; the credible intervals from allowing the data to be non-randomly missing were wider than following the missing-at-random assumptions and the complete case analyses. These wider credible intervals recognise the variation within and across the experts in the likely differences in outcomes between those with missing data and those with observed EQ-5D-3L data.

In conclusion, we have designed and exemplified a practical tool for eliciting the expert opinion required by recommended approaches to the sensitivity analyses of RCTs. We show how this approach allows the trial analysis to fully recognise the uncertainty that arises from making alternative plausible assumptions about the reasons for missing data. This tool can be widely used in the design, analysis and interpretation of future trials. This research project has now been published in *Clinical Trials*,<sup>107</sup> and to facilitate the use of this practical tool for other trials, materials have now been made available for download.<sup>107</sup>

## The comparative aortic morphology of intact and ruptured abdominal aortic aneurysms

Most AAAs are broadly fusiform in shape and, to date, the AAA diameter provides the best guide to the risk of aneurysm rupture. Some small studies have suggested that other factors, such as wall stress and the volume of luminal thrombus, might be just as important,<sup>108</sup> but none of these factors has been subject to a prospective investigation. Because automated or semi-automated three-dimensional reconstruction of aortic CT scans is now widely available and essential to the planning of endovascular repair, we wished to test the hypothesis that morphological features (other than maximum aortic diameter) might be associated with a ruptured AAA rather than an intact AAA and hence could be useful in assessing the risk of AAA rupture.

Using a standard methodology,<sup>26</sup> we measured the aortic morphology of 907 patients who had undergone elective repair of an intact AAA at St George's Hospital between 2009 and 2013 and 294 cases of ruptured AAA (blood outside the AAA sac and adequate-quality CT scan) from the IMPROVE trial. All CT scans were anonymised and held only trial numbers or St George's Hospital database identifying numbers. The following parameters were measured: proximal aneurysm neck (suprarenal aortic diameter, diameter of 1 mm below the distal renal artery, neck length,  $\alpha$  neck angle and neck conicality), maximum AAA diameter and thrombus volume, iliac bifurcation middle angle, and common iliac artery diameter and iliac tortuosity index.

Analysis was conducted in accordance with a prespecified analysis plan using a logistic regression approach in which analyses were stratified by sex. Regression models were adjusted for two prespecified confounders: maximum aneurysm diameter and age. In order to adjust for maximum aneurysm diameter, we formed narrow categories of the diameter and adjusted for the categorised variable in the models. These narrow categories were formed after careful examinations of the overlap of the AAA diameters in both populations.

The distribution of the morphological variables by ruptured or intact AAA and by sex is shown in *Table 21*. The association between aneurysm morphology and rupture of an AAA, when adjusting for all eight morphology variables and the prespecified confounders, is shown in *Table 22*. Neck diameter was associated with rupture in women, in whom an increase of 4.1 mm led to an adjusted OR of 2.06 (95% CI 1.10 to 3.86;  $p = 0.02$ ). Furthermore, aneurysm neck angle  $\alpha$  was also associated with rupture, but only in males. The adjusted OR was 1.53 (95% CI 1.22 to 1.92;  $p < 0.01$ ) per 18.3° increase.

The maximum iliac tortuosity index and iliac bifurcation middle angle both showed strong evidence of an inverse association with rupture in both sexes. An increase of 0.3 in the tortuosity index led to an adjusted OR of 0.27 (95% CI 0.20 to 0.37;  $p < 0.01$ ) in men and of 0.28 (95% CI 0.13 to 0.63;  $p < 0.01$ ) in women. For a 22.6° increase in the iliac bifurcation middle angle, there was an adjusted OR of 0.36 (95% CI 0.27 to 0.49;  $p < 0.01$ ) in men and of 0.49 (95% CI 0.29 to 0.83;  $p = 0.01$ ) in women.

**TABLE 21** Mean (SD) of key morphological variables (based on analysis sample)

Measurement	Sex, mean (SD)			
	Males (N = 1046)		Females (N = 151)	
	Elective repair (n = 800)	Rupture repair (n = 246)	Elective repair (n = 103)	Rupture repair (n = 48)
Aneurysm neck diameter at 1 mm (mm)	24.2 (4)	25.4 (3.8)	22 (4)	23.9 (5.2)
Aneurysm neck length (mm) <sup>a</sup>	31.5 (14.1)	30.9 (13.8)	29 (13.2)	29.8 (13.9)
Aneurysm neck angle $\alpha$ (degrees) <sup>a</sup>	20.9 (16.9)	31.5 (19)	26.6 (20.2)	32.9 (19.7)
Maximum common iliac artery diameter (mm) <sup>a</sup>	20.2 (7.3)	21 (8.7)	17.8 (6.8)	18 (5.3)
Neck conicality (mm)	0.5 (0.9)	0.6 (1.2)	0.6 (1.3)	0.6 (0.9)
Aortic aneurysm thrombus volume (mm <sup>3</sup> ) <sup>a</sup>	97.1 (85.8)	190.8 (125)	80 (63.5)	109.1 (82.5)
Maximum iliac tortuosity index <sup>a</sup>	1.5 (0.2)	1.3 (0.3)	1.5 (0.3)	1.2 (0.3)
Maximum aortic aneurysm diameter (mm)	65.9 (11.2)	84.3 (14.5)	62.9 (8.6)	70.9 (9.9)
Iliac bifurcation middle angle (degrees)	60.5 (22.8)	46.7 (15.9)	67.0 (22.9)	48.1 (26.5)
Age (years)	80.5 (8.3)	79.2 (7.4)	81.8 (8.2)	83.6 (6.8)
Suprarenal aortic diameter (mm)	27.4 (3.4)	26.1 (3.1)	26.1 (3.9)	24.7 (3.8)

a Non-normally distributed variables.

Morphological variables	Sex							
	Males (n = 1044) <sup>a</sup>				Females (n = 151)			
	Univariate OR (95% CI)	p-value	Multivariable OR (95% CI)	p-value	Univariate OR (95% CI)	p-value	Multivariable OR (95% CI)	p-value
Aneurysm neck diameter at 1 mm per 4.1-mm increase	1.15 (0.96 to 1.37)	0.134	1.17 (0.92 to 1.49)	0.209	1.55 (1.04 to 2.31)	0.033	2.06 (1.10 to 3.86)	0.024
Aneurysm neck length per 14.0-mm increase	1.13 (0.94 to 1.36)	0.191	1.24 (0.99 to 1.55)	0.060	0.97 (0.62 to 1.53)	0.910	1.14 (0.63 to 2.08)	0.668
Aneurysm neck α angle per 18.3° increase	1.34 (1.12 to 1.61)	0.001	1.53 (1.22 to 1.92)	< 0.001	1.20 (0.81 to 1.78)	0.373	1.10 (0.66 to 1.84)	0.707
Maximum common iliac artery diameter per 7.5-mm increase	0.96 (0.81 to 1.15)	0.663	1.22 (0.97 to 1.53)	0.088	0.86 (0.53 to 1.40)	0.549	0.70 (0.30 to 1.61)	0.399
Conicality per 1.0% per 1-mm increase	0.99 (0.84 to 1.17)	0.895	1.11 (0.90 to 1.37)	0.327	1.04 (0.71 to 1.53)	0.838	1.20 (0.70 to 2.05)	0.502
Aneurysm thrombus volume per 100.2-mm <sup>3</sup> increase	1.05 (0.87 to 1.28)	0.86	1.08 (0.83 to 1.41)	0.548	1.01 (0.56 to 1.83)	0.974	0.82 (0.36 to 1.88)	0.642
Maximum iliac tortuosity index per 0.3 increase	0.28 (0.21 to 0.37)	< 0.001	0.27 (0.20 to 0.37)	< 0.001	0.31 (0.15 to 0.63)	0.001	0.28 (0.13 to 0.63)	0.002
Iliac bifurcation angle per 22.6° increase	0.36 (0.28 to 0.47)	< 0.001	0.36 (0.27 to 0.49)	< 0.001	0.45 (0.27 to 0.76)	0.003	0.49 (0.29 to 0.83)	0.009
<sup>a</sup> Two men whose age was missing do not appear in the adjusted models.								
<b>Note</b>								
Odds ratios per SD change for key morphological variables from the multivariable imputed analysis, adjusted for all other key morphological variables.								

The results for patients, by quintiles of those morphological variables with significant associations with rupture, were also examined. Neck diameter demonstrates a positive linear trend among men across quintiles and a similar but less defined relationship in women. Neck angle,  $\alpha$ , showed an increasing positive linear association with rupture across the quintiles, but this relationship was unclear in women. The negative linear association between quintiles of tortuosity index and rupture among men was replicated in women, except for the fourth quintile, in which the adjusted OR increased slightly. The adjusted ORs for the quintiles of iliac bifurcation middle angle showed an extremely similar relationship to that of tortuosity index, in which a linear negatively associated relationship was visible in both sexes. The discrepancies and wide 95% CIs were likely to be attributable to the small group numbers in the analysis of women.

These data suggest that iliac artery parameters, including the aortic bifurcation angle and iliac tortuosity index, in addition to aortic diameter, might be helpful in assessing the risk of rupture. The cases of ruptured aneurysms from the IMPROVE trial had (after adjustment for aortic diameter and the other morphological variables), on average, narrower aortic bifurcation angles and less iliac artery tortuosity than cases of intact aneurysms. It may also be important to note that, after adjustment for aortic diameter and other morphological characteristics, thrombus volume was not associated with ruptured aneurysms compared with intact aneurysms.

These data and analyses have several limitations, particularly the relatively poor repeatability of the measurement of proximal neck angle and iliac bifurcation angle. For these reasons, newer software has been obtained, which allows for more repeatable measurement of angles. This measurement is ongoing and, therefore, the above analyses are regarded as preliminary. They have been reported and discussed at the International Meeting for Aortic Diseases in Liège, Belgium, in September 2016. The novel findings concerning iliac bifurcation angles and tortuosity also have been considered in our ongoing collaborations with the computation flow dynamics laboratory in Western Australia (reported in the next two sections).

## Computational fluid dynamics of ruptured abdominal aortic aneurysm

Knowledge of how aortic morphology influences AAA biomechanics is still developing. In a single case from the IMPROVE trial, we have considered whether or not regions of high wall stress in the aneurysm sac can predict the site of aneurysm rupture,<sup>109</sup> with further work in progress. The effects of proximal neck angle and iliac bifurcation angle on both wall shear stress (WSS) and wall stress have been previously reported. Previously, it has been indicated that AAA wall stress increased with both iliac bifurcation angle and aortic neck angle, whereas AAA WSS remained almost constant.<sup>110</sup> This might suggest that AAAs with higher proximal neck angles and iliac bifurcation angles are at a higher risk of rupture. However, the recent comparisons of the morphology of ruptured AAAs and intact AAAs (see *The comparative aortic morphology of intact and ruptured abdominal aortic aneurysms*) have questioned these suggestions and hinted that AAAs with wider iliac bifurcations might be less prone to rupture, despite other morphological factors.

Therefore, fluid–structure interaction simulations were carried out on a range of idealised AAA geometries to conclusively determine the influence of both proximal neck angle and iliac bifurcation angle on AAA wall stress and WSS.

We found a positive linear relationship between peak AAA WSS (i.e. the peak WSS observed in the AAA sac region) and iliac bifurcation angle (see *Appendix 2, Figure 32*). The mean peak WSS across all geometries was 4.52 Pa with maximum and minimum values of 2.91 Pa and 6.19 Pa, respectively. Therefore, peak WSS increased more than twofold when the iliac bifurcation angle increased from 30° to 150°. Peak WSS in the AAA increased only when the proximal neck angle was > 30° and when the velocity field also changed to > 30°. In contrast, peak wall stress (but not von Mises stress) increased linearly with iliac bifurcation angle, but there was no clear association with time-averaged WSS (TAWSS) (see *Appendix 2, Figure 32*).



These observations from fluid–structure interaction simulations may be important to support our findings of an apparent association between bifurcation angle and likelihood of rupture, with ruptured AAAs tending to have a smaller iliac bifurcation angle than an intact AAA (see *The comparative aortic morphology of intact and ruptured abdominal aortic aneurysms*). The simulation data have been submitted for publication.


## Morphological and computational flow dynamic characteristics of common iliac aneurysms

Common iliac aneurysms are rare (compared with AAAs); much less is known about their natural history<sup>111</sup> and the evidence base for their management is scant, although both open repair and endovascular repair are clinically effective.<sup>112</sup> In the IMPROVE trial, there were seven cases of rupture of an isolated common iliac aneurysm (in the absence of a significant AAA). In scientific studies such as computational flow dynamics, CIAs have the advantage of often having a normal or nearly normal contralateral common iliac artery for comparison. Initially, our interest was focused on whether the distribution of WSS or intraluminal thrombus predicted the site of CIA rupture. Common iliac aneurysms sometimes have one or more patent distribution arteries. So, using a single case study with several branches of the internal iliac artery, we undertook a simulation study to evaluate the effect of these outflow arteries on haemodynamics in the iliac aneurysm. We concluded that accounting for small downstream arteries may not be vital to accurate computations of upstream flow.<sup>113</sup> Other preliminary investigations included the residence time of platelets and monocytes, velocity fields, TAWSS, oscillatory shear index and endothelial cell activation potential. We found that high cell residence times, low TAWSS, high oscillatory shear index and high endothelial cell activation potential all correlate with regions of intraluminal thrombus development.<sup>114</sup> Initial investigations showed that the point of CIA rupture was usually in a region of low TAWSS (*Figure 15*).

After the indication that the iliac bifurcation angle and iliac artery tortuosity might be influential in discriminating the morphology of ruptured AAAs compared with intact AAAs, investigations were expanded to include a more comprehensive assessment of the morphology and computational flow dynamics of both ruptured CIAs and intact CIAs and their contralateral common iliac arteries. In particular, the underlying hypothesis was that the wider the iliac artery bifurcation was, the lower the WSS in the distal aneurysm would be, leading to an enhanced risk of rupture.





Through a network of collaborations, a total of 23 good-quality CT scans of CIAs, suitable for both morphological assessment and computational flow dynamics, were identified (10 cases of rupture and 13 cases of elective repair of an intact CIA; in 2/23 cases the aneurysms were bilateral). Visual inspection of the three-dimensional reconstructions of the CT scans suggested that the gross anatomy could be categorised as one of four types (*Table 23*), with most of the ruptures being of the saccular or forward-projecting type. The ruptures had a larger average CIA diameter than the intact CIAs (82.1 mm compared with 50.3 mm, respectively) and contained larger thrombus and calcium volumes than the intact CIAs. On average, the ruptured cases had wider bifurcation angles (91° compared with 67° for intact CIA cases) and more tortuous abdominal aortas than the intact CIA cases. For fusiform aneurysms, five out of eight cases had a right CIA but the other forms had predominantly left CIAs.

Although wider bifurcation angles were associated with intact AAAs compared with ruptured AAAs, the converse would appear to hold for an isolated CIA, in which rupture is associated with wide iliac bifurcation angles. These relationships provide novel mechanistic insights into the role of haemodynamics (and cellular activation) in precipitating the catastrophic event of aneurysm rupture and are subject to ongoing computational flow dynamic investigations.



**FIGURE 15** Rupture (marked by an x) usually occurs in regions of low TAWSS.

**TABLE 23** Categories of gross anatomy of common iliac aneurysms

CIA type	Gross anatomy	Image
Saccular	Large round aneurysm	
Forward-projecting	The aneurysm protrudes forward with a large area in the sagittal plane, maintaining a comparatively small area in the axial and coronal views	
Fusiform	A less severe dilatation that extends over a section of the artery in the direction of flow	
Kinked	There is a tight bend in the CIA, with the aneurysm immediately distal to this feature; in our data, all occurred on the left side	

**Added value from collaborations and future use of IMPROVE trial data**

This chapter provides a flavour of the added value emanating from a cohort of carefully phenotyped participants in a randomised trial. Some of the projects have been completed, whereas others will continue. In addition, we hope that data from the IMPROVE trial will be used in future high-quality collaborative studies, particularly to progress the management of patients with intact and ruptured AAAs.

## Chapter 9 Concluding remarks and suggestions for further research

There are few randomised trials carried out in contexts in which emergency surgery is required to save a patient's life. As such, this trial presented important challenges in design, implementation and interpretation.

### Trial design

An understanding of the trial design is pivotal to understanding and interpreting the findings of the IMPROVE trial. The pragmatic design (randomisation of patients at the point of clinical diagnosis by a senior clinician rather than after rupture had been proved on diagnostic imaging) has been criticised because it allowed the randomisation of patients without a rupture. In contrast, the design had the real advantage of reflecting the real-life situation in the emergency room, allowing for non-selective randomisation and randomisation of the most severely ill and unstable patients and stimulating rapid recruitment. Originally, another reason for the trial design was that it was feared that delays in CT and transfer to theatre in the endovascular strategy group might offset any benefits from EVAR; by the time the trial started, emergency CT scans were more accessible and CT was ubiquitous in both randomised groups. However, randomisation before CT to assess both rupture and the suitability for EVAR meant that we were comparing an endovascular strategy (EVAR with the default of open repair when either aortic morphology or operational reasons precluded EVAR) with open repair. Patients also were randomised before anaesthetic opinion about their suitability for general anaesthesia and whether or not the necessary endovascular facilities were available (such as theatre and staffing, including a CT radiographer). The IMPROVE trial was comparing different strategies for managing patients with suspected aneurysm rupture and, for this reason, was bound to have a higher rate of treatment non-compliance than most randomised trials, but it also allowed for a high external validity. The IMPROVE trial design contrasts with the 'cleaner' but highly selective designs of the Dutch<sup>19</sup> and French<sup>22</sup> randomised trials, in which patients were not randomised until after CT had indicated the presence of a rupture and when the patients were sufficiently stable to give informed consent. In the IMPROVE trial, the consent process included consent from relatives and, under the Mental Capacity Act 2005,<sup>25</sup> if approved by a senior non-treating clinician. Overall, the IMPROVE trial was designed to inform service provisions that would result in better outcomes for patients with ruptured AAAs and to collect data on health economic outcomes as well as the primary outcome of mortality and the clinical outcome of reinterventions.

### Implementation

The early phases of recruitment were slow because of regulatory difficulties and the need for sites to fulfil the credential criterion of having completed at least five cases of emergency EVAR with reasonable outcomes, a criterion approved by the Trial Steering Committee. However, in the last 18 months, recruitment was at the rate of  $\approx 20$  participants per month, with more than half of eligible (non-moribund) participants being randomised. This differs from the very selective randomisation in the Dutch<sup>19</sup> and French<sup>22</sup> trials, each of which took  $\approx 7$  years to recruit just over 100 participants. There has been criticism that the credential criteria did not allow for adequate experience in emergency EVAR. However, the timing of the trial was important. Recruitment took place between 2009 and 2013, before the National Abdominal Aortic Aneurysm Screening Programme was fully rolled out, which had an impact on the number of ruptures in men. The falling numbers of ruptures that have been operated on in England after this time emphasises the relevance of these considerations (Table 24).

**TABLE 24** The proportion of EVAR procedures compared with open repair procedures used for ruptured AAA repair in England, since the start of the IMPROVE trial

Year	<i>n</i>	Percentage of procedures	
		EVAR	Open repair
2009/10	1888	20.2	79.8
2010/11	1861	26.3	73.7
2011/12	1898	24.9	75.1
2012/13	1893	30.0	70.0
2013/14	1717	33.3	66.7
2014/15	1438	35.6	64.4
2015/16	1545	39.7	60.3

**Note**

Data are from HES.

## Interpretation

The early results from the IMPROVE trial showed few advantages for an endovascular strategy. By 30 days, mortality and reinterventions were similar in the two groups; only women (22% of the cohort) seemed to benefit from the endovascular strategy, in part because of their very high mortality after open repair. However, on average, participants in the endovascular strategy group (in which 64% were morphologically suitable for EVAR) spent less time in intensive care and went home sooner than those in the open repair group, and more often directly to home, leading to lower average costs. Similarly, despite their more selective designs, the Dutch and French trials also found no difference in 30-day mortality between their EVAR and open repair groups.

After 1 year, again none of the three trials showed a significantly higher mortality for open repair, although there was good evidence that the absolute mortality rate, particularly at 30 days, was influenced by aortic morphology and that those participants who were suitable for EVAR had lower mortality than those who were not suitable for EVAR, irrespective of the type of repair. This was a real advantage for the non-selective design of the IMPROVE trial. More importantly for participants in the IMPROVE trial, average QoL at both 3 and 12 months was better in the endovascular strategy than in the open repair group, with a QALY gain of borderline significance. Because the majority of costs were related to the primary admission and, at 1 year, average costs remained lower for the endovascular strategy group, the endovascular strategy was cost-effective at 1 year.

The IMPROVE trial is the only one of the three recent European trials to report comprehensive 3-year outcomes. Over time, there was a consistent trend for survival, for QoL to be slightly better and for costs to be lower, although not always significantly so, in the endovascular strategy group. These trends are amplified by 3 years.

At 3 years, the survival curves had diverged. Compared with the open repair group, the endovascular strategy had lower mortality, a finding that was particularly evident in the 502 participants for whom repair of a ruptured aneurysm had started. The reasons for the mid-term difference in survival are possibly related to the severity and invasiveness of the initial intervention and the subsequent need for intensive care. Participants in the open repair group had, on average, longer critical care stays than the endovascular strategy group (6.3 days compared with 4.2 days, respectively), and 46 participants in the open repair group required renal replacement therapy postoperatively, compared with 32 in the endovascular strategy group. Because both prolonged stay in critical care and acute kidney injury<sup>115,116</sup> are known to be associated with higher long-term mortality, it may be the differences in critical care that result in the mid-term divergence of the survival curves.

By 3 years, there was no significant difference in QoL between the groups, but the earlier gains in QoL, together with the survival gain, led to QALYs being significantly greater for the endovascular strategy group. The reintervention rate was similar between the randomised groups, but the endovascular strategy group had less severe reinterventions, leading to the overall costs still being lower for the endovascular strategy group. These factors then combine to give a very high probability (90%) of dominance for the endovascular strategy on the cost-effectiveness plane.

### **Contrasting results of the randomised trials in the elective setting and emergency setting**

After aneurysm rupture, an endovascular strategy offers no reduction in operative mortality at 30 or 90 days but offers an interim survival advantage at 3 years, which, together with the early gains in QoL, leads to a QALY gain after 3 years. Aneurysm-related reinterventions, particularly the more severe reinterventions, took place at a similar rate in both groups. For ruptures, the cost differences observed at 30 days (non-significantly in favour of the endovascular strategy group)<sup>21</sup> were not eroded by an increased burden of reinterventions in later follow-up; therefore, the endovascular strategy was deemed cost-effective. All of these results are in sharp contrast to those of earlier trials of elective EVAR compared with open repair of AAAs (*Table 25*).

The earlier trials of elective EVAR compared with open repair enrolled only selected participants who were known to be suitable for either treatment and mostly adhered strictly to the IFU of the likely endovascular device. In these trials in the elective setting, participants were younger, on average, by  $\approx 3$  years, and the proportion of women was smaller than in the IMPROVE trial. The trials found that 30-day mortality was 2.5 times lower for the EVAR groups than for the open repair groups but that, after 3 years, there was no difference in mortality between the groups. The reintervention rate to 5 years and beyond, was always much higher in the EVAR groups and, if anything, by 1 year, the open repair group had a higher average QoL and lower average health-care costs. Therefore, there was no evidence that EVAR was cost-effective.

The reasons for these differences in the comparative effectiveness of the endovascular strategy and open repair in the emergency and elective settings remain speculative. The shock associated with rupture, especially in those with pre-existing cardiac disease, probably kills many patients irrespective of the type of repair, but EVAR is less invasive and can be conducted under local anaesthesia, so that patients recover more rapidly than after open repair. The proportion of women in the IMPROVE trial (22%) was much higher than in the trials of elective aneurysm repair, and the advantages of the endovascular strategy were greater in women than in men. The continuing burden of major laparotomy-related reinterventions after open repair for ruptures (which are not seen after elective open repair) might contribute to both mid-term

**TABLE 25** Comparison of mid-term health outcomes from randomised trials for endovascular vs. open repair for elective and ruptured AAA repair

Parameter	Repair	
	Elective	Rupture
30-day mortality	2.5-fold higher for open repair <sup>88</sup>	No difference <sup>51</sup>
3-year mortality	No difference <sup>88</sup>	Endovascular strategy better
Length of primary hospital stay	No difference <sup>41,117</sup>	Shorter for endovascular strategy <sup>23</sup>
Reintervention rate	Twofold to threefold higher after EVAR <sup>88</sup>	No difference
Major or severe reinterventions	Twofold to threefold higher after EVAR <sup>89</sup>	No difference
QoL	Better after open repair or no difference at 1 year <sup>41,118,119</sup>	Better at 3 months and 1 year for endovascular strategy
Costs	EVAR higher <sup>41,120</sup>	Endovascular strategy slightly lower
Cost-effectiveness	EVAR not cost-effective <sup>91,119–121</sup>	Endovascular strategy is cost-effective

mortality and costs in the open repair group, whereas endovascular devices and the technical skills to deploy them may have improved since the trials of elective repair were conducted. The reconvergence of the survival curves beyond 3 years is unexplained too, but this phenomenon has also been observed in the analysis of Medicare<sup>47</sup> and registry data.<sup>79</sup> Possible explanations include excess cancer deaths and late failure of EVAR.

### **Metrics for reporting reinterventions after emergency aneurysm repair and patient perspectives**

The categorisation of reinterventions for the mid-term follow-up in the IMPROVE trial was based on clinician opinion of the severity of the intervention and whether or not the life of the patient was threatened if the reintervention was not successful. The scoring system used was based on the one developed for the very long-term follow-up of the EVAR 1 trial,<sup>89</sup> with additional reinterventions that were more specific to rupture and laparotomy-related complications scored by consensus of the IMPROVE trial investigators. The acceptance of scoring reinterventions on a scale from 1 to 5 would argue that similar scoring systems, with specific reporting metrics for events such as secondary rupture and late conversions to open repair, should be incorporated into the National Vascular Registry and similar data sets. Perhaps more importantly, the low number of patients and members of the public who were consulted had very different opinions to clinicians about the severity of reinterventions. They were unanimous in ranking amputation as the most feared complication or reintervention. These observations argue for the need for further work to incorporate patients' opinions into the metrics used for reporting the outcomes of ruptured AAA repair.

### **Implications for future health care**

The findings from the IMPROVE trial suggest that an endovascular strategy is better than open repair for a ruptured AAA. Therefore, a strong case can be made that all providers of emergency vascular services should be able to offer both emergency EVAR and open repair at all times (24 hours a day, 7 days a week). This requires considerable logistics with respect to the availability of appropriate personnel, facilities and consumables. Not all IMPROVE trial centres could offer randomisation every day of the week because specialist endovascular teams and/or facilities were not available. As a result, 26 out of 259 participants with a confirmed rupture and morphological suitability for EVAR and who were randomised to the endovascular strategy subsequently underwent open repair because the endovascular team and/or facility was not immediately available. The evidence from other centres across the world suggests that the use of standard, well-rehearsed protocols for ruptured aneurysm repair can reduce operative mortality, particularly for EVAR.<sup>54,122</sup> The development of optimal protocols and training is being addressed by the relevant professional bodies in the UK. The IMPROVE trial has shown that about one-third of patients are not morphologically suitable for standard EVAR, and using EVAR in morphologically unsuitable patients is associated with a high 30-day mortality. Therefore, the real challenges in the future may be associated with:

- providing sufficient capacity for emergency endovascular services
- the potential further restructuring of services for emergency vascular care to allow patients to be treated in centres that also have expertise in either emergency open surgery or complex endovascular surgery (e.g. using fenestrated or branched endografts), for the treatment of patients who are not morphologically suitable for standard EVAR
- ensuring the equitable availability and continuing cost-effectiveness of emergency vascular services.

Data from HES indicate that the proportion of emergency AAA repairs being carried out by EVAR is increasing year on year (see *Table 24*). The conduct and results of the IMPROVE trial may have contributed to these changes and further emphasises the need to provide sufficient capacity for emergency endovascular services. Given the findings of the IMPROVE trial, it would seem important for the health service to have sufficient capacity to ensure that the proportion of emergency AAA repairs that are undertaken by EVAR rather than open repair increases further.



## Suggestions for further research

These arise both from the trial itself and the associated studies described in *Chapters 4, 7 and 8*. Two very crucial pieces of further research are suggested:

1. Formal assessment of whether or not avoidance of general anaesthesia improves the survival of patients undergoing EVAR for ruptured AAA repair.
2. Improving resuscitation techniques for older persons with circulatory collapse, including the identification of evidence-based blood pressure targets, which can be incorporated into guidelines. This research should include but not be limited to ruptured aneurysms.

Other significant recommendations for further research include:

- To consider whether or not emergency paramedical staff and general practitioners could diagnose ruptured AAA with sufficient accuracy to allow the direct transfer of patients from home to a specialist vascular centre.
- To assess metrics, other than mortality, for reporting the outcomes of emergency surgery, which include the viewpoints of patients, timelines to treatment and avoidance of secondary transfers.
- To assess whether or not further centralisation of emergency vascular services may be required to allow provision of sufficient expertise in emergency complex endovascular repair (using fenestrated or branched endografts) and open repair of juxtarenal aneurysms and other aortoiliac aneurysms that are unsuitable for standard EVAR, as well as to increase the availability of emergency standard EVAR and open repair at all times (24 hours a day, 7 days a week).
- With the introduction of AAA screening for men, an increasing proportion of ruptures is likely to be in women and there is a need for the acquisition and analysis of more sex-specific data that might lead to further suggestions for improving outcomes for women.

In addition, and not specifically related to ruptured AAAs:

- to consider the practice of consent waivers and post-randomisation consent for trials of emergency medical treatment that is required to save a patient's life.

## Final words

This trial would not have been possible without the real commitment and enthusiasm of the vascular surgical community in the UK, as part of their enthusiasm to provide better-quality care for their patients.





# Acknowledgements

## Contributions of authors

**Pinar Ulug** (Trial Manager) was involved in the conduct, acquisition of data, analysis and reporting phases.

**Robert J Hinchliffe** (Professor of Vascular Surgery) was involved in the design, conduct and reporting phases, as well as in additional collaborative research.

**Michael J Sweeting** (Trial Statistician) was involved in the conduct, analysis and reporting phases.

**Manuel Gomes** (Senior Research Fellow in Health Economics) conducted the health economic analyses.

**Matthew T Thompson** (Professor of Vascular Surgery) was involved in the design, core laboratory and reporting phases, as well as additional collaborative research.

**Simon G Thompson** (Professor of Statistics) was involved in the design, analysis and reporting phases.

**Richard J Grieve** (Professor of Health Economics Methodology) was involved in the design, analysis and reporting phases, as well as additional collaborative research.

**Raymond Ashleigh** (Consultant Radiologist) was involved in the design, core laboratory and reporting phases, as well as in additional collaborative research.

**Roger M Greenhalgh** (Emeritus Professor of Surgery) was involved in the design and reporting phases.

**Janet T Powell** (Professor of Vascular Biology and Medicine) was involved in the design, conduct, analysis and reporting phases, as well as in additional collaborative research.

## Publications

Hinchliffe RJ, Powell JT, Cheshire NJ, Thompson MM. Endovascular repair of ruptured abdominal aortic aneurysm: a strategy in need of definitive evidence. *J Vasc Surg* 2009;**49**:1077–80.

Powell JT. Time to IMPROVE the management of ruptured abdominal aortic aneurysm: IMPROVE trialists. *Eur J Vasc Endovasc Surg* 2009;**38**:237–8.

The IMPROVE Trial Management Committee. Getting research in the NHS started: can we assess new technologies in a timely manner? *Lancet* 2010;**375**:2072.

Hinchliffe RJ, Ribbons T, Ulug P, Powell JT. The transfer of patients with ruptured abdominal aortic aneurysm from general hospitals to specialist vascular centres: results of a Delphi consensus study. *Emerg Med J* 2013;**30**:483–6.

Doyle BJ, McGloughlin TM, Miller K, Powell JT, Norman PE. Regions of high wall stress can predict the future location of rupture of abdominal aortic aneurysm. *CVIR* 2014;**37**:815–18.

IMPROVE Trial Investigators. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomised trial. *BMJ* 2014;**348**:f7661.

IMPROVE Trial Investigators. Observations from the IMPROVE trial concerning the clinical care of patients with ruptured abdominal aortic aneurysm. *Br J Surg* 2014;**101**:216–24.

IMPROVE Trial Investigators. An endovascular strategy for suspected ruptured abdominal aortic aneurysm brings earlier home discharge but not early survival or cost benefits. *Eur J Vasc Endovasc Surg* 2014;**47**:333–4.

IMPROVE Trial Investigators. Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomised trial. *Eur Heart J* 2015;**36**:2061–9.

IMPROVE Trial Investigators. The effect of aortic morphology on peri-operative mortality of ruptured abdominal aortic aneurysm. *Eur Heart J* 2015;**36**:1328–34.

Powell JT, Hinchcliffe RJ. Emerging strategies to treat ruptured abdominal aortic aneurysms. *Expert Rev Cardiovasc Ther* 2015;**13**:1411–8.

Powell JT, Ulug P. Flexibility in trial enrolment decisions. *BMJ* 2015;**351**:h4608.

Sweeting MJ, Balm R, Desgranges P, Ulug P, Powell JT, on behalf of Ruptured Aneurysm Trialists. Individual-patient meta-analysis of three randomised trials comparing endovascular versus open repair for ruptured abdominal aortic aneurysm. *Br J Surg* 2015;**102**:1229–39.

Sweeting MJ, Ulug P, Powell JT, Desgranges P, Balm R, for the Ruptured Aneurysm Trialists. Ruptured aneurysm trials: the importance of longer-term outcomes and meta-analysis for 1-year mortality. *Eur J Vasc Endovasc Surg* 2015;**50**:297–302.

Mason AJ, Gomes M, Grieve R, Ulug P, Powell JT, Carpenter J. Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: application to the IMPROVE trial. *Clin Trials* 2017;**14**:357–67.

IMPROVE Trial Investigators. Comparative clinical effectiveness and cost-effectiveness of an endovascular strategy versus open repair for ruptured abdominal aortic aneurysm: 3-year results of the IMPROVE randomised trial. *BMJ* 2017;**359**:j4859.

Kelsey LJ, Powell JT, Norman PE, Miller K, Doyle BJ. A comparison of hemodynamic metrics and intraluminal thrombus burden in a common iliac artery aneurysm. *Int J Numer Method Biomed Eng* 2017;**33**:e2821.

Sweeting MJ, Ulug P, Roy J, Hultgren R, Indrakusuma R, Balm R, *et al.* Value of risk scores in the decision to palliate patients with ruptured abdominal aortic aneurysm [published online ahead of print April 6, 2018]. *Br J Surg* 2018.

Powell JT, Sweeting MJ, Ulug P, Thompson MM, Hinchcliffe RJ, IMPROVE Trial Investigators. Re-interventions after repair of ruptured abdominal aortic aneurysm: a report from the IMPROVE randomised trial. *Eur J Vasc Endovasc Surg* 2018;**5**:625–32.

## Data sharing statement

Patient-level data can be made available from the corresponding author after authorisation by the Trial Management Committee and contractual agreement with Imperial College London. Consent from participants for data sharing was not obtained but any shared data will be anonymised.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.



# References

1. Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic abdominal aortic aneurysms. *Cochrane Database Syst Rev* 2015;**2**:CD001835. <https://doi.org/10.1002/14651858.CD001835.pub4>
2. Davis M, Harris M, Earnshaw JJ. Implementation of the National Health Service Abdominal Aortic Aneurysm Screening Program in England. *J Vasc Surg* 2013;**57**:1440–5. <https://doi.org/10.1016/j.jvs.2012.10.114>
3. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG, EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. *Lancet* 2004;**364**:843–8. [https://doi.org/10.1016/S0140-6736\(04\)16979-1](https://doi.org/10.1016/S0140-6736(04)16979-1)
4. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. *Br J Surg* 2002;**89**:714–30. <https://doi.org/10.1046/j.1365-2168.2002.02122.x>
5. Best VA, Price JF, Fowkes FG. Persistent increase in the incidence of abdominal aortic aneurysm in Scotland, 1981–2000. *Br J Surg* 2003;**90**:1510–15. <https://doi.org/10.1002/bjs.4342>
6. Norman PE, Powell JT. Abdominal aortic aneurysm: the prognosis in women is worse than in men. *Circulation* 2007;**115**:2865–9. <https://doi.org/10.1161/CIRCULATIONAHA.106.671859>
7. Anjum A, von Allmen R, Greenhalgh R, Powell JT. Explaining the decrease in mortality from abdominal aortic aneurysm rupture. *Br J Surg* 2012;**99**:637–45. <https://doi.org/10.1002/bjs.8698>
8. Aylin P, Bottle A, Majeed A. Use of administrative data or clinical databases as predictors of risk of death in hospital: comparison of models. *BMJ* 2007;**334**:1044. <https://doi.org/10.1136/bmj.39168.496366.55>
9. Filipovic M, Seagroatt V, Goldacre MJ. Differences between women and men in surgical treatment and case fatality rates for ruptured aortic abdominal aneurysm in England. *Br J Surg* 2007;**94**:1096–9. <https://doi.org/10.1002/bjs.5784>
10. Holt PJ, Poloniecki JD, Gerrard D, Loftus IM, Thompson MM. Meta-analysis and systematic review of the relationship between volume and outcome in abdominal aortic aneurysm surgery. *Br J Surg* 2007;**94**:395–403. <https://doi.org/10.1002/bjs.5710>
11. Veith FJ, Gargiulo NJ. Endovascular aortic repair should be the gold standard for ruptured AAAs, and all vascular surgeons should be prepared to perform them. *Perspect Vasc Surg Endovasc Ther* 2007;**19**:275–82. <https://doi.org/10.1177/1531003507304438>
12. Dillon M, Cardwell C, Blair PH, Ellis P, Kee F, Harkin DW. Endovascular treatment for ruptured abdominal aortic aneurysm. *Cochrane Database Syst Rev* 2007;**1**:CD005261. <https://doi.org/10.1002/14651858.CD005261.pub2>
13. Visser JJ, van Sambeek MR, Hamza TH, Hunink MG, Bosch JL. Ruptured abdominal aortic aneurysms: endovascular repair versus open surgery – systematic review. *Radiology* 2007;**245**:122–9. <https://doi.org/10.1148/radiol.2451061204>
14. Mastracci TM, Garrido-Olivares L, Ciná CS, Clase CM. Endovascular repair of ruptured abdominal aortic aneurysms: a systematic review and meta-analysis. *J Vasc Surg* 2008;**47**:214–21. <https://doi.org/10.1016/j.jvs.2007.07.052>

15. Visser JJ, van Sambeek MR, Hunink MG, Redekop WK, van Dijk LC, Hendriks JM, Bosch JL. Acute abdominal aortic aneurysms: cost analysis of endovascular repair and open surgery in hemodynamically stable patients with 1-year follow-up. *Radiology* 2006;**240**:681–9. <https://doi.org/10.1148/radiol.2403051005>
16. Hinchliffe RJ, Bruijstens L, MacSweeney ST, Braithwaite BD. A randomised trial of endovascular and open surgery for ruptured abdominal aortic aneurysm – results of a pilot study and lessons learned for future studies. *Eur J Vasc Endovasc Surg* 2006;**32**:506–13. <https://doi.org/10.1016/j.ejvs.2006.05.016>
17. Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med* 2004;**351**:1607–18. <https://doi.org/10.1056/NEJMoa042002>
18. Amsterdam Acute Aneurysm Trial Collaborators. Amsterdam Acute Aneurysm trial: background, design, and methods. *Vascular* 2006;**14**:130–5. <https://doi.org/10.2310/6670.2006.00027>
19. Reimerink JJ, Hoornweg LL, Vahl AC, Wisselink W, van den Broek TA, Legemate DA, et al. Endovascular repair versus open repair of ruptured abdominal aortic aneurysms: a multicenter randomized controlled trial. *Ann Surg* 2013;**258**:248–56. <https://doi.org/10.1097/SLA.0b013e31828d4b76>
20. Desgranges P, Kobeiter H, Castier Y, Sénéchal M, Majewski M, Krimi A. The Endovasculaire vs Chirurgie dans les Anévrysmes Rompus PROTOCOL trial update. *J Vasc Surg* 2010;**51**:267–70. <https://doi.org/10.1016/j.jvs.2009.10.128>
21. IMPROVE Trial Investigators. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomised trial. *BMJ* 2014;**348**:f7661. <https://doi.org/10.1136/bmj.f7661>
22. Desgranges P, Kobeiter H, Katsahian S, Bouffi M, Gouny P, Favre JP, et al. Editor's choice – ECAR (Endovasculaire ou Chirurgie dans les Anevrysmes aorto-iliaques Rompus): a French randomized controlled trial of endovascular versus open surgical repair of ruptured aortoiliac aneurysms. *Eur J Vasc Endovasc Surg* 2015;**50**:303–10. <https://doi.org/10.1016/j.ejvs.2015.03.028>
23. IMPROVE Trial Investigators. Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomized trial. *Eur Heart J* 2015;**36**:2061–9. <https://doi.org/10.1093/eurheartj/ehv125>
24. Royal College of Emergency Medicine. *Best Practice Guidelines for the Management and Transfer of Patients with a Diagnosis of Ruptured Abdominal Aortic Aneurysm to a Specialist Vascular Centre*. URL: [www.rcem.ac.uk/docs/College%20Guidelines/5z8.%20Management%20and%20Transfer%20of%20Patients%20with%20a%20diagnosis%20of%20Ruptured%20Abdominal%20Aortic%20Aneurysm.pdf](http://www.rcem.ac.uk/docs/College%20Guidelines/5z8.%20Management%20and%20Transfer%20of%20Patients%20with%20a%20diagnosis%20of%20Ruptured%20Abdominal%20Aortic%20Aneurysm.pdf) (accessed 16 November 2017).
25. Great Britain. *Mental Capacity Act 2005*. London: The Stationery Office; 2015.
26. Ghatwary T, Karthikesalingam A, Patterson B, Hinchliffe R, Morgan R, Loftus I, et al. St George's Vascular Institute Protocol: an accurate and reproducible methodology to enable comprehensive characterization of infrarenal abdominal aortic aneurysm morphology in clinical and research applications. *J Endovasc Ther* 2012;**19**:400–14. <https://doi.org/10.1583/11-3731MR.1>
27. Hoornweg LL, Wisselink W, Vahl AC, Reekers JA, van Delden OM, Legemate DA, Balm R. Interobserver and intraobserver variability of interpretation of CT-angiography in patients with a suspected abdominal aortic aneurysm rupture. *Eur J Vasc Endovasc Surg* 2008;**35**:295–300. <https://doi.org/10.1016/j.ejvs.2007.09.017>
28. Curtis L. *Unit Costs of Health and Social Care 2012*. Canterbury: Personal Social Services Research Unit, University of Kent; 2012.

29. Department of Health and Social Care. *National Schedule of Reference Costs for NHS Trusts, 2011–2012*. London: Department of Health and Social Care; 2012.
30. Hardman DT, Fisher CM, Patel MI, Neale M, Chambers J, Lane R, Appleberg M. Ruptured abdominal aortic aneurysms: who should be offered surgery? *J Vasc Surg* 1996;**23**:123–9. [https://doi.org/10.1016/S0741-5214\(05\)80042-4](https://doi.org/10.1016/S0741-5214(05)80042-4)
31. Acosta S, Ogren M, Bergqvist D, Lindblad B, Dencker M, Zdanowski Z. The Hardman index in patients operated on for ruptured abdominal aortic aneurysm: a systematic review. *J Vasc Surg* 2006;**44**:949–54. <https://doi.org/10.1016/j.jvs.2006.07.041>
32. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;**30**:377–99. <https://doi.org/10.1002/sim.4067>
33. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. *Stat Med* 1997;**16**:1017–29. [https://doi.org/10.1002/\(SICI\)1097-0258\(19970515\)16:9<1017::AID-SIM508>3.0.CO;2-V](https://doi.org/10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V)
34. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* 1999;**94**:13. <https://doi.org/10.1080/01621459.1999.10474144>
35. Bellamy SL, Lin JY, Ten Have TR. An introduction to causal modeling in clinical trials. *Clin Trials* 2007;**4**:58–73. <https://doi.org/10.1177/1740774506075549>
36. National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisals*. London: National Institute for Health and Care Excellence; 2013.
37. Dolan P, Gudex C, Kind P, Williams A. *A Social Tariff for EuroQoL: Results from a UK General Population Survey*. CHE Discussion Paper 138. York: Centre for Health Economics, University of York; 1999.
38. Organisation for Economic and Cooperation and Development (OECD). *Purchasing Power Parities and Exchange Rates for all OECD countries*. Paris: OECD. URL: [www.oecd.org/std/prices-ppp/purchasingpowerparitiespppsdata.htm](http://www.oecd.org/std/prices-ppp/purchasingpowerparitiespppsdata.htm) (accessed 16 November 2017).
39. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. *Health Econ* 2004;**13**:461–75. <https://doi.org/10.1002/hec.843>
40. Hoornweg LL, Wisselink W, Vahl A, Balm R, Amsterdam Acute Aneurysm Trial Collaborators. The Amsterdam Acute Aneurysm Trial: suitability and application rate for endovascular repair of ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg* 2007;**33**:679–83. <https://doi.org/10.1016/j.ejvs.2006.12.011>
41. Brown LC, Powell JT, Thompson SG, Epstein DM, Sculpher MJ, Greenhalgh RM. The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy. *Health Technol Assess* 2012;**16**(9). <https://doi.org/10.3310/hta16090>
42. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;**7**:177–88. [https://doi.org/10.1016/0197-2456\(86\)90046-2](https://doi.org/10.1016/0197-2456(86)90046-2)
43. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60. <https://doi.org/10.1136/bmj.327.7414.557>
44. Björck M, Wanhainen A. Nonocclusive mesenteric hypoperfusion syndromes: recognition and treatment. *Semin Vasc Surg* 2010;**23**:54–64. <https://doi.org/10.1053/j.semvascsurg.2009.12.009>
45. Azhar B, Patel SR, Holt PJ, Hinchliffe RJ, Thompson MM, Karthikesalingam A. Misdiagnosis of ruptured abdominal aortic aneurysm: systematic review and meta-analysis. *J Endovasc Ther* 2014;**21**:568–75. <https://doi.org/10.1583/13-4626MR.1>



46. Egorova N, Giacobelli J, Greco G, Gelijns A, Kent CK, McKinsey JF. National outcomes for the treatment of ruptured abdominal aortic aneurysm: comparison of open versus endovascular repairs. *J Vasc Surg* 2008;**48**:1092–100, 1100.e1–2. <https://doi.org/10.1016/j.jvs.2008.06.036>
47. Edwards ST, Schermerhorn ML, O'Malley AJ, Bensley RP, Hurks R, Cotterill P, Landon BE. Comparative effectiveness of endovascular versus open repair of ruptured abdominal aortic aneurysm in the Medicare population. *J Vasc Surg* 2014;**59**:575–82. <https://doi.org/10.1016/j.jvs.2013.08.093>
48. van Beek SC, Conijn AP, Koelemay MJ, Balm R. Editor's Choice - Endovascular aneurysm repair versus open repair for patients with a ruptured abdominal aortic aneurysm: a systematic review and meta-analysis of short-term survival. *Eur J Vasc Endovasc Surg* 2014;**47**:593–602. <https://doi.org/10.1016/j.ejvs.2014.03.003>
49. Moghadamyeghaneh Z, Sgroi MD, Chen SL, Kabutay NK, Stamos MJ, Fujitani RM. Risk factors and outcomes of postoperative ischemic colitis in contemporary open and endovascular abdominal aortic aneurysm repair. *J Vasc Surg* 2016;**63**:866–72. <https://doi.org/10.1016/j.jvs.2015.10.064>
50. Björck M. Surgery for ruptured abdominal aortic aneurysm. *BMJ* 2014;**348**:g95. <https://doi.org/10.1136/bmj.g95>
51. Sweeting MJ, Balm R, Desgranges P, Ulug P, Powell JT, Ruptured Aneurysm Trialists. Individual-patient meta-analysis of three randomized trials comparing endovascular versus open repair for ruptured abdominal aortic aneurysm. *Br J Surg* 2015;**102**:1229–39. <https://doi.org/10.1002/bjs.9852>
52. Groves EM, Khoshchreh M, Le C, Malik S. Effects of weekend admission on the outcomes and management of ruptured aortic aneurysms. *J Vasc Surg* 2014;**60**:318–24. <https://doi.org/10.1016/j.jvs.2014.02.052>
53. Salhab M, Farmer J, Osman I. Impact of delay on survival in patients with ruptured abdominal aortic aneurysm. *Vascular* 2006;**14**:38–42. <https://doi.org/10.2310/6670.2006.00011>
54. Starnes BW, Quiroga E, Hutter C, Tran NT, Hatsukami T, Meissner M, et al. Management of ruptured abdominal aortic aneurysm in the endovascular era. *J Vasc Surg* 2010;**51**:9–17. <https://doi.org/10.1016/j.jvs.2009.08.038>
55. Van Herzeele I, Sevdalis N, Lachat M, Desender L, Rudarakanchana N, Rancic Z. Team training in ruptured EVAR. *J Cardiovasc Surg* 2014;**55**:193–206.
56. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al. No surgical innovation without evaluation: the IDEAL recommendations. *Lancet* 2009;**374**:1105–12. [https://doi.org/10.1016/S0140-6736\(09\)61116-8](https://doi.org/10.1016/S0140-6736(09)61116-8)
57. National Institute for Health and Care Excellence. *Endovascular Aortic Stent-Grafts are Not Recommended for Patients with Ruptured Aneurysms Except in the Context of Research*. National Institute for Health and Care Excellence; 2009. URL: [www.nice.org.uk/guidance/ta167/chapter/1-Guidance](http://www.nice.org.uk/guidance/ta167/chapter/1-Guidance) (accessed 6 February 2018).
58. Mayer D, Rancic Z, Veith FJ, Lachat M. Part two: against the motion. EVAR offers no survival benefit over open repair for the treatment of ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg* 2015;**49**:119–27. <https://doi.org/10.1016/j.ejvs.2014.11.016>
59. Björck M, Mani K. Improving outcomes for ruptured abdominal aortic aneurysm. *Lancet* 2014;**383**:933–4. [https://doi.org/10.1016/S0140-6736\(14\)60385-8](https://doi.org/10.1016/S0140-6736(14)60385-8)
60. Mell MW, Wang NE, Morrison DE, Hernandez-Boussard T. Interfacility transfer and mortality for patients with ruptured abdominal aortic aneurysm. *J Vasc Surg* 2014;**60**:553–7. <https://doi.org/10.1016/j.jvs.2014.02.061>

61. Symons NR, Moorthy K, Almoudaris AM, Bottle A, Aylin P, Vincent CA, Faiz OD. Mortality in high-risk emergency general surgical admissions. *Br J Surg* 2013;**100**:1318–25. <https://doi.org/10.1002/bjs.9208>
62. Hinchliffe RJ, Ribbons T, Ulug P, Powell JT. Transfer of patients with ruptured abdominal aortic aneurysm from general hospitals to specialist vascular centres: results of a Delphi consensus study. *Emerg Med J* 2013;**30**:483–6. <https://doi.org/10.1136/emered-2012-201239>
63. IMPROVE Trial Investigators. Observations from the IMPROVE trial concerning the clinical care of patients with ruptured abdominal aortic aneurysm. *Br J Surg* 2014;**101**:216–24. <https://doi.org/10.1002/bjs.9410>
64. Gallerani M, Volpato S, Boari B, Pala M, De Giorgi A, Fabbian F, *et al.* Outcomes of weekend versus weekday admission for acute aortic dissection or rupture: a retrospective study on the Italian National Hospital Database. *Int J Cardiol* 2013;**168**:3117–19. <https://doi.org/10.1016/j.ijcard.2013.04.065>
65. Bell CM, Redelmeier DA. Mortality among patients admitted to hospitals on weekends as compared with weekdays. *N Engl J Med* 2001;**345**:663–8. <https://doi.org/10.1056/NEJMsa003376>
66. Mayer D, Rancic Z, Pfammatter T, Veith FJ, Lachat M. Choice of treatment for the patient with urgent AAA: practical tips. *J Cardiovasc Surg* 2009;**50**:595–8.
67. Mayer D, Aeschbacher S, Pfammatter T, Veith FJ, Norgren L, Magnuson A, *et al.* Complete replacement of open repair for ruptured abdominal aortic aneurysms by endovascular aneurysm repair: a two-center 14-year experience. *Ann Surg* 2012;**256**:688–95. <https://doi.org/10.1097/SLA.0b013e318271cebd>
68. Schanzer A, Greenberg RK, Hevelone N, Robinson WP, Eslami MH, Goldberg RJ, Messina L. Predictors of abdominal aortic aneurysm sac enlargement after endovascular repair. *Circulation* 2011;**123**:2848–55. <https://doi.org/10.1161/CIRCULATIONAHA.110.014902>
69. Dick F, Diehm N, Opfermann P, von Allmen R, Tevaearai H, Schmidli J. Endovascular suitability and outcome after open surgery for ruptured abdominal aortic aneurysm. *Br J Surg* 2012;**99**:940–7. <https://doi.org/10.1002/bjs.8780>
70. van Beek SC, Reimerink JJ, Vahl AC, Wisselink W, Reekers JA, Legemate DA, Balm R, Amsterdam Acute Aneurysm Trial Collaborators. Outcomes after open repair for ruptured abdominal aortic aneurysms in patients with friendly versus hostile aortoiliac anatomy. *Eur J Vasc Endovasc Surg* 2014;**47**:380–7. <https://doi.org/10.1016/j.ejvs.2014.01.003>
71. Alexander S, Bosch JL, Hendriks JM, Visser JJ, Van Sambeek MR. The 30-day mortality of ruptured abdominal aortic aneurysms: influence of gender, age, diameter and comorbidities. *J Cardiovasc Surg* 2008;**49**:633–7.
72. Sternbergh WC III, Carter G, York GW, Yoselevitz M, Money SR. Aortic neck angulation predicts adverse outcome with endovascular abdominal aortic aneurysm repair. *J Vasc Surg* 2001;**35**:482–6. <https://doi.org/10.1067/mva.2002.119506>
73. Baderkhan H, Gonçalves FM, Oliveira NG, Verhagen HJ, Wanhainen A, Björck M, Mani K. Challenging anatomy predicts mortality and complications after endovascular treatment of ruptured abdominal aortic aneurysm. *J Endovasc Ther* 2016;**23**:919–27. <https://doi.org/10.1177/1526602816658494>
74. Hultgren R, Zommorodi S, Gambe M, Roy J. A majority of admitted patients with ruptured abdominal aortic aneurysm undergo and survive corrective treatment: a population-based retrospective cohort study. *World J Surg* 2016;**40**:3080–7. <https://doi.org/10.1007/s00268-016-3705-9>

75. Neville AL, Nemtsev D, Manasrah R, Bricker SD, Putnam BA. Mortality risk stratification in elderly trauma patients based on initial arterial lactate and base deficit levels. *Am Surg* 2011;**77**:1337–41.
76. Hasler RM, Nuesch E, Jüni P, Bouamra O, Exadaktylos AK, Lecky F. Systolic blood pressure below 110 mmHg is associated with increased mortality in blunt major trauma patients: multicentre cohort study. *Resuscitation* 2011;**82**:1202–7. <https://doi.org/10.1016/j.resuscitation.2011.04.021>
77. Hasler RM, Nuesch E, Jüni P, Bouamra O, Exadaktylos AK, Lecky F. Systolic blood pressure below 110 mmHg is associated with increased mortality in penetrating major trauma patients: multicentre cohort study. *Resuscitation* 2012;**83**:476–81. <https://doi.org/10.1016/j.resuscitation.2011.10.018>
78. Oyetunji TA, Chang DC, Crompton JG, Greene WR, Efron DT, Haut ER, *et al.* Redefining hypotension in the elderly: normotension is not reassuring. *Arch Surg* 2011;**146**:865–9. <https://doi.org/10.1001/archsurg.2011.154>
79. Robinson WP, Schanzer A, Aiello FA, Flahive J, Simons JP, Doucet DR, *et al.* Endovascular repair of ruptured abdominal aortic aneurysms does not reduce later mortality compared with open repair. *J Vasc Surg* 2016;**63**:617–24. <https://doi.org/10.1016/j.jvs.2015.09.057>
80. Kapma MR, Dijkstra LM, Reimerink JJ, de Groof AJ, Zeebregts CJ, Wisselink W, *et al.* Cost-effectiveness and cost-utility of endovascular versus open repair of ruptured abdominal aortic aneurysm in the Amsterdam Acute Aneurysm Trial. *Br J Surg* 2014;**101**:208–15. <https://doi.org/10.1002/bjs.9356>
81. Rollins KE, Shak J, Ambler GK, Tang TY, Hayes PD, Boyle JR. Mid-term cost-effectiveness analysis of open and endovascular repair for ruptured abdominal aortic aneurysm. *Br J Surg* 2014;**101**:225–31. <https://doi.org/10.1002/bjs.9409>
82. Sweeting MJ, Ulug P, Powell JT, Desgranges P, Balm R, Ruptured Aneurysm Trialists. Ruptured aneurysm trials: the importance of longer-term outcomes and meta-analysis for 1-year mortality. *Eur J Vasc Endovasc Surg* 2015;**50**:297–302. <https://doi.org/10.1016/j.ejvs.2015.04.015>
83. IMPROVE Trial Investigators. The effect of aortic morphology on peri-operative mortality of ruptured abdominal aortic aneurysm. *Eur Heart J* 2015;**36**:1328–34. <https://doi.org/10.1093/eurheartj/ehu521>
84. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res* 2005;**14**:1523–32. <https://doi.org/10.1007/s11136-004-7713-0>
85. Noorani A, Page A, Walsh SR, Varty K, Hayes PD, Boyle JR. Mid-term outcomes following emergency endovascular aortic aneurysm repair for ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg* 2012;**43**:382–5. <https://doi.org/10.1016/j.ejvs.2011.12.023>
86. Hayes PD, Sadat U, Walsh SR, Noorani A, Tang TY, Bowden DJ, *et al.* Cost-effectiveness analysis of endovascular versus open surgical repair of acute abdominal aortic aneurysms based on worldwide experience. *J Endovasc Ther* 2010;**17**:174–82. <https://doi.org/10.1583/09-2941.1>
87. van Beek SC, Vahl A, Wisselink W, Reekers JA, Legemate DA, Balm R, Amsterdam Acute Aneurysm Trial Collaborators. Midterm re-interventions and survival after endovascular versus open repair for ruptured abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg* 2015;**49**:661–8. <https://doi.org/10.1016/j.ejvs.2015.02.015>
88. Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Becquemin JP, Greenhalgh RM, EVAR-1, DREAM, OVER and ACE Trialists. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. *Br J Surg* 2017;**104**:166–78. <https://doi.org/10.1002/bjs.10430>

89. Patel R, Sweeting MJ, Powell JT, Greenhalgh RM, EVAR trial investigators. Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. *Lancet* 2016;**388**:2366–74. [https://doi.org/10.1016/S0140-6736\(16\)31135-7](https://doi.org/10.1016/S0140-6736(16)31135-7)
90. van Beek SC, Vahl AC, Wisselink W, Balm R, Amsterdam Acute Aneurysm Trial Collaborators. Fate of patients unwilling or unsuitable to undergo surgical intervention for a ruptured abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg* 2015;**49**:163–5. <https://doi.org/10.1016/j.ejvs.2014.10.007>
91. Epstein D, Sculpher MJ, Powell JT, Thompson SG, Brown LC, Greenhalgh RM. Long-term cost-effectiveness analysis of endovascular versus open repair for abdominal aortic aneurysm based on four randomized clinical trials. *Br J Surg* 2014;**101**:623–31. <https://doi.org/10.1002/bjs.9464>
92. Karthikesalingam A, Holt PJ, Vidal-Diez A, Ozdemir BA, Poloniecki JD, Hinchliffe RJ, Thompson MM. Mortality from ruptured abdominal aortic aneurysms: clinical lessons from a comparison of outcomes in England and the USA. *Lancet* 2014;**383**:963–9. [https://doi.org/10.1016/S0140-6736\(14\)60109-4](https://doi.org/10.1016/S0140-6736(14)60109-4)
93. Robinson WP, Schanzer A, Li Y, Goodney PP, Nolan BW, Eslami MH, *et al.* Derivation and validation of a practical risk score for prediction of mortality after open repair of ruptured abdominal aortic aneurysms in a US regional cohort and comparison to existing scoring systems. *J Vasc Surg* 2013;**57**:354–61. <https://doi.org/10.1016/j.jvs.2012.08.120>
94. Chen JC, Hildebrand HD, Salvian AJ, Taylor DC, Strandberg S, Myckatyn TM, Hsiang YN. Predictors of death in nonruptured and ruptured abdominal aortic aneurysms. *J Vasc Surg* 1996;**24**:614–20. [https://doi.org/10.1016/S0741-5214\(96\)70077-0](https://doi.org/10.1016/S0741-5214(96)70077-0)
95. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. *Int J Epidemiol* 1999;**28**:964–74. <https://doi.org/10.1093/ije/28.5.964>
96. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. *Eur Heart J* 2014;**35**:1925–31. <https://doi.org/10.1093/eurheartj/ehu207>
97. Sweeting MJ, Ulug P, Roy J, Hultgren R, Indrakusuma R, Balm R, *et al.* Value of risk scores in the decision to palliate patients with ruptured abdominal aortic aneurysm [published online ahead of print April 6, 2018]. *Br J Surg* 2018.
98. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, *et al.* Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology* 2010;**21**:128–38. <https://doi.org/10.1097/EDE.0b013e3181c30fb2>
99. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006;**26**:565–74. <https://doi.org/10.1177/0272989X06295361>
100. Vos CG, de Vries JP, Werson DA, van Dongen EP, Schreve MA, Ünlü Ç. Evaluation of five different aneurysm scoring systems to predict mortality in ruptured abdominal aortic aneurysm patients. *J Vasc Surg* 2016;**64**:1609–16. <https://doi.org/10.1016/j.jvs.2016.05.099>
101. Samy AK, Murray G, MacBain G. Glasgow Aneurysm Score. *Cardiovasc Surg* 1994;**2**:41–4.
102. Tambyraja A, Murie J, Chalmers R. Predictors of outcome after abdominal aortic aneurysm rupture: Edinburgh Ruptured Aneurysm Score. *World J Surg* 2007;**31**:2243–7. <https://doi.org/10.1007/s00268-007-9181-5>
103. von Meijenfildt GC, van Beek SC, Bastos Gonçalves F, Verhagen HJ, Zeebregts CJ, Vahl AC, *et al.* Development and external validation of a model predicting death after surgery in patients with a ruptured abdominal aortic aneurysm: the Dutch Aneurysm Score. *Eur J Vasc Endovasc Surg* 2017;**53**:168–74. <https://doi.org/10.1016/j.ejvs.2016.10.024>

104. Harris DG, Garrido D, Oates CP, Kalsi R, Huffner ME, Toursavadkahi S, *et al.* Repair of ruptured abdominal aortic aneurysm after cardiac arrest. *J Vasc Surg* 2016;**64**:1497–502. <https://doi.org/10.1016/j.jvs.2016.05.085>
105. Chang W, Cheng J, Allaire J. *Shiny: Web Application Framework for R*. 2015. URL: <https://CRAN.R-project.org/package=shiny> (accessed 16 November 2017).
106. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. *J Clin Epidemiol* 2010;**63**:355–69. <https://doi.org/10.1016/j.jclinepi.2009.06.003>
107. Mason AJ, Gomes M, Grieve R, Ulug P, Powell JT, Carpenter J. Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: application to the IMPROVE trial. *Clin Trials* 2017;**14**:357–67. <https://doi.org/10.1177/1740774517711442>
108. Bluestein D, Dumont K, De Beule M, Ricotta J, Impellizzeri P, Verheghe B, Verdonck P. Intraluminal thrombus and risk of rupture in patient specific abdominal aortic aneurysm – FSI modelling. *Comput Methods Biomech Biomed Engin* 2009;**12**:73–81. <https://doi.org/10.1080/10255840903077170>
109. Doyle BJ, McGloughlin TM, Miller K, Powell JT, Norman PE. Regions of high wall stress can predict the future location of rupture of abdominal aortic aneurysm. *Cardiovasc Intervent Radiol* 2014;**37**:815–18. <https://doi.org/10.1007/s00270-014-0864-7>
110. Xenos M, Alemu Y, Zamfir D, Einav S, Ricotta JJ, Labropoulos N, *et al.* The effect of angulation in abdominal aortic aneurysms: fluid-structure interaction simulations of idealized geometries. *Med Biol Eng Comput* 2010;**48**:1175–90. <https://doi.org/10.1007/s11517-010-0714-y>
111. Richards T, Goode SD, Hinchliffe R, Altaf N, MacSweeney S, Braithwaite B. The importance of anatomical suitability and fitness for the outcome of endovascular repair of ruptured abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg* 2009;**38**:285–90. <https://doi.org/10.1016/j.ejvs.2009.05.018>
112. Patel NV, Long GW, Cheema ZF, Rimar K, Brown OW, Shanley CJ. Open vs. endovascular repair of isolated iliac artery aneurysms: a 12-year experience. *J Vasc Surg* 2009;**49**:1147–53. <https://doi.org/10.1016/j.jvs.2008.11.101>
113. Kelsey LJ, Miller K, Norman PE, Powell JT, Doyle BJ. The influence of downstream branching arteries on upstream haemodynamics. *J Biomech* 2016;**49**:3090–6. <https://doi.org/10.1016/j.jbiomech.2016.07.023>
114. Kelsey LJ, Powell JT, Norman PE, Miller K, Doyle BJ. A comparison of hemodynamic metrics and intraluminal thrombus burden in a common iliac artery aneurysm. *Int J Numer Method Biomed Eng* 2017;**33**. <https://doi.org/10.1002/cnm.2821>
115. Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. *Circulation* 2009;**119**:2444–53. <https://doi.org/10.1161/CIRCULATIONAHA.108.800011>
116. Williams TA, Ho KM, Dobb GJ, Finn JC, Knuiman M, Webb SA, Royal Perth Hospital ICU Data Linkage Group. Effect of length of stay in intensive care unit on hospital and long-term mortality of critically ill adult patients. *Br J Anaesth* 2010;**104**:459–64. <https://doi.org/10.1093/bja/aeq025>
117. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT, Matsumura JS, Kohler TR, *et al.* Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. *JAMA* 2009;**302**:1535–42. <https://doi.org/10.1001/jama.2009.1426>



118. Prinssen M, Buskens E, Blankensteijn JD. Quality of life endovascular and open repair. Results of a randomised trial. *Eur J Vasc Endovasc Surg* 2004;**27**:121–7. <https://doi.org/10.1016/j.ejvs.2003.11.006>
119. Stroupe KT, Lederle FA, Matsumura JS, Kyriakides TC, Jonk YC, Ge L, Freischlag JA, Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm in the OVER trial. *J Vasc Surg* 2012;**56**:901–9.e2. <https://doi.org/10.1016/j.jvs.2012.01.086>
120. Prinssen M, Buskens E, de Jong SE, Buth J, Mackaay AJ, van Sambeek MR, *et al.* Cost-effectiveness of conventional and endovascular repair of abdominal aortic aneurysms: results of a randomized trial. *J Vasc Surg* 2007;**46**:883–90. <https://doi.org/10.1016/j.jvs.2007.07.033>
121. Lederle FA, Stroupe KT, Kyriakides TC, Ge L, Freischlag JA, Open vs Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. Long-term cost-effectiveness in the Veterans Affairs open vs endovascular repair study of aortic abdominal aneurysm: a randomized clinical trial. *JAMA Surg* 2016;**151**:1139–44. <https://doi.org/10.1001/jamasurg.2016.2783>
122. Mehta M, Taggart J, Darling RC, Chang BB, Kreienberg PB, Paty PS, *et al.* Establishing a protocol for endovascular treatment of ruptured abdominal aortic aneurysms: outcomes of a prospective analysis. *J Vasc Surg* 2006;**44**:1–8. <https://doi.org/10.1016/j.jvs.2006.02.057>
123. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. *Health Technol Assess* 2006;**10**(44). <https://doi.org/10.3310/hta10440>
124. Dixon S, Mason S, Knowles E, Colwell B, Wardrope J, Snooks H, *et al.* Is it cost effective to introduce paramedic practitioners for older people to the ambulance service? Results of a cluster randomised controlled trial. *Emerg Med J* 2009;**26**:446–51. <https://doi.org/10.1136/emj.2008.061424>
125. Powell JT, Sweeting MJ, Ulug P, Thompson MM, Hinchliffe RJ, IMPROVE Trial Investigators. Re-interventions after repair of ruptured abdominal aortic aneurysm: a report from the IMPROVE randomised trial. *Eur J Vasc Endovasc Surg* 2018;**5**:625–32. <https://doi.org/10.1016/j.ejvs.2018.01.028>



# Appendix 1 Trial progress and recruitment

## The IMPROVE trial organisation and committees

Grant applicants: Professor Janet T Powell (Chief Investigator), Mr Bruce Braithwaite, Professor Nicholas J Cheshire, Professor Roger M Greenhalgh, Professor Richard J Grieve, Dr Tajek B Hassan, Professor Robert J Hinchliffe, Dr Simon Howell, Dr Fionna Moore, Dr Anthony A Nicholson, Professor Chee V Soong (deceased), Professor Matthew T Thompson and Professor Simon G Thompson.

Data and trial management: Dr Pinar Ulug (Trial Manager) and Ms Francine Heatley (Trial Manager, maternity cover, 2012–13), Ms Aisha Anjum (Trial Monitor, 2012–14) and Ms Gosia Kalinowska (Trial Administrator, 2014).

Statistical analyses: Dr Michael J Sweeting and Professor Simon G Thompson.

Health economics costs analyses: Dr Manuel Gomes and Professor Richard J Grieve.

Trial Management Committee: Professor Janet T Powell (Chairperson), Dr Raymond Ashleigh, Dr Manuel Gomes, Professor Roger M Greenhalgh, Professor Richard J Grieve, Professor Robert J Hinchliffe, Dr Michael J Sweeting, Professor Matthew T Thompson, Professor Simon G Thompson and Dr Pinar Ulug.

Trial Steering Committee: Professor Ian Roberts (Chairperson), Professor Sir Peter RF Bell, Mrs Anne Cheetham, Ms Jenny Stephany (2009–2012) and Professor Alison Halliday.

Data Monitoring and Ethics Committee: Professor Charles Warlow (Chairperson), Mr Peter Lamont, Professor Jonathan Moss and Professor Jan Tijssen.

Credentialing committee: Mr Bruce Braithwaite and Dr Anthony A Nicholson.

Core laboratory: Professor Matthew T Thompson, Dr Raymond Ashleigh and Luke Thompson.

The IMPROVE trial local investigators by participating NHS trust (in order of site start date from the earliest (September 2009) to the most recent (February 2013); numbers in parentheses indicate the number of participants entered into the trial:

- UK – Colin D Bicknell and Nicholas J Cheshire (to October 2014), Imperial College Healthcare NHS Trust, London (20); Jonathan R Boyle, Addenbrooke's Hospital, Cambridge (40); Ferdinand Serracino-Inglott and J Vince Smyth (December 2012 to November 2013), Manchester Royal Infirmary, Manchester (69); Matthew T Thompson and Robert J Hinchliffe, St George's Hospital, London (75); Rachel Bell, St Thomas' Hospital, London (81); Noel Wilson, Kent and Canterbury Hospital, Canterbury (23); Matt Bown and Martin Dennis (to December 2010), Leicester Royal Infirmary, Leicester (18); Meryl Davis, Royal Free Hospital, London (1); Raymond Ashleigh, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester (21); Simon Howell, Leeds General Infirmary, Leeds (23); Michael G Wyatt, Freeman Hospital, Newcastle (23); Domenico Valenti, King's College Hospital NHS Foundation Trust, London (2); Paul Bachoo, Aberdeen Royal Infirmary, Aberdeen (4); Paul Walker, The James Cook University Hospital, Middlesbrough (5); Shane MacSweeney, Queen's Medical Centre, Nottingham (34); Jonathan N Davies, Royal Cornwall Hospital, Truro (5); Dynesh Rittoo and Simon D Parvin (to December 2011), Royal Bournemouth Hospital, Bournemouth (22); Syed Waquar Yusuf, Royal Sussex County Hospital, Brighton (5); Colin Nice, Queen Elizabeth Hospital, Gateshead (5); Ian Chetter,



Hull Royal Infirmary, Hull (32); Adam Howard, Colchester General Hospital, Colchester (24); Patrick Chong, Frimley Park Hospital, Surrey (14); Raj Bhat, Ninewells Hospital, Dundee (8); David McLain, Royal Gwent Hospital, Newport; Andrew Gordon and Ian Lane (to June 2012), University Hospital of Wales, Cardiff (4); Simon Hobbs, New Cross Hospital, Wolverhampton (3); Woolagasen Pillay, Doncaster Royal Infirmary, Doncaster (8); Timothy Rowlands and Amin El-Tahir (to November 2012), Royal Derby Hospital, Derby (13); John Asquith, Royal Stoke University Hospital, Stoke-on-Trent (15); and Stephen P Cavanagh, The York Hospital, York (3).

- Canada – Luc Dubois and Thomas L Forbes (to August 2014), London Health Sciences Centre and Western University, London, Ontario (13).

Trial co-ordinators: Emily Ashworth, Ayoola Awopetu, Sara Baker, Hashem Barakat, Patricia Bourke, Claire Brady, Joanne Brown, Jennie Bryce, Christine Bufton, Debbie Campbell, Tina Chance, Angela Chrisopoulou, Marie Cockell, Andrea Croucher, Gail Curran, Leela Dabee, Nikki Dewhirst, Jo Evans, Christopher Fenner, Andy Gibson, Siobhan Gorst, Moira Gough, Norma Gourlay, Lynne Graves, Michelle Griffin, Josie Hatfield, Florence Hogg, Susannah Howard, Cían Hughes, Thomas Hughes, Alex James, Elizabeth Keene, Michelle Lapworth, Ian Massey, David Metcalfe, Awad Mohalhal, Teresa Novick, Daré Oladokun, Gareth Owen, Noala Parr, David Pintar, Joanna Smeed, Tom Smith, Sarah Spencer, Helen Thompson, Claire Thomson, Orla Thunder, Tom Wallace, Sue Ward, Vera Wealleans, Lesley Wilson, Janet Woods, Manu Zachariah and Ting Zheng.

Writing committee for reporting of 30-day outcomes: Janet T Powell (Chairperson), Michael J Sweeting, Matthew T Thompson, Raymond Ashleigh, Rachel Bell, Manuel Gomes, Roger M Greenhalgh, Richard J Grieve, Francine Heatley, Robert J Hinchliffe, Simon G Thompson and Pinar Ulug.


Writing committee for reporting of 1-year and 3-year outcomes: Raymond Ashleigh, Manuel Gomes, Roger M Greenhalgh, Richard J Grieve, Robert J Hinchliffe, Janet T Powell (Chairperson), Michael J Sweeting, Matthew T Thompson, Simon G Thompson and Pinar Ulug.

## **Referral of patients with ruptured aneurysms, trial recruitment, participant flow and completeness of participant follow-up**


The trial started in April 2009, with the recruitment of 600 participants initially planned to take place between October 2009 and December 2011 in 20–24 centres across the UK. Obtaining all of the relevant permissions for the trial to start in these centres was much slower than anticipated (*Figure 16*). The availability of centres to start recruiting is shown in *Figure 17* and recruitment to December 2011 is shown in *Figure 18*. The slow recruitment led us to investigate whether or not patients were being appropriately referred into the trial centres.

## **The referral of patients with ruptured abdominal aortic aneurysm and the development of guidelines for patient transfer**


The aims of these studies were to explore areas of consensus and disagreement concerning the interhospital transfer of patients with a clinical diagnosis of ruptured AAA. A three-round Delphi questionnaire approach was used among vascular and endovascular surgery from the IMPROVE trial and emergency medicine specialists, from IMPROVE trial centres and the NHS Wessex Clinical Strategic Network, to explore patient characteristics and clinical management issues for emergency interhospital transfer. Agreement was reported when 70% of respondents were in agreement. Initially, there was agreement that transfer patients should be: < 85 years of age, either alert or with fluctuating consciousness, with moderate or minimal systemic disease and needing no or some help with daily living. Round 3 clarified that patients requiring inotropes and those who were institutionalised for mental infirmity should be transferred. Those with cardiac arrest in a



**FIGURE 16** Time from NHS Site-Specific Information Form submission to NHS approval by December 2010. The vertical axis shows the site number. The average time to approval for 22 centres was 7 months. Site-Specific Information Forms initiate the permission process in the Integrated Research Application System.



**FIGURE 17** Progress with centres that were able to recruit. The target number of centres had opened by October 2010, > 12 months behind schedule.




**FIGURE 18** Recruitment to December 2011.

current episode should not be transferred. There was no agreement regarding whether or not those who were institutionalised with physical infirmities, unconscious and/or intubated patients or those with severe systemic disease should be transferred. Speed was accepted as important, with agreement for specialty trainees to arrange transfer, if consultants were not on-site. Consultant–consultant discussion was recommended for patients with severe systemic disease. CT confirmation of diagnosis was considered unnecessary before transfer (but ultrasound assessment was desirable) and transfers should not be delayed by waiting for specific tests. There was no agreement about blood tests and electrocardiography before transfer or whether or not blood should accompany the patient being transferred. There was no agreement regarding whether or not specific staff and/or facilities needed to be in place at the specialist hospital. A systolic blood pressure of  $\geq 70$  mmHg was sufficient for transfer without the need for intravenous fluids, unless deterioration occurred. Overall, broad agreement about the type of patient who should be eligible for transfer was achieved but disagreements about patient management issues, before and during transfer, remained. These findings were reported by Hinchliffe *et al.*<sup>62</sup> and led to the development of guidelines for patient referral, which have been adopted by the Royal College of Emergency Medicine, The Vascular Society of Great Britain and Ireland and the Royal Society of Radiologists.<sup>24</sup>

## Trial extensions and final trial recruitment

Owing to the slow start to recruitment, the trial was awarded a 15-month extension, with the new target of recruiting 600 participants by the end of June 2013 and with follow-up and reporting to be completed by July 2014 (which meant that many of the participants who were recruited in 2013 would have been followed up for  $< 1$  year). Additional centres were opened to achieve this. However, the ongoing reorganisation of vascular surgical services resulted in some centres, such as King's College Hospital NHS Foundation Trust (London), Queen Elizabeth Hospital (Gateshead) and New Cross Hospital (Wolverhampton), being closed. The recruitment target of 600 participants was achieved during the revised recruitment period and additional participants were randomised during early July 2013, during the period when sites were being notified of the close to recruitment (*Figure 19*).



**FIGURE 19** Progress of recruitment.

All centres also maintained a log of non-recruited patients, providing reasons (*Table 26*). Both the recruited and non-recruited participants are shown in the trial CONSORT diagram (*Figure 20*). In summary, 1275 patients were identified with a diagnosis of ruptured AAA, 623 were randomised and 652 were not randomised.

The Data Monitoring Committee approved the post-randomisation exclusion of 10 patients (three in the endovascular strategy group and seven in the open repair group) deemed ineligible because of violation of the inclusion. Two patients had a secondary rupture with previous aneurysm repair, one patient was admitted electively for aneurysm repair, three patients were randomised without consent before reaching the trial centre and the in-hospital clinical diagnosis was not ruptured aneurysm and four patients could not be identified in any hospital records. It is assumed that these four patients were randomised before reaching hospital and did not arrive alive.


The 30-day outcomes that were reported included mortality (the primary outcome measure), reinterventions, length of hospital stay, place of discharge and aneurysm morphology.

The new outcome measures that were included at the 1-year time point were QoL and use of health resources, both obtained from questionnaires, and cost-effectiveness. The Health Economist for the trial, Richard J Grieve, was spearheading methodological developments that would add to the robustness of the cost-effectiveness evaluations and we realised that half of the participants remained alive at 3 years after randomisation; a further extension request was submitted and granted. This second extension provided for cost-effectiveness reporting over a longer and more relevant time horizon and the follow-up of all participants for 3 years after randomisation, with closure and final reporting in December 2016. For the 1- to 3-year time period, the responsibility for collecting reintervention data was transferred from the local trial co-ordinators to the trial manager and audit team. Because the large majority of participants were from English sites, we planned to use HES to supplement the audit, particularly to collect information about aneurysm-related reinterventions at non-trial hospitals. Our final sources of data concerning first reinterventions are shown in *Table 27*.

**TABLE 26** Non-randomised patients, with reasons

Participating centre <sup>a</sup>	Reason (n)					Total excluded (n)
	Within inclusion criteria <sup>b</sup>	Patient preference <sup>c</sup>	Operational <sup>d</sup>	Clinician preference	Unknown	
Imperial College London (St Mary's Hospital and Charing Cross Hospital)	13	1	0	3	1	18
Addenbrooke's Hospital	29	0	2	7	13	51
Manchester Royal Infirmary	3	1	0	0	0	4
St George's Hospital	11	1	0	1	5	18
St Thomas' Hospital	24	6	0	0	0	30
Kent and Canterbury Hospital	4	1	1	0	0	6
Leicester Royal Infirmary	49	7	31	3	4	94
Wythenshawe Hospital	8	0	1	5	34	48
Leeds General Infirmary	22	4	4	3	6	39
Freeman Hospital	40	2	24	1	11	78
King's College Hospital	0	0	0	0	2	2
James Cook University Hospital	9	1	2	1	0	13
Queen's Medical Centre	44	2	1	13	0	60
Royal Cornwall Hospital	7	0	6	0	1	14
Royal Bournemouth Hospital	0	2	0	0	0	2
Royal Sussex County Hospital	1	0	15	0	0	16
Queen Elizabeth Hospital	5	0	3	0	0	8
Hull Royal Infirmary	5	1	0	8	0	14
Colchester General Hospital	19	3	0	0	15	37
Frimley Park Hospital	4	1	4	0	0	9
Royal Gwent Hospital and University Hospital of Wales	13	1	12	0	0	26
New Cross Hospital	3	0	2	1	0	6
Doncaster Royal Infirmary	4	0	1	0	1	6
Royal Derby Hospital	8	6	0	1	4	19
Royal Stoke University Hospital	6	0	0	0	0	6
London Health Sciences Centre and Western University	23	2	2	1	0	28
Total	354	42	111	48	97	652

<sup>a</sup> Four participating centres did not provide data for non-randomised patients.  
<sup>b</sup> Includes participants who were unfit for CT and/or intervention; EVAR suitability was pre-established.  
<sup>c</sup> Refusal of trial, preference for a specific treatment or preference for no treatment.  
<sup>d</sup> No radiology cover, EVAR suite not available, etc.



**FIGURE 20** A CONSORT diagram for outcomes to 30 days. a, Breach of protocol; numbers include two and three symptomatics in the endovascular strategy group and the open repair group, respectively. b, 28 morphologically suitable for EVAR.

**TABLE 27** Source of aneurysm-related reintervention data in 502 participants in whom repair of a rupture had started

Time period for first reintervention (years)	Primary source according to the protocol	Participants per data source (n)				Participants identified with reinterventions (n)
		Trial co-ordinator	HES <sup>a</sup>	Participant questionnaires	Audit	
0–1	Trial co-ordinator	162	5	2	22	191, with 0 at non-trial hospitals
1–3	Audit, supported by HES	20	10	1	17	48, with 2 at non-trial hospitals

a Health Episode Statistics for England only, providing data for trial and non-trial hospitals to 3 years after participant discharge from primary admission. During the first year, all data from HES or questionnaires were subsequently verified by the trial co-ordinators; there were an additional six participants with other surgery not related to the AAA. Between 1 and 3 years, all data from HES or questionnaires were verified by audit. Data from the trial co-ordinators were verified by audit.

Audit also identified participants with first and subsequent reinterventions beyond 3 years.

Owing to delays in obtaining data from HES to report aneurysm-related admissions and reinterventions at non-trial hospitals (received 16 December 2016), a further extension of 3 months, to 31 March 2017, was obtained. CONSORT diagrams show the completeness of follow-up at 1 year and 3 years (*Figures 20 and 8*, respectively). At these stages, information from HES and similar sources was used to check for hospital admissions and procedures during the first 1 and 3 years after randomisation.

The trial, its extensions and its reporting deadlines are summarised in *Figure 21*.

	April 2009	2010	2011	2012	2013	2014	2015	2016	2017	
Initial contract	Recruitment and reporting of 30-day and 1-year outcomes									
Recruitment		330 patients								
Plus first extension	To allow for recruitment of 600 patients by June 2013 (accomplished)									
Recruitment		613 patients								
Outputs					30-day mortality BMJ/BJS		(1) Morphology and 30-day outcomes (2) 1-year clinical effectiveness and cost-effectiveness outcome (3) Individual patient data meta-analysis of three trials		Interim 3-year results to Vascular Society	3-year results at Charing Cross Symposium and Society for Vascular Surgery
Plus second extension		To allow for 3-year follow-up of all patients by July 2016 and individual patient meta-analyses of all European trials								No cost extension for HES data
Future outputs										(1) 3-year clinical effectiveness and cost-effectiveness (2) Risk scoring (3) Further morphology data (4) Video overview

**FIGURE 21** Overview of the trial. BJS, *British Journal of Surgery*; BMJ, *British Medical Journal*; HES, Hospital Episode Statistics.





## Appendix 2 Additional tables and figures

**TABLE 28** Unit costs (GBP) for 1-year analyses

Description	Unit	Cost (£)		Source
		Open repair	Endovascular strategy	
Medical devices and parts				
Endovascular stent and parts	Patient		5700	Medtronic (Minneapolis, MN, USA) and Cook Medical (Bloomington, IN, USA) <sup>a</sup>
Vascular graft (straight)	Patient	623		Maquet (Rastatt, Germany)
Vascular graft (bifurcated)	Patient	901		Maquet
Consumables				
Endovascular package	Patient		600	Maquet and Cook Medical
Mechanical retractor	Patient	90		Health-Care Equipment (Surrey, UK)
Cell salvage	Patient	74		Davies <i>et al.</i> 2006 <sup>123</sup>
Surgical instrument set	Patient	51	51	Health-Care Equipment
Anaesthetics and other drugs	Patient	184	41	<i>British National Formulary</i> 2012 <sup>b</sup>
Contrast agent	ml	0.10	0.10	IMPROVE trial centres <sup>b</sup>
Blood	Unit	132	132	NHS Blood and Transplant 2012
Platelets	Unit	205	205	NHS Blood and Transplant 2012
Fresh-frozen plasma	Unit	25	25	NHS Blood and Transplant 2012
CT scan	Unit	105	105	NHS Reference Costs 2012 <sup>29</sup>
Emergency room	Minute	0.40	0.40	Dixon <i>et al.</i> 2009 <sup>124</sup>
Overheads				
Theatre	Minute	2.65	2.65	IMPROVE trial centres
Staff <sup>c</sup>				
Surgeon (consultant)	Minute	2.20	2.20	PSSRU 2012 <sup>28</sup>
Surgeon (registrar)	Minute	1.16	1.16	PSSRU 2012 <sup>28</sup>
Anaesthetist (consultant)	Minute	2.20	2.20	PSSRU 2012 <sup>28</sup>
Anaesthetist (registrar)	Minute	1.16	1.16	PSSRU 2012 <sup>28</sup>
ODA	Minute	0.58	0.58	PSSRU 2012 <sup>28</sup>
Scrub nurse	Minute	0.72	0.72	PSSRU 2012 <sup>28</sup>
Runner	Minute	0.58	0.58	PSSRU 2012 <sup>28</sup>
Senior house officer	Minute	0.83		PSSRU 2012 <sup>28</sup>
Radiologist (consultant)	Minute		2.20	PSSRU 2012 <sup>28</sup>
Radiologist (registrar)	Minute		1.16	PSSRU 2012 <sup>28</sup>
Radiographer	Minute		0.58	PSSRU 2012 <sup>28</sup>
Radiologist nurse	Minute		0.72	PSSRU 2012 <sup>28</sup>

continue

continued

**TABLE 28** Unit costs (GBP) for 1-year analyses (*continued*)

Description	Unit	Cost (£)		Source
		Open repair	Endovascular strategy	
Critical care				
ITU/HDU: one organ supported	Bed-day	630	630	NHS Reference Costs 2012 <sup>29</sup>
ITU/HDU: two organs supported	Bed-day	870	870	NHS Reference Costs 2012 <sup>29</sup>
ITU/HDU: three organs supported	Bed-day	1214	1214	NHS Reference Costs 2012 <sup>29</sup>
ITU/HDU: four organs supported	Bed-day	1410	1410	NHS Reference Costs 2012 <sup>29</sup>
ITU/HDU: five organs supported	Bed-day	1587	1587	NHS Reference Costs 2012 <sup>29</sup>
ITU/HDU: six organs supported	Bed-day	1759	1759	NHS Reference Costs 2012 <sup>29</sup>
ITU/HDU: seven organs supported	Bed-day	2000	2000	NHS Reference Costs 2012 <sup>29</sup>
Other hospital care				
Inpatient coronary care unit	Bed-day	436	436	NHS Reference Costs 2012 <sup>29</sup>
Inpatient stroke unit	Bed-day	309	309	NHS Reference Costs 2012 <sup>29</sup>
Inpatient routine ward <sup>d</sup>	Bed-day	260	260	NHS Reference Costs 2012 <sup>29</sup>
Outpatient doctor visit	Visit	139	139	PSSRU 2012 <sup>28</sup>
Outpatient nurse visit	Visit	85	85	PSSRU 2012 <sup>28</sup>
Outpatient haemodialysis	Session	65	65	NHS Blood and Transplant, Price list 2011/12
Community care				
Nursing home	Bed-day	105	105	PSSRU 2012 <sup>28</sup>
Family doctor visit <sup>e</sup>	Visit	55	55	PSSRU 2012 <sup>28</sup>
Nurse at home visit <sup>e</sup>	Visit	18	18	PSSRU 2012 <sup>28</sup>

HDU, high-dependency unit; ITU, intensive therapy unit; ODA, operating department assistant; PSSRU, Personal Social Services Research Unit.

a Average (range from £5400 to £6500) list price of the EVAR stents and parts that are most supplied to NHS hospitals for ruptured AAAs [Endurant™ (Medtronic, Minneapolis, MN, USA) and Zenith Flex® (Cook Medical, Bloomington, IN, USA)].

b Local and general anaesthesia components were taken from one IMPROVE trial centre.

c Typical levels of staff use in theatre were recorded in 10 IMPROVE trial centres.

d The same tariff was applied to routine wards in both primary and secondary hospitals.

e Assuming 15-minute appointments.

#### Note

Reproduced from the IMPROVE Trial Investigators.<sup>23</sup> © The Authors 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

**TABLE 29** Survey of staff (who were present in the operating suite for endovascular repair and open repair); from 10 IMPROVE trial centres in November 2012

	Trial centre number (n)												
Staff use by type of operation	1	2	3	4	5	6	7	8	9	10	Total (n)	Base case	Sensitivity analysis
Open repair													
Anaesthetist (consultant)	0	0	1	1	1	1	1	0	1	1	10	✓	✓
Anaesthetist (registrar)	1	1	1	1	1	1	1	1	1	1	7	✓	✓
Vascular surgeon (consultant)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Vascular surgeon (registrar)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
ODA (grade 5)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Scrub nurse (grade 6)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Runner (grade 5)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
House officer (level 2)	0	1	0	1	0	0	0	0	0	1	3	?	✓
Second nurse (grade 5)	0	1	0	0	0	0	0	0	0	0	1	?	✓
Second runner (grade 5)	1	0	1	0	0	0	0	1	0	0	3	?	✓
Second surgeon (consultant)	0	0	0	1	0	0	0	0	0	0	1	?	✓
Second surgeon (registrar)	0	0	0	1	0	0	0	0	0	1	2	?	✓
EVAR													
Anaesthetist (consultant)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Anaesthetist (registrar)	0	0	1	0	0	1	1	0	1	1	5	✓	✓
Vascular surgeon (consultant)	1	1	1	1	1	1	1	1	1	1	9	✓	✓
Vascular surgeon (registrar)	0	1	1	1	1	1	1	1	1	1	10	✓	✓
ODA (grade 5)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Scrub nurse (grade 6)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Runner (grade 5)	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Radiographer	1	1	1	1	1	1	1	1	1	1	10	✓	✓
Radiologist (consultant)	1	1	1	0	1	1	1	1	1	1	9	✓	✓
Radiology nurse (grade 6)	1	1	0	0	0	1	0	1	1	1	6	✓	✓
Second runner (grade 5)	0	0	1	0	0	0	0	1	0	0	2	?	✓
Radiologist (registrar)	0	0	0	0	1	0	1	0	1	0	3	?	✓
ODA, operating department assistant.													

**TABLE 30** Resource use and costs (GBP) to 30 days, by randomised group

Cost component	Treatment group	
	Endovascular strategy (N = 316)	Open repair (N = 297)
Primary admissions		
Time in emergency room (minutes), mean (SD) <sup>a</sup>	93 (370)	73 (157)
Cost (£)	136 (138)	119 (51)
Devices and consumables (£), mean (SD)	4337 (2915)	2523 (2036)
Time in theatre (minutes), mean (SD) <sup>b</sup>	156 (100)	180 (107)
Cost (£)	2050 (1290)	2101 (1264)
Days in critical care, mean (SD)	4.2 (5.9)	6.3 (7.7)
Cost (£)	5249 (8779)	8100 (11,020)
Days on routine ward, mean (SD) <sup>c</sup>	5.2 (5.0)	5.7 (6.7)
Cost (£)	1425 (1591)	1518 (1814)
Reinterventions, n (%)	44 (14)	48 (16)
Cost (£), mean (SD)	172 (581)	224 (1042)
Readmissions		
Number of readmissions, n (%)	6 (1.7)	5 (1.9)
Cost (£), mean (SD)	64 (554)	34 (290)
Total hospital stay (days), mean (SD)	9.8 (9.0)	12.2 (10.2)
Total cost (£), mean (SD)	13,433 (10,354)	14,619 (12,353)
Incremental cost (£) (95% CI)	-1186 (-2997 to 625)	

a Includes costs of CT and contrast agent.

b The unit cost of theatre time for those who actually received the EVAR procedure was £885 per hour and, for those who actually received open repair, was £675 per hour; reflecting the additional staff required for the EVAR procedure.

c Participants who did not undergo aneurysm repair (8.9%) were assumed to stay on a routine ward throughout the hospitalisation.

**Note**

For ≈8% of participants, resource use data were missing; results reported are following multiple imputations. Unit costs are reported *Table 28*.

**TABLE 31** Variables considered for multiple imputations and imputation models considered

Variable	Missing values, <i>n</i> (%) <sup>a</sup>	Imputation model
Baseline variables and vital status		
Randomised group (endovascular strategy vs. open repair)	0 (0)	None required
Age	0 (0)	None required
Sex	0 (0)	None required
Loss of consciousness during care episode	27 (4)	Logistic regression
Admission haemoglobin	6 (1)	Predictive mean matching
Admission creatinine	13 (2)	Predictive mean matching
Acute myocardial ischaemia	52 (8)	Logistic regression
Maximum aortic diameter	95 (15)	Predictive mean matching
Aneurysm neck diameter <sup>b</sup>	230 (38)	Predictive mean matching
Aneurysm proximal neck angle <sup>b</sup>	132 (22)	Predictive mean matching
Aneurysm neck length <sup>b</sup>	132 (22)	Predictive mean matching
Death within 1 year	2 (0)	None done
Resource use variables		
Primary admission: time in theatre	22 (4)	Predictive mean matching
Primary admission: days in critical care	13 (2)	Predictive mean matching
Primary admission: days in routine ward	48 (8)	Predictive mean matching
Primary admission: reintervention time in theatre	22 (4)	Predictive mean matching
Readmissions at 3 months: days in critical care	20 (6)	Predictive mean matching
Readmissions at 12 months: days in critical care	32 (11)	Predictive mean matching
Readmission at 3 months: days in routine ward	19 (6)	Predictive mean matching
Readmission at 12 months: days in routine ward	31 (10)	Predictive mean matching
Outpatient visits at 3 months	37 (12)	Predictive mean matching
Outpatient visits at 12 months	47 (16)	Predictive mean matching
Family doctor visits at 3 months	75 (24)	Predictive mean matching
Family doctor visits at 12 months	83 (28)	Predictive mean matching
Nurse at-home visits at 3 months	62 (19)	Predictive mean matching
Nurse at-home visits at 12 months	68 (23)	Predictive mean matching
QoL variables		
EQ-5D at 3 months	66 (21)	Predictive mean matching
EQ-5D at 12 months	72 (24)	Predictive mean matching

a For baseline variables, vital status and primary admissions, the overall sample size was the total number of randomised participants (*n* = 613). For other resource use and QoL variables, the relevant sample sizes were the total numbers of participants who were eligible for the 3-month and 12-month follow-ups (*n* = 318 and *n* = 301, respectively).

b Measurements from the core laboratory.

**TABLE 32** Quality-of-life (EQ-5D) health state profiles for participants with a proven rupture, who commenced an operation and who were alive and fully completed the questionnaire at 3 months and 12 months post randomisation

EQ-5D component	Time point, n (%)			
	3 months <sup>a</sup>		12 months <sup>b</sup>	
	Endovascular strategy (N = 138)	Open repair (N = 114)	Endovascular strategy (N = 127)	Open repair (N = 102)
Mobility				
1	74 (54)	51 (45)	63 (50)	55 (54)
2	64 (46)	60 (53)	65 (51)	48 (47)
3	1 (1)	3 (3)	0 (0)	2 (2)
Self-care				
1	116 (84)	76 (67)	112 (88)	82 (80)
2	21 (15)	34 (30)	15 (12)	20 (20)
3	1 (1)	5 (4)	1 (1)	4 (4)
Usual activities				
1	60 (43)	49 (43)	59 (46)	61 (60)
2	71 (51)	51 (45)	63 (50)	36 (35)
3	8 (6)	15 (13)	5 (4)	9 (9)
Pain/discomfort				
1	82 (59)	58 (51)	76 (60)	62 (61)
2	53 (38)	52 (46)	51 (40)	36 (35)
3	4 (3)	4 (4)	1 (1)	7 (7)
Anxiety/depression				
1	101 (73)	83 (73)	93 (73)	74 (73)
2	37 (29)	27 (24)	33 (26)	27 (26)
3	1 (1)	4 (4)	2 (2)	2 (2)

a Thirty (18%) and 36 (24%) participants had incomplete 3-month questionnaires in the endovascular strategy and open repair groups, respectively.

b Thirty-four (21%) and 38 (27%) participants had incomplete 12-month questionnaires in the endovascular strategy and open repair groups, respectively.

#### Notes

Key: 1 = no problems, 2 = some problems and 3 = severe problems.

Results are presented for the samples with complete information. The numbers of complete responses/eligible participants are as follows: at 3-months, 138/168 (82%) (endovascular strategy) and 114/150 (76%) (open repair); at 12-months, 127/161 (79%) (endovascular strategy) and 102/140 (73%) (open repair).

**TABLE 33a** Unadjusted and adjusted HRs for the endovascular strategy compared with open repair, for both all-cause mortality and aneurysm-related mortality for all available follow-up data: overall

	<i>n</i>	HR (95% CI)	<i>p</i> -value
All-cause mortality			
Unadjusted	613	0.92 (0.75 to 1.13)	0.41
Adjusted <sup>a</sup> (complete cases)	397	0.89 (0.69 to 1.16)	0.39
Adjusted <sup>a</sup> (multiply imputed)	613	0.91 (0.74 to 1.12)	0.38
Aneurysm-related mortality			
Unadjusted	613	0.89 (0.69 to 1.16)	0.41
Adjusted <sup>a</sup> (complete cases)	397	0.88 (0.64 to 1.22)	0.45
Adjusted <sup>a</sup> (multiply imputed)	613	0.90 (0.69 to 1.16)	0.42

<sup>a</sup> Adjusted for age, sex, Hardman index, lowest systolic blood pressure and neck length.

**TABLE 33b** Unadjusted and adjusted<sup>a</sup> HRs for the endovascular strategy compared with open repair, for both all-cause mortality and aneurysm-related mortality for all available follow-up data: by time period

	<i>n</i> (remaining under follow-up)	HR (95% CI)	<i>p</i> -value
All-cause mortality			
0–3 months	613	0.98 (0.76 to 1.26)	0.88
> 3 months	373	0.80 (0.57 to 1.15)	0.23
Aneurysm-related mortality			
0–3 months	613	0.90 (0.69 to 1.17)	0.43
> 3 months	373	0.91 (0.34 to 2.43)	0.85

<sup>a</sup> Adjusted for age, sex, Hardman index, lowest systolic blood pressure and neck length.

**TABLE 34** Reinterventions in the first 3 years of follow-up, by operation commenced, for participants with a final diagnosis of ruptured AAA

AAA-related reintervention	Participants with ruptured AAA in whom repair started ( <i>N</i> = 502)		<i>p</i> -value
	Endovascular strategy commenced <sup>a</sup> ( <i>N</i> = 182)	Open repair commenced <sup>b</sup> ( <i>N</i> = 320)	
Participants with at least one reintervention, <i>n/N</i> (%)	52/182 (29)	88/320 (28)	0.80
Reinterventions/person-years (rate per 100 person-years), (%)	77/338.1 (22.8)	153/513.0 (29.8)	0.054
Arterial, <i>n</i> (%)	66 (86)	89 (58)	< 0.001
Laparotomy, <i>n</i> (%)	2 (3)	48 (31)	
Other, <i>n</i> (%)	9 (12)	16 (10)	

continued



**TABLE 34** Reinterventions in the first 3 years of follow-up, by operation commenced, for participants with a final diagnosis of ruptured AAA (*continued*)

		Participants with ruptured AAA in whom repair started ( <i>N</i> = 502)		
AAA-related reintervention		Endovascular strategy commenced <sup>a</sup> ( <i>N</i> = 182)	Open repair commenced <sup>b</sup> ( <i>N</i> = 320)	<i>p</i> -value
Severity of arterial reinterventions, <i>n</i> (%)				
1*		1 (2)	0 (0)	< 0.001
2**		23 (35)	11 (12)	
3***		17 (26)	26 (29)	
4****		10 (15)	4 (4)	
5*****		15 (23)	48 (54)	
Severity of laparotomy reinterventions, <i>n</i> (%)				
Major		1 (50)	7 (15)	0.41
Minor		1 (50)	40 (83)	
Unknown (scored 4)			1	
<b>Randomisation to 3 months</b>				
Participants with at least one reintervention, <i>n/N</i> (%)		29/182 (16)	79/320 (25)	0.022
Reinterventions/person-years (rate per 100 person-years), (%)		39/33.0 (118.3)	130/49.6 (262.0)	< 0.001
Arterial, <i>n</i> (%)		30 (77)	79 (61)	0.011
Laparotomy, <i>n</i> (%)		2 (5)	36 (28)	
Other, <i>n</i> (%)		7 (18)	15 (12)	
Severity of arterial reinterventions, <i>n</i> (%)				
1*		1 (3)	0 (0)	0.017
2**		9 (30)	10 (13)	
3***		8 (27)	22 (28)	
4****		4 (13)	4 (5)	
5*****		8 (27)	43 (54)	
Severity of laparotomy reinterventions, <i>n</i> (%)				
Major		1 (50)	3 (8)	0.17
Minor		1 (50)	32 (89)	
Unknown (scored 4)			1	
<b>3 months to 3 years</b>				
Participants with at least one reintervention, <i>n/N</i> (%)		26/125 (21)	16/188 (9)	0.002
Reinterventions/person-years (rate per 100 person-years), (%)		38/305.1 (12.5)	23/463.4 (5.0)	< 0.001
Arterial, <i>n</i> (%)		36 (95)	10 (43)	< 0.001
Laparotomy, <i>n</i> (%)		0 (0)	12 (52)	
Other, <i>n</i> (%)		2 (5)	1 (4)	

**TABLE 34** Reinterventions in the first 3 years of follow-up, by operation commenced, for participants with a final diagnosis of ruptured AAA (*continued*)

	Participants with ruptured AAA in whom repair started ( <i>N</i> = 502)		
AAA-related reintervention	Endovascular strategy commenced <sup>a</sup> ( <i>N</i> = 182)	Open repair commenced <sup>b</sup> ( <i>N</i> = 320)	<i>p</i> -value
Severity of arterial reinterventions, <i>n</i> (%)			
1*	0 (0)	0 (0)	0.07
2**	14 (39)	1 (10)	
3***	9 (25)	4 (40)	
4****	6 (17)	0 (0)	
5*****	7 (19)	5 (50)	
Severity of laparotomy reinterventions, <i>n</i> (%)			
Major		4 (33)	
Minor		8 (67)	
a Includes five individuals who converted to open repair (four died within 30-days and one survived).			
b Includes one participant with laparotomy who was palliated (open and close).			

**TABLE 35** Unadjusted and adjusted HRs for the endovascular strategy compared with open repair, for time to first AAA reintervention and time to any reintervention within the first 3 years of follow-up

Rate per 100 person-years (n/person-years)					
Endovascular strategy	Open repair	Model	N	HR (95% CI)	p-value
Time to first AAA-related reintervention					
22.6 (75/332.2)	21.0 (66/314.2)	Unadjusted	613	1.10 (0.79 to 1.54)	0.59
		Adjusted <sup>a</sup> (complete cases)	397	1.09 (0.73 to 1.62)	0.67
		Adjusted <sup>a</sup> (multiply imputed)	613	1.10 (0.79 to 1.54)	0.57
Time to any AAA-related reintervention (Andersen–Gill model)					
26.0 (121/464.5)	28.3 (110/388.3)	Unadjusted	613	1.02 (0.79 to 1.32)	0.89
		Adjusted <sup>a</sup> (complete cases)	397	0.93 (0.68 to 1.27)	0.64
		Adjusted <sup>a</sup> (multiply imputed)	613	1.02 (0.79 to 1.33)	0.87
Randomisation to 3 months					
182.5 (81/44.4)	222.7 (89/40.0)	Unadjusted	613	0.88 (0.65 to 1.19)	0.40
		Adjusted <sup>a</sup> (complete cases)	397	0.78 (0.55 to 1.11)	0.17
		Adjusted <sup>a</sup> (multiply imputed)	613	0.87 (0.64 to 1.18)	0.37
3 months to 3 years					
9.5 (40/420.1)	6.0 (21/348.3)	Unadjusted	313	1.57 (0.93 to 2.67)	0.09
		Adjusted <sup>a</sup> (complete cases)	217	1.67 (0.82 to 3.43)	0.16
		Adjusted <sup>a</sup> (multiply imputed)	313	1.54 (0.90 to 2.62)	0.12
a Adjusted for age, sex, Hardman index, lowest systolic blood pressure and neck length.					

**TABLE 36a** Indications for re-interventions within 90 days of randomisation

Aneurysm-related indication for 502 repairs with rupture started	Randomised to EVAR strategy (n = 259)	Randomised to open repair (n = 243)	Treated with EVAR (n = 182)	Treated with open repair (n = 320)
Access site	4	1	3	2
Abdominal compartment syndrome	7	10	2	15
Bowel ischaemia <sup>a</sup>	14	16	5	25
Closure open abdomen	5	5	1	9
Distal aneurysm	1	1	2	0
Endograft kinking <sup>b</sup>	2	0	2	0
Endoleak <sup>c</sup>	3	1	4	0
False aneurysm	1	0	1	0
Graft thrombosis/occlusion	3	0	1	2
Graft infection: aorta	0	2	0	2
Graft infection: femoro-femoral	2	0	2	0
Limb ischaemia	22	13	8	27
Ostomy (stoma)	1	1	1	1
Re-bleeding	3	7	1	9
<b>Other indications</b>				
Coronary or brain ischaemia	3	2	2	3
Miscellaneous <sup>d</sup>	0	3	1	2
Nutritional support	0	1	0	1
Pulmonary embolism	0	2	1	1
Renal failure	0	1	0	1
Tracheostomy for ventilator weaning	5	7	2	10
Upper GI bleed	1	5	1	5
Total re-interventions	77 in 55 patients	78 in 53 patients	40 in 29 patients	115 in 79 patients

**Note**

There were 27 re-interventions for life threatening indications which occurred in patients randomised to the endovascular aneurysm repair (EVAR) strategy vs. 41 in those randomised to open repair. Fifteen of these re-interventions for life threatening indications occurred in patients who received EVAR vs. 53 in those who received open repair. There were two patients in whom two indications were treated simultaneously, one treated for re-bleeding and bowel ischaemia, and one treated for type 1A endoleak and bowel ischaemia. GI = gastrointestinal.

a Without abdominal compartment syndrome being diagnosed.

b Prophylactic re-intervention to avoid graft thrombosis or occlusion.

c Two type 1A, two type 2.

d Two perforation sigmoid colon, one pleural effusion.

© 2018 The Authors.<sup>125</sup> Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**TABLE 36b** Indications for re-interventions from 3 months to 3 years

Aneurysm-related indication for 313 repairs with rupture started who survived beyond 90 days	Randomised to EVAR strategy (n = 167)	Randomised to open repair (n = 146)	Treated with EVAR (n = 125)	Treated with open repair (n = 188)
Access site	3	1	2	2
Bowel ischaemia	2	1	0	3
Distal aneurysm	3	4	3	4
Endograft kinking <sup>a</sup>	2	2	4	0
Endograft migration	1	0	1	0
Endoleak <sup>b</sup>	14	2	16	0
False aneurysm	1	0	1	0
Graft thrombosis/occlusion	6	1	4	3
Graft infection: aorta	0	2	0	2
Graft infection: femoro-femoral	0	0	0	0
Incisional hernia	0	3	0	3
Limb ischaemia	2	2	3	1
Ostomy (stoma)	0	1	0	1
Proximal aneurysm	1	0	1	0
Secondary rupture <sup>c</sup>	2	0	2	0
Symptomatic adhesions	1	1	0	2
<b>Other indications</b>				
Nutritional support	0	1	0	1
Renal failure	1	0	1	0
Total re-interventions	39 in 27 patients	21 in 15 patients	38 in 26 patients	22 in 16 patients

**Note**

In those randomised to the endovascular aneurysm repair (EVAR) strategy, 17/39 of the re-interventions were for a life threatening condition vs. 7/21 in those randomised to open repair. In those having undergone EVAR 14/38 of the re-interventions were for life threatening conditions vs. 10/22 in those having undergone open repair. There were three patients in whom two indications were treated simultaneously, one for type 1A endoleak and arteriovenous fistula formation for renal failure, one for bowel ischaemia and incisional hernia, and one for type 1B endoleak and common iliac aneurysm.

a Prophylactic re-intervention to avoid graft thrombosis or occlusion.

b Four type 1A (one also had type 2), two type 1B (one also had type 2), nine type 2 only, and one type 3.

c One patient with a type 1A endoleak and renal failure requiring dialysis and one with a type 1B endoleak.

© 2018 The Authors.<sup>125</sup> Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**TABLE 37** The effect of aortic morphology on re-interventions in the first 3 years of follow up

Morphological variable	Re-interventions	Treated with EVAR (n = 182)	Treated with open repair (n = 320)	Combined (n = 502)
		Time to any AAA related re-intervention		
Maximum AAA diameter (per 17 mm increase)	All	0.97 (0.72–1.32)	0.95 (0.77–1.18)	0.95 (0.80–1.12)
		p = .86	p = .65	p = .52
	Arterial	1.02 (0.74–1.39)	0.85 (0.66–1.09)	0.90 (0.74–1.09)
Aneurysm neck diameter at distal renal artery (per 4 mm increase)	All	1.00 (0.77–1.30)	1.21 (0.99–1.49)	1.15 (0.98–1.35)
		p = .98	p = .06	p = .09
	Arterial	0.98 (0.74–1.29)	0.94 (0.72–1.24)	0.95 (0.78–1.16)
Aneurysm neck length (per 16 mm increase)	All	0.80 (0.58–1.10)	0.89 (0.72–1.10)	0.87 (0.73–1.03)
		p = .16	p = .28	p = .12
	Arterial	0.74 (0.53–1.04)	0.89 (0.69–1.16)	0.84 (0.69–1.03)
Neck conicality (per 1.6% per mm length, change increase)	All	0.72 (0.45–1.15)	0.91 (0.74–1.11)	0.87 (0.72–1.06)
		p = .17	p = .36	p = .16
	Arterial	0.65 (0.39–1.10)	1.07 (0.87–1.31)	0.97 (0.77–1.22)
Proximal aneurysm neck ( $\alpha$ ) angle (per 20° increase)	All	1.01 (0.77–1.31)	1.05 (0.89–1.24)	1.04 (0.90–1.19)
		p = .96	p = .56	p = .62
	Arterial	0.96 (0.72–1.29)	0.90 (0.70–1.16)	0.93 (0.77–1.12)
Maximum common iliac diameter (per 9 mm increase) <sup>a</sup>	All	1.32 (1.01–1.72)	1.06 (0.91–1.24)	1.11 (0.98–1.26)
		p = .041	p = .45	p = .11
	Arterial	1.48 (1.13–1.93)	1.11 (0.92–1.35)	1.20 (1.04–1.39)
		p = .004	p = .28	p = .013

**Note**

Data are hazard ratio (95% CI). Aortic morphology and the risk of experiencing any re-intervention within 3 years (with multiple imputation for missing variables). Multivariate model adjusted for all six morphological variables in addition to age, sex, Hardman index, lowest recorded systolic blood pressure, and randomised group. Hazard ratios are presented per SD increase of morphological parameter. These analyses are restricted to 502 patients with confirmed rupture who received an operation by treatment received (endovascular aneurysm repair [EVAR], open or EVAR converted to open). All aneurysm related re-interventions (and only arterial re-interventions) are considered separately.

<sup>a</sup> Excluding eight patients with a ruptured common iliac aneurysm.

© 2018 The Authors.<sup>125</sup> Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**TABLE 38** Quality-of-life (EQ-5D-3L) utility scores, QALYs and life-years up to 3 years for participants with fully observed outcomes (complete cases)

	Treatment group				Mean difference (95% CI)	p-value
	Endovascular strategy		Open repair			
	n	Mean (SD)	n	Mean (SD)		
EQ-5D-3L <sup>a</sup> for ruptured AAA survivors						
3 months	138	0.76 (0.23)	114	0.69 (0.30)	0.073 (0.007 to 0.138)	0.030
12 months	127	0.78 (0.19)	102	0.74 (0.32)	0.043 (−0.024 to 0.110)	0.211
36 months	117	0.75 (0.24)	91	0.74 (0.31)	0.012 (−0.063 to 0.088)	0.746
Life-years (up to 3 years) <sup>b</sup>	313	1.71 (1.43)	295	1.60 (1.41)	0.113 (−0.114 to 0.339)	0.329
QALYs (3-year)						
Ruptured AAA survivors	91	2.22 (0.50)	68	2.16 (0.64)	0.052 (−0.126 to 0.230)	0.563
Ruptured AAA survivors and deceased	193	1.08 (1.14)	183	0.88 (1.10)	0.207 (−0.021 to 0.435)	0.074
All randomised participants <sup>c</sup>	250	1.01 (1.10)	237	0.88 (1.08)	0.131 (−0.063 to 0.325)	0.187

a The EQ-5D-3L is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).

b For all randomised participants.

c This includes participants without a proven rupture, who were assumed to have, on average, the same QoL as elective patients.

**TABLE 39** Incremental net benefit (GBP) (95% CI) within 3 years of randomisation, by subgroup, at the recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)

	Incremental (95% CI)		INB (95% CI)	p-value
Subgroup	Cost (£)	QALYs		
Sex				
Male (n = 480)	−4066 (−7573 to −557)	0.092 (−0.099 to 0.283)	6824 (204 to 13,444)	0.440
Female (n = 133)	2817 (−3806 to 9439)	0.358 (0.038 to 0.712)	7914 (−4401 to 20,229)	
Hardman index score				
0 (n = 164)	−4017 (−9758 to 1725)	0.016 (−0.141 to 0.465)	8878 (−1686 to 19,442)	0.279
1 (n = 254)	−2448 (−7022 to 2126)	0.005 (−0.244 to 0.254)	2594 (−5943 to 11,131)	
≥ 2 (n = 121)	−923 (−7306 to 5461)	0.423 (0.092 to 0.755)	13,622 (2025 to 25,219)	
Neck length				
< 22 mm (n = 234)	−769 (−5595 to 4057)	0.216 (−0.027 to 0.459)	7243 (−1216 to 15,702)	0.461
≥ 22 mm (n = 247)	−4250 (−8859 to 358)	0.111 (−0.131 to 0.352)	7568 (−959 to 16,095)	
Lowest systolic blood pressure				
< 90 mmHg (n = 263)	−3881 (−8604 to 842)	0.067 (−0.185 to 0.319)	5881 (−2949 to 14,711)	0.275
≥ 90 mmHg (n = 305)	−1540 (−5879 to 2798)	0.213 (−0.013 to 0.439)	7932 (−14.2 to 15,878)	

**TABLE 40** Coefficients for the best-fitting model (backwards selection) and the clinically simplified (bedside) model

Best-fitting model			Bedside model		
Variable	$\beta$ (SE)	<i>p</i> -value	Rule	OR	Score allocated <sup>a</sup>
Intercept	−0.3040 (0.8024)				
$\left(\frac{age-50}{5}\right)^3$	0.0028 (0.0008)	0.001	Aged $\geq 76$ years	1.40	2
Haemoglobin	−0.0897 (0.0524)	0.087	Haemoglobin level of $< 11$ g/dl	2.10	4
$\left(\frac{creatinine}{5}\right)$	0.4522 (0.1613)	0.005	Creatinine concentration of $\geq 120$ $\mu$ mol/l	1.63	3
$\left(\frac{sbp+1}{100}\right)^{-2}$	0.4665 (0.1339)	$< 0.001$	Systolic blood pressure of $< 100$ mmHg	1.71	3
$\log\left(\frac{necklength+1}{10}\right)$	−0.7070 (0.1954)	$< 0.001$	Neck length of $< 15$ mm	1.92	4
$\left(\frac{neckangle+1}{10}\right)$	−0.0989 (0.0614)	0.107	Neck angle of $< 45^\circ$	1.94	4
Male	−0.4919 (0.2651)	0.063	Female	2.11	4
Acute ischaemia	1.0363 (0.3659)	0.005	Acute ischaemia	2.78	6

<sup>a</sup> Integer points based on rounding  $6.6 \times \log$ -odds ratio.

**TABLE 41** Derivation of previously published ruptured AAA risk scores


Variable	VSGNE	Hardman index	Vancouver
Aged $> 76$ years	+2	+1	+0.062 for each 1-year increase in age
Cardiac arrest	+2	+1	+0.60
Loss of consciousness	+1	+1	+1.14
Suprarenal clamp	+1	–	–
ECG ischaemia	–	+1	–
Creatinine concentration of $> 190$ $\mu$ mol/l	–	+1	–
Haemoglobin level of $< 9$ g/dl	–	+1	–

–, not used; ECG, electrocardiography; VSGNE, Vascular Study Group of New England.


**TABLE 42** Discriminative performance of the developed IMPROVE risk score for predicting 30-day mortality, validated both internally (using IMPROVE trial data) and externally (using data from the AJAX and ECAR RCTs and the Amsterdam and STAR cohorts)

Model	Data set, c-statistic (SD)				
	Development	Validation			
	IMPROVE RCT (n = 536)	AJAX RCT (n = 113)	ECAR RCT (n = 105)	Amsterdam cohort (n = 513)	STAR cohort (n = 284)
IMPROVE score	0.715 <sup>a</sup> (0.023)	0.677 (0.052)	0.619 (0.069)	0.724 (0.022)	0.693 (0.031)
IMPROVE bedside score	0.691 <sup>a</sup> (0.023)	0.662 (0.054)	0.631 (0.070)	0.664 (0.024)	0.632 (0.033)
VSGNE	0.667 (0.023)	0.691 <sup>b</sup> (0.053)	0.632 <sup>b</sup> (0.063)	0.682 <sup>c</sup> (0.024)	0.683 <sup>b</sup> (0.031)
Hardman index	0.658 (0.023)	0.784 (0.043)	0.694 (0.062)	0.697 (0.023)	0.669 (0.032)
Vancouver	0.653 (0.024)	0.700 <sup>b</sup> (0.059)	0.657 <sup>b</sup> (0.064)	0.685 <sup>c</sup> (0.024)	0.745 <sup>b</sup> (0.029)
VSGNE, Vascular Study Group of New England.					
a Cross-validated c-statistic (optimism corrected).					
b Excluding preoperative cardiac arrest.					
c Excluding preoperative cardiac arrest and loss of consciousness.					
<b>Note</b>					
Comparison with other published risk scores also shown.					







**FIGURE 22** The HR of time to discharge from primary admission hospital (endovascular strategy/endovascular repair compared with open repair) by randomised group. Copyright © 2015 The Authors. BJS published by John Wiley & Sons, Inc., on behalf of BJS Society Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.




**FIGURE 23** Effect of systolic blood pressure (lowest recorded) on probability of 30-day mortality (95% CIs are presented).




**FIGURE 24** Survival to 1 year in the AJAX, ECAR and IMPROVE trials. (a) AJAX; (b) ECAR; (c) IMPROVE (all participants); (d) IMPROVE (data for the 308 IMPROVE participants with a ruptured aneurysm who were suitable for EVAR); and (e) individual patient meta-analysis of 1-year mortality for participants as randomised in AJAX, ECAR and IMPROVE. Reprinted from *Eur J Vasc Endovasc Surg*, 50, Sweeting MJ, Ulug P, Powell JT, Desgranges P, Balm R, Ruptured Aneurysm Trialists, Ruptured aneurysm trials: the importance of longer-term outcomes and meta-analysis for 1-year mortality, 297–302, Copyright (2015) with permission from Elsevier. (*continued*)




**FIGURE 24** Survival to 1 year in the AJAX, ECAR and IMPROVE trials. (a) AJAX; (b) ECAR; (c) IMPROVE (all participants); (d) IMPROVE (data for the 308 IMPROVE participants with a ruptured aneurysm who were suitable for EVAR); and (e) individual patient meta-analysis of 1-year mortality for participants as randomised in AJAX, ECAR and IMPROVE. Reprinted from *Eur J Vasc Endovasc Surg*, 50, Sweeting MJ, Ulug P, Powell JT, Desgranges P, Balm R, Ruptured Aneurysm Trialists, Ruptured aneurysm trials: the importance of longer-term outcomes and meta-analysis for 1-year mortality, 297–302, Copyright (2015) with permission from Elsevier.




**FIGURE 25** Uncertainty in the mean cost (GBP) and QALY differences at 1 year after randomisation for 613 participants and their joint distribution for endovascular strategy compared with open repair. Reproduced with permission from the IMPROVE Trial Investigators.<sup>23</sup> © The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).




**FIGURE 26** Sensitivity analysis that considers the effect on the INMB at 1 year (at £30,000 per QALY) of alternative assumptions, compared with the base case for 613 participants.




**FIGURE 27** Kaplan–Meier survival curves for overall aneurysm-related mortality for 613 participants, by randomised group.




**FIGURE 28** Prespecified subgroup analyses showing HRs for the endovascular strategy group compared with the open repair group for overall mortality at 3 years in 613 participants.




**FIGURE 29** Sensitivity analysis that considers the effect on the INMB at 3 years (at £30,000 per QALY) of alternative assumptions, compared with the base case for 613 participants.



**FIGURE 30** Non-linear effects of (a) age, (b) admission systolic blood pressure and (c) neck length on the log-odds of mortality. FP fit is shown together with estimated log-odds by deciles of candidate predictor.



**FIGURE 31** Calibration plots for the best-fitting model and the bedside model in the IMPROVE trial data set. (a) Best-fitting model; and (b) bedside model.



**FIGURE 32** Variation of WSSs in the aorta with iliac bifurcation angle. (a) WSS; (b) TAWSS; (c) wall stress; and (d) ECAP. ECAP, endothelial cell activation potential. MPa, megapascal.





A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and flow.

EME  
HS&DR  
**HTA**  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health*

***Published by the NIHR Journals Library***